RESULT_COUNT: 532,PAGE_SIZE: 10000,CURRENT_PAGE: 1,TOTAL_PAGES: 1,API_CALL_CREDITS: 1
TICKER,FIGI_TICKER,FIGI,TITLE,PUBLICATION_DATE,URL,SUMMARY
LGND,LGND:US,BBG000BKF014,Abbvie Inks Immuno-Oncology Deal with Harpoon Therapeutics,2017-10-20 21:36:09 +0000,https://finance.yahoo.com/news/abbvie-inks-immuno-oncology-deal-213609693.html?.tsrc=rss,AbbVie (ABBV) and Harpoon Therapeutics announced that they inked an immuno-oncology research collaboration to generate novel T-cell engagers for the treatment of cancer.
LGND,LGND:US,BBG000BKF014,"Innoviva Clears Key Benchmark, Hitting 80-Plus RS Rating",2017-10-20 16:07:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/feHZr-ih0Ts/innoviva-clears-key-benchmark-hitting-80-plus-rs-rating-cm862737,Innoviva INVA saw a welcome improvement to its Relative Strength RS Rating on Friday rising from 72 to 81 ibd display video id 2102289 width 50 float left autostart true IBD s proprietary rating tracks share price movement with a 1 worst to 99 best
LGND,LGND:US,BBG000BKF014,Gilead Sciences Shows Rising Relative Price Performance; Still Shy Of Key Threshold,2017-10-20 16:05:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PaTnl58qEF0/gilead-sciences-shows-rising-relative-price-performance-still-shy-of-key-threshold-cm862718,The Relative Strength RS Rating for Gilead Sciences GILD entered a new percentile Friday as it got a lift from 68 to 73 ibd display video id 2360792 width 50 float left autostart true This unique rating identifies technical performance by showing how
LGND,LGND:US,BBG000BKF014,Novartis Reports Positive Results on Thrombocytopenia Drug,2017-10-19 14:52:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7zIrLHnOVhE/novartis-reports-positive-results-on-thrombocytopenia-drug-cm861901,Novartis AG NVS announced encouraging results on Revolade from the EXTEND study The open label extension study from four trials TRA100773A TRA100773B TRA102537 RAISE and TRA108057 REPEAT showed long term disease control in chronic persistent immune thrombocytopenia ITP patients
LGND,LGND:US,BBG000BKF014,Impax Laboratories and Amneal Pharmaceuticals Agree to Merge,2017-10-18 14:17:02 +0000,https://finance.yahoo.com/news/impax-laboratories-amneal-pharmaceuticals-agree-141702817.html?.tsrc=rss,Impax Laboratories (IPXL) and Amneal Pharmaceuticals announced an agreement to merge to form a new publicly traded company.
LGND,LGND:US,BBG000BKF014,"Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals",2017-10-18 13:55:01 +0000,https://finance.yahoo.com/news/zacks-industry-outlook-highlights-novo-135501090.html?.tsrc=rss,"Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals"
LGND,LGND:US,BBG000BKF014,Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks,2017-10-17 22:52:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/G3L8_TQwCK8/innovative-pipelines-regulatory-catalysts-to-drive-pharma-stocks-cm861063,Although pharma and biotech stocks had gone through a rough patch due to the drug pricing controversy the sector is showing signs of recovery with investors being more comfortable with the drug pricing scenario and focusing on the fundamentals of the sector instead Innovation mergers
LGND,LGND:US,BBG000BKF014,Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks,2017-10-17 19:55:07 +0000,https://finance.yahoo.com/news/innovative-pipelines-regulatory-catalysts-drive-195507406.html?.tsrc=rss,Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks
LGND,LGND:US,BBG000BKF014,Inovio Initiates Bladder Cancer Study With Roche's Tecentriq,2017-10-17 16:53:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OuYnPS4RTFM/inovio-initiates-bladder-cancer-study-with-roches-tecentriq-cm860802,Inovio Pharmaceuticals Inc INO announced that it has initiated a phase Ib II study to evaluate the combination of two immunotherapy candidates and Roche Holding AG s RHHBY anti PDL1 inhibitor Tecentriq in advanced bladder cancer Inovio s candidates include INO 5401 a T cell
LGND,LGND:US,BBG000BKF014,Stocks Showing Market Leadership: PTC Therapeutics Earns 92 RS Rating,2017-10-17 14:54:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8GvxdIyFhQ4/stocks-showing-market-leadership-ptc-therapeutics-earns-92-rs-rating-cm860690,PTC Therapeutics PTCT saw a welcome improvement to its Relative Strength RS Rating on Tuesday with an increase from 81 to 92 ibd display video id 449419 width 50 float left autostart true This proprietary rating measures market leadership by showing how
LGND,LGND:US,BBG000BKF014,Exelixis Earns Relative Strength Rating Upgrade,2017-10-17 14:53:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JE_WDkUmyVw/exelixis-earns-relative-strength-rating-upgrade-cm860672,Exelixis EXEL saw a positive improvement to its Relative Strength RS Rating on Tuesday rising from 89 to 95 ibd display video id 2102289 width 50 float left autostart true IBD s proprietary RS Rating identifies market leadership by showing how a stock s
LGND,LGND:US,BBG000BKF014,Inovio Initiates Bladder Cancer Study With Roche&apos;s Tecentriq,2017-10-17 14:51:02 +0000,https://finance.yahoo.com/news/inovio-initiates-bladder-cancer-study-145102648.html?.tsrc=rss,Inovio Pharmaceuticals (INO) will evaluate a combination of checkpoint inhibitor and T cell activator as a potential treatment for advanced bladder cancer in a new early stage study.
LGND,LGND:US,BBG000BKF014,Stocks Showing Improving Market Leadership: Five Prime Therapeutics Earns 83 RS Rating,2017-10-16 15:21:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HR9yLMIVH3Y/stocks-showing-improving-market-leadership-five-prime-therapeutics-earns-83-rs-rating-cm860172,Five Prime Therapeutics FPRX had its Relative Strength RS Rating upgraded from 80 to 83 Monday ibd display video id 2102289 width 50 float left autostart true This unique rating tracks market leadership by showing how a stock s price movement over the last
LGND,LGND:US,BBG000BKF014,Shire&apos;s New Formulation of Oncaspar Gets CHMP Recommendation,2017-10-16 14:02:02 +0000,https://finance.yahoo.com/news/shire-apos-formulation-oncaspar-gets-140202707.html?.tsrc=rss,"Shire&apos;s (SHPG) marketing authorization application for a new (dried) formulation of its leukemia drug, Oncaspar, received CHMP recommendation for approval in EU."
LGND,LGND:US,BBG000BKF014,"AcelRx's Opioid Painkiller Dsuvia Gets CRL, Shares Plunge",2017-10-13 17:12:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zeeudaaeebk/acelrxs-opioid-painkiller-dsuvia-gets-crl-shares-plunge-cm859516,AcelRx Pharmaceuticals Inc ACRX plunged nearly 60 after it announced that the FDA has issued a complete response letter CRL to its new drug application NDA for Dsuvia The company is looking to get Dsuvia tablets approved for treating moderate to severe acute pain following a trauma
LGND,LGND:US,BBG000BKF014,"AcelRx&apos;s Opioid Painkiller Dsuvia Gets CRL, Shares Plunge",2017-10-13 15:05:03 +0000,https://finance.yahoo.com/news/acelrx-apos-opioid-painkiller-dsuvia-150503217.html?.tsrc=rss,"AcelRx (ACRX) receives CRL for its opioid painkiller, Dusvia. The FDA has requested resubmission with additional safety data and recommended changes to drug administration."
LGND,LGND:US,BBG000BKF014,Intra-Cellular Therapies Shows Rising Price Performance With Jump To 83 RS Rating,2017-10-12 15:17:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NwExEYVWiwg/intra-cellular-therapies-shows-rising-price-performance-with-jump-to-83-rs-rating-cm858868,On Thursday Intra Cellular Therapies ITCI reached an important technical milestone with its Relative Strength RS Rating jumping into the 80 plus percentile with an upgrade to 83 a rise from 80 the day before ibd display video id 449433 width 50 float
LGND,LGND:US,BBG000BKF014,Stocks With Rising Relative Price Strength: Ionis Pharmaceuticals,2017-10-12 15:17:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HTGBb3nrq3c/stocks-with-rising-relative-price-strength-ionis-pharmaceuticals-cm858866,On Thursday Ionis Pharmaceuticals IONS hit an important performance benchmark with its Relative Strength RS Rating moving into the 90 plus percentile with an improvement to 91 an increase from 88 the day before ibd display video id 449419 width 50 float
LGND,LGND:US,BBG000BKF014,Aerie Pharmaceuticals Scores Relative Strength Rating Upgrade,2017-10-12 15:16:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FC964KSpffo/aerie-pharmaceuticals-scores-relative-strength-rating-upgrade-cm858864,On Thursday Aerie Pharmaceuticals AERI hit an important technical milestone with its Relative Strength RS Rating jumping into the 90 plus percentile with an improvement to 93 a rise from 82 the day before ibd display video id 449423 width 50 float
LGND,LGND:US,BBG000BKF014,Stocks Showing Rising Market Leadership: Aerie Pharmaceuticals Earns 82 RS Rating,2017-10-11 15:16:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/04zCniEIB4k/stocks-showing-rising-market-leadership-aerie-pharmaceuticals-earns-82-rs-rating-cm858237,When considering what names to put on your watch list focus on stocks with an 80 or higher RS Rating Aerie Pharmaceuticals AERI now meets that criteria with a jump from 74 to 82 Wednesday ibd display video id 2102289 width 50 float left autostart true IBD
LGND,LGND:US,BBG000BKF014,"Flexion Therapeutics Clears Technical Benchmark, Hitting 90-Plus RS Rating",2017-10-09 14:54:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JuT9Y_XEL74/flexion-therapeutics-clears-technical-benchmark-hitting-90-plus-rs-rating-cm857013,On Monday Flexion Therapeutics FLXN received an upgrade to its Relative Strength RS Rating from 85 to 92 ibd display video id 449419 width 50 float left autostart true This proprietary rating measures technical performance by using a 1 worst to 99
LGND,LGND:US,BBG000BKF014,"Forget Teva (TEVA), Buy These 5 Drug Stocks Instead",2017-10-09 14:20:02 +0000,https://finance.yahoo.com/news/forget-teva-teva-buy-5-142002954.html?.tsrc=rss,"With another challenge cropping up for Teva (TEVA) in the form of earlier-than-expected generic competition for the 40 mg dose of Copaxone, here is a look at 5 drug stocks that look better-positioned."
LGND,LGND:US,BBG000BKF014,See what the IHS Markit Score report has to say about Ligand Pharmaceuticals Inc.,2017-10-09 12:07:12 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120712911.html?.tsrc=rss,Ligand Pharmaceuticals Inc NASDAQ NMS:LGND
LGND,LGND:US,BBG000BKF014,Flexion Therapeutics Hits 80-Plus Relative Strength Rating Benchmark,2017-10-06 15:48:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2Ny2LFc5T3k/flexion-therapeutics-hits-80-plus-relative-strength-rating-benchmark-cm856356,When considering what names to put on your watch list look for stocks with an 80 or higher RS Rating Flexion Therapeutics FLXN now meets that criteria with an increase from 80 to 85 Friday ibd display video id 2102289 width 50 float left autostart true IBD
LGND,LGND:US,BBG000BKF014,Stocks Showing Improving Market Leadership: Intra-Cellular Therapies Earns 83 RS Rating,2017-10-06 15:48:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mdIP0PdveBU/stocks-showing-improving-market-leadership-intra-cellular-therapies-earns-83-rs-rating-cm856355,When building your watch list look for stocks with an 80 or higher RS Rating Intra Cellular Therapies ITCI just cleared that benchmark with an upgrade from 78 to 83 ibd display video id 449433 width 50 float left autostart true This exclusive rating from Investor
LGND,LGND:US,BBG000BKF014,Stocks With Rising Relative Price Strength: Innoviva,2017-10-06 15:47:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/H8WvCVQQrrM/stocks-with-rising-relative-price-strength-innoviva-cm856348,Innoviva INVA saw a positive improvement to its Relative Strength RS Rating on Friday rising from 78 to 82 ibd display video id 449423 width 50 float left autostart true This exclusive rating from Investor s Business Daily identifies market leadership with a
LGND,LGND:US,BBG000BKF014,Stocks To Watch: Adamas Pharmaceuticals Sees Relative Strength Rating Jump To 92,2017-10-06 15:47:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/guIrSNRJUhs/stocks-to-watch-adamas-pharmaceuticals-sees-relative-strength-rating-jump-to-92-cm856341,Adamas Pharmaceuticals ADMS saw a positive improvement to its Relative Strength RS Rating on Friday with an upgrade from 87 to 92 ibd display video id 449419 width 50 float left autostart true IBD s unique rating identifies market leadership with a 1 worst
LGND,LGND:US,BBG000BKF014,Stocks With Rising Relative Strength: Amgen,2017-10-05 14:53:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JGTD2v0qZew/stocks-with-rising-relative-strength-amgen-cm855785,In a welcome move Amgen AMGN saw its Relative Strength Rating improve from 70 to 73 on Thursday ibd display video id 449433 width 50 float left autostart true This proprietary rating identifies market leadership by using a 1 worst to 99 best score that
LGND,LGND:US,BBG000BKF014,Global Blood Therapeutic Earns Relative Strength Rating Upgrade,2017-10-05 14:53:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dC2Ibj7Y5CY/global-blood-therapeutic-earns-relative-strength-rating-upgrade-cm855784,Global Blood Therapeutic GBT saw a positive improvement to its Relative Strength RS Rating on Thursday rising from 87 to 92 ibd display video id 2102289 width 50 float left autostart true This unique rating tracks technical performance by using a 1 worst to
LGND,LGND:US,BBG000BKF014,Aerie Pharmaceuticals Earns Relative Strength Rating Upgrade; Hits Key Threshold,2017-10-05 14:52:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Kc8537qcLgg/aerie-pharmaceuticals-earns-relative-strength-rating-upgrade-hits-key-threshold-cm855781,On Thursday Aerie Pharmaceuticals AERI cleared a key technical benchmark with its Relative Strength RS Rating jumping into the 80 plus percentile with an improvement to 81 a rise from 74 the day before ibd display video id 2102289 width 50 float
LGND,LGND:US,BBG000BKF014,Ligand (LGND) Signs Deal to Acquire Crystal Bioscience,2017-10-05 14:52:02 +0000,https://finance.yahoo.com/news/ligand-lgnd-signs-deal-acquire-145202978.html?.tsrc=rss,"Ligand (LGND) inked a deal to acquire Crystal Bioscience, a leader in chicken-derived fully-human antibody generation, for $25 million in cash."
LGND,LGND:US,BBG000BKF014,Stocks With Rising Relative Strength: Intra-Cellular Therapies,2017-10-05 14:50:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GhiDt7LxnUU/stocks-with-rising-relative-strength-intra-cellular-therapies-cm855750,Intra Cellular Therapies ITCI saw a welcome improvement to its Relative Strength RS Rating on Thursday rising from 70 to 78 ibd display video id 449433 width 50 float left autostart true IBD s unique rating tracks share price performance with a 1 worst to
LGND,LGND:US,BBG000BKF014,Amicus Therapeutics (FOLD) Soars: Stock Adds 9.2% in Session,2017-10-05 12:51:12 +0000,https://finance.yahoo.com/news/amicus-therapeutics-fold-soars-stock-125112562.html?.tsrc=rss,"Amicus Therapeutics (FOLD) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes."
LGND,LGND:US,BBG000BKF014,Palatin Technologies (PTN) in Focus: Stock Moves 13.2% Higher,2017-10-05 12:39:12 +0000,https://finance.yahoo.com/news/palatin-technologies-ptn-focus-stock-123912348.html?.tsrc=rss,"Palatin Technologies (PTN) was a big mover last session, as the company saw its shares rise more than 13% on the day."
LGND,LGND:US,BBG000BKF014,"Ligand to Acquire Crystal Bioscience, the Leader in Chicken-derived Fully-human Antibody Generation, for $25 Million in Cash plus Additional Potential Payments",2017-10-04 20:05:00 +0000,https://finance.yahoo.com/news/ligand-acquire-crystal-bioscience-leader-200500359.html?.tsrc=rss,"Ligand Pharmaceuticals Incorporated and Crystal Bioscience, Inc. announce the signing of a merger agreement whereby Ligand will acquire Crystal, a leader in avian genetics and the generation of fully-human therapeutic antibodies."
LGND,LGND:US,BBG000BKF014,LGND Crosses Above Average Analyst Target,2017-10-04 14:31:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hlmWoQswWS8/lgnd-crosses-above-average-analyst-target-cm855088,In recent trading shares of Ligand Pharmaceuticals Inc Symbol LGND have crossed above the average analyst 12 month target price of 136 20 changing hands for 137 17 share When a stock reaches the target an analyst has set the analyst logically has two ways to react downgrade on
LGND,LGND:US,BBG000BKF014,Catabasis Pharmaceuticals (CATB) Surges: Stock Moves 7.2% Higher,2017-10-04 12:30:12 +0000,https://finance.yahoo.com/news/catabasis-pharmaceuticals-catb-surges-stock-123012113.html?.tsrc=rss,"Catabasis Pharmaceuticals (CATB) was a big mover last session, as the company saw its shares rise more than 7% on the day amid huge volumes."
LGND,LGND:US,BBG000BKF014,Aerie Pharmaceuticals Sees IBD RS Rating Climb To 73,2017-10-03 15:02:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rRZKsx0GOPc/aerie-pharmaceuticals-sees-ibd-rs-rating-climb-to-73-cm854621,The Relative Strength RS Rating for Aerie Pharmaceuticals AERI moved into a new percentile Tuesday as it got a lift from 65 to 73 ibd display video id 449433 width 50 float left autostart true IBD s unique RS Rating identifies market leadership by
LGND,LGND:US,BBG000BKF014,Stocks Showing Rising Market Leadership: Flexion Therapeutics Earns 85 RS Rating,2017-10-03 15:01:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zIwj4I-3Cmk/stocks-showing-rising-market-leadership-flexion-therapeutics-earns-85-rs-rating-cm854615,Flexion Therapeutics FLXN saw a positive improvement to its Relative Strength RS Rating on Tuesday rising from 78 to 85 ibd display video id 449419 width 50 float left autostart true This exclusive rating from Investor s Business Daily measures share
LGND,LGND:US,BBG000BKF014,Acorda Therapeutics Shows Market Leadership With Jump To 91 RS Rating,2017-10-03 15:01:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6volWQtxWYY/acorda-therapeutics-shows-market-leadership-with-jump-to-91-rs-rating-cm854609,Acorda Therapeutics ACOR saw a welcome improvement to its Relative Strength RS Rating on Tuesday rising from 80 to 91 ibd display video id 449433 width 50 float left autostart true This exclusive rating from Investor s Business Daily tracks share price
LGND,LGND:US,BBG000BKF014,Stocks With Rising Relative Price Strength: Innoviva,2017-10-03 15:01:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Zi_sYHT9lXU/stocks-with-rising-relative-price-strength-innoviva-cm854608,The Relative Strength RS Rating for Innoviva INVA jumped into a new percentile Tuesday with an increase from 79 to 82 ibd display video id 449423 width 50 float left autostart true This exclusive rating from Investor s Business Daily tracks market
LGND,LGND:US,BBG000BKF014,"Ionis Pharmaceuticals Clears Technical Benchmark, Hitting 80-Plus RS Rating",2017-10-03 15:00:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lV3llHuggT0/ionis-pharmaceuticals-clears-technical-benchmark-hitting-80-plus-rs-rating-cm854602,One important metric to look for in a stock is an 80 or higher Relative Strength Rating Ionis Pharmaceuticals IONS cleared that benchmark Tuesday with a jump from 74 to 82 Tuesday ibd display video id 449419 width 50 float left autostart true IBD s unique RS
LGND,LGND:US,BBG000BKF014,MannKind (MNKD) in Focus: Stock Moves 7.8% Higher,2017-10-03 12:49:12 +0000,https://finance.yahoo.com/news/mannkind-mnkd-focus-stock-moves-124912124.html?.tsrc=rss,"MannKind (MNKD) shares rose nearly 8% in the last trading session, amid huge volumes."
LGND,LGND:US,BBG000BKF014,"ETFs with exposure to Ligand Pharmaceuticals, Inc. : October 2, 2017",2017-10-02 14:56:06 +0000,http://finance.yahoo.com/r/3023294b-9439-31ec-a5a0-0715d1fa08e9/etfs-with-exposure-to-ligand-pharmaceuticals-inc-october-2-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Ligand Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to LGND-US. Comparing the performance and risk of Ligand Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
LGND,LGND:US,BBG000BKF014,See what the IHS Markit Score report has to say about Ligand Pharmaceuticals Inc.,2017-10-02 12:06:41 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120641850.html?.tsrc=rss,Ligand Pharmaceuticals Inc NASDAQ NMS:LGND
LGND,LGND:US,BBG000BKF014,Flexion Therapeutics Sees Relative Strength Rating Improve To 75,2017-09-29 14:38:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KrGJhZAgoEQ/flexion-therapeutics-sees-relative-strength-rating-improve-to-75-cm853122,The Relative Strength RS Rating for Flexion Therapeutics FLXN entered a higher percentile Friday as it got a lift from 69 to 75 ibd display video id 2102289 width 50 float left autostart true This proprietary rating tracks technical performance by using a
LGND,LGND:US,BBG000BKF014,Ionis Pharmaceuticals Hits 80-Plus Relative Strength Rating Benchmark,2017-09-29 14:38:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HnMtzplTfU0/ionis-pharmaceuticals-hits-80-plus-relative-strength-rating-benchmark-cm853118,When building your watch list focus on stocks with an 80 or higher RS Rating Ionis Pharmaceuticals IONS now meets that criteria with an increase from 75 to 81 Friday ibd display video id 2102289 width 50 float left autostart true This proprietary rating
LGND,LGND:US,BBG000BKF014,Adamas Pharmaceuticals Hits 80-Plus Relative Strength Rating Benchmark,2017-09-29 14:36:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DLRGQQPPx1A/adamas-pharmaceuticals-hits-80-plus-relative-strength-rating-benchmark-cm853090,One important metric to look for in a stock is an 80 or higher Relative Strength Rating Adamas Pharmaceuticals ADMS just hit that mark with a jump from 79 to 84 Friday ibd display video id 449433 width 50 float left autostart true IBD s proprietary RS Rating
LGND,LGND:US,BBG000BKF014,Stocks Flashing Renewed Technical Strength: Acceleron Pharma,2017-09-29 14:35:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/W8XKA7lNm1E/stocks-flashing-renewed-technical-strength-acceleron-pharma-cm853086,The Relative Strength RS Rating for Acceleron Pharma XLRN climbed into a new percentile Friday with an increase from 79 to 84 ibd display video id 449423 width 50 float left autostart true This exclusive rating from Investor s Business Daily identifies
LGND,LGND:US,BBG000BKF014,Ligand&apos;s Captisol Deals Set to Drive Growth in the Long Run,2017-09-29 13:25:01 +0000,https://finance.yahoo.com/news/ligand-apos-captisol-deals-set-132501020.html?.tsrc=rss,"Ligand&apos;s (LGND) Captisol formulation technology platform allows it to partner with several leading drug companies, thus helping it earn milestones and royalty payments in turn."
LGND,LGND:US,BBG000BKF014,"Ligand Pharmaceuticals, Inc. :LGND-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017",2017-09-29 13:03:37 +0000,http://finance.yahoo.com/r/5fd20e6a-2563-3368-929c-6ffe7cd150de/ligand-pharmaceuticals-inc-lgnd-us-earnings-analysis-q2-2017-by-the-numbers-september-29-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis Ligand Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 28.00 million, Net Earnings of USD 6.06 million. Gross margins widened from 82.58% to 87.54% compared to the same period last year, operating (EBITDA) margins now 56.16% from 36.66%. Change in operating ... Read more
<b>(Read more...)</b>"
LGND,LGND:US,BBG000BKF014,"Ligand Pharma, Chipotle Mexican Grill, Arcelormittal, Ichor Holdings  and Micron Technology  highlighted as Zacks Bull and Bear of the Day",2017-09-27 16:53:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cfTEnVYMtfg/ligand-pharma-chipotle-mexican-grill-arcelormittal-ichor-holdings-and-micron-technology-highlighted-as-zacks-bull-and-bear-of-the-day-cm851933,For Immediate Release Chicago IL September 27 2017 Zacks Equity Research Ligand Pharma Nasdaq 160 LGND 160 Free Report as the Bull of the Day Chipotle Mexican Grill NYSE 160 CMG 160 Free Report as the Bear of the Day In addition Zacks Equity Research
LGND,LGND:US,BBG000BKF014,"Ligand Pharma, Chipotle Mexican Grill, Arcelormittal, Ichor Holdings and Micron Technology highlighted as Zacks Bull and Bear of the Day",2017-09-27 15:14:03 +0000,https://finance.yahoo.com/news/ligand-pharma-chipotle-mexican-grill-151403845.html?.tsrc=rss,"Ligand Pharma, Chipotle Mexican Grill, Arcelormittal, Ichor Holdings and Micron Technology highlighted as Zacks Bull and Bear of the Day"
LGND,LGND:US,BBG000BKF014,Bull of the Day: Ligand Pharma (LGND),2017-09-27 13:55:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3E2v2kndnyE/bull-of-the-day-ligand-pharma-lgnd-cm851781,One of the hottest areas of the market has been the drug stocks Over the last month alone there are five drug stocks in the S amp P 500 that are up over 10 With so many stocks on the move you may feel like you ve missed the boat Today s Bull of the Day is a stock in this industry which
LGND,LGND:US,BBG000BKF014,Bull of the Day: Ligand Pharma (LGND),2017-09-27 11:00:11 +0000,https://finance.yahoo.com/news/bull-day-ligand-pharma-lgnd-110011650.html?.tsrc=rss,Bull of the Day: Ligand Pharma (LGND)
LGND,LGND:US,BBG000BKF014,Aimmune Therapeutics (AIMT) in Focus: Stock Moves 6.3% Higher,2017-09-26 14:57:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OFZpbN7lwbE/aimmune-therapeutics-aimt-in-focus-stock-moves-63-higher-cm850970,Aimmune Therapeutics Inc AIMT was a big mover last session as the company saw its shares rise more than 6 on the day The move came on solid volume too with far more shares changing hands than in a normal session This continues the recent uptrend for the company as the stock is now up 25
LGND,LGND:US,BBG000BKF014,Ascendis Pharma (ASND) Looks Good: Stock Adds 5.5% in Session,2017-09-26 14:56:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4FJb2ilDh34/ascendis-pharma-asnd-looks-good-stock-adds-55-in-session-cm850961,Ascendis Pharma A S ASND was a big mover last session as the company saw its shares rise nearly 6 on the day The move came on solid volume too with far more shares changing hands than in a normal session This breaks the recent trend of the company as the stock is now trading above
LGND,LGND:US,BBG000BKF014,Ascendis Pharma (ASND) Looks Good: Stock Adds 5.5% in Session,2017-09-26 12:50:12 +0000,https://finance.yahoo.com/news/ascendis-pharma-asnd-looks-good-125012031.html?.tsrc=rss,"Ascendis Pharma (ASND) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes."
LGND,LGND:US,BBG000BKF014,Aimmune Therapeutics (AIMT) in Focus: Stock Moves 6.3% Higher,2017-09-26 12:43:12 +0000,https://finance.yahoo.com/news/aimmune-therapeutics-aimt-focus-stock-124312779.html?.tsrc=rss,"Aimmune Therapeutics (AIMT) shares rose more than 6% in the last trading session, amid huge volumes."
LGND,LGND:US,BBG000BKF014,Ligand to Host Analyst Day on November 14th in New York City,2017-09-25 13:00:00 +0000,https://finance.yahoo.com/news/ligand-host-analyst-day-november-130000846.html?.tsrc=rss,"Ligand Pharmaceuticals Incorporated will host an Analyst Day on Tuesday, November 14, 2017 from 4:00 p.m. to 5:30 p.m. Eastern time in New York City."
LGND,LGND:US,BBG000BKF014,3 Stocks With Nike-Like Return Potential,2017-09-24 01:47:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/k6Qr--uHFnE/3-stocks-with-nike-like-return-potential-cm850081,Sportswear and athletic shoe giant Nike NYSE NKE 160 has created a lot of wealth over the years Early investors have enjoyed an eye popping 29 500 return in 37 years or roughly 17 per year Nike shares have also nearly tripled over the last decade and more than doubled in
LGND,LGND:US,BBG000BKF014,3 Stocks With Nike-Like Return Potential,2017-09-24 00:21:00 +0000,http://finance.yahoo.com/r/505eaac3-c611-3b61-9b7e-15c0d92531c3/3-stocks-with-nike-like-return-potential.aspx?yptr=yahoo&.tsrc=rss,It is almost impossible to find stocks that can match the shoe giant&apos;s outsized returns over the long haul -- but these three tickers might actually come close.
LGND,LGND:US,BBG000BKF014,"Alcoa, Cheesecake Factory, Luminex, Ligand Pharmaceuticals and Centene highlighted as Zacks Bull and Bear of the Day",2017-09-20 15:42:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pYRJVUyXDpQ/alcoa-cheesecake-factory-luminex-ligand-pharmaceuticals-and-centene-highlighted-as-zacks-bull-and-bear-of-the-day-cm848348,For Immediate Release Chicago IL September 20 2017 Zacks Equity Research Alcoa NYSE 160 AA 160 Free Report as the Bull of the Day Cheesecake Factory Nasdaq 160 CAKE Free Report as the Bear of the Day In addition Zacks Equity Research provides analysis on
LGND,LGND:US,BBG000BKF014,"Alcoa, Cheesecake Factory, Luminex, Ligand Pharmaceuticals and Centene highlighted as Zacks Bull and Bear of the Day",2017-09-20 13:53:01 +0000,https://finance.yahoo.com/news/alcoa-cheesecake-factory-luminex-ligand-135301124.html?.tsrc=rss,"Alcoa, Cheesecake Factory, Luminex, Ligand Pharmaceuticals and Centene highlighted as Zacks Bull and Bear of the Day"
LGND,LGND:US,BBG000BKF014,3 Healthcare Stocks to Buy on Renewed Obamacare Repeal Talks,2017-09-19 21:36:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YwFGd7ozUks/3-healthcare-stocks-to-buy-on-renewed-obamacare-repeal-talks-cm848021,Healthcare has been a newsworthy topic for decades and that is unlikely to cease anytime soon as the Republican effort to repeal and replace the Affordable Care Act or Obamacare ramps up ahead of a key Sept 30 deadline One of the most recent bills from Republican Sens Lindsey Graham
LGND,LGND:US,BBG000BKF014,3 Healthcare Stocks to Buy on Renewed Obamacare Repeal Talks,2017-09-19 19:41:07 +0000,https://finance.yahoo.com/news/3-healthcare-stocks-buy-renewed-194107285.html?.tsrc=rss,"Healthcare has been a newsworthy topic for decades, and that is unlikely to cease anytime soon as the Republican effort to repeal and replace the Affordable Care Act, or Obamacare, ramps up ahead of a key Sept. 30 deadline."
LGND,LGND:US,BBG000BKF014,Glaxo's Shingles Candidate Gets Positive FDA Committee Vote,2017-09-14 17:38:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PTYsiVXTvO8/glaxos-shingles-candidate-gets-positive-fda-committee-vote-cm845841,GlaxoSmithKline plc GSK recently announced that an FDA advisory panel has unanimously voted recommending approval for its shingles vaccine candidate Shingrix in older patients Glaxo said the FDA s Vaccines and Related Biological Products Advisory Committee were impressed by
LGND,LGND:US,BBG000BKF014,Glaxo&apos;s Shingles Candidate Gets Positive FDA Committee Vote,2017-09-14 15:25:03 +0000,https://finance.yahoo.com/news/glaxo-apos-shingles-candidate-gets-152503006.html?.tsrc=rss,"Glaxo (GSK) declared that an FDA advisory panel has unanimously voted recommending approval for its shingles vaccine candidate, Shingrix, in older patients."
LGND,LGND:US,BBG000BKF014,Pfizer Lung Cancer Drug's Overall Survival Data Unfavorable,2017-09-12 16:39:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/L4bkJOC_IbU/pfizer-lung-cancer-drugs-overall-survival-data-unfavorable-cm844436,Pfizer Inc PFE announced final overall survival data from a phase III study PROFILE 1014 evaluating its cancer drug Xalkori for first line treatment of ALK positive non small cell lung cancer NSCLC Xalkori is currently approved for the treatment of ALK or ROS1 positive locally
LGND,LGND:US,BBG000BKF014,5 Top-Ranked Biotech Stocks to Buy Right Now,2017-09-11 15:41:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mxrvHm0Xspo/5-top-ranked-biotech-stocks-to-buy-right-now-cm843699,Biotech stocks are back in favor thanks to two recent major developments that led to a rally in the sector The first catalyst was Gilead Sciences GILD announcement that it will be acquiring immunotherapy focused company Kite Pharma KITE while the FDA approval of the first gene therapy in
LGND,LGND:US,BBG000BKF014,5 Top-Ranked Biotech Stocks to Buy Right Now,2017-09-11 13:33:01 +0000,https://finance.yahoo.com/news/5-top-ranked-biotech-stocks-133301388.html?.tsrc=rss,"If you are looking to invest in the biotech sector, here is a peek at 5 buy-ranked biotech stocks including Regeneron Pharmaceuticals (REGN)."
LGND,LGND:US,BBG000BKF014,See what the IHS Markit Score report has to say about Ligand Pharmaceuticals Inc.,2017-09-11 12:01:33 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120133534.html?.tsrc=rss,Ligand Pharmaceuticals Inc NASDAQ NMS:LGND
LGND,LGND:US,BBG000BKF014,4 Biotech Stocks to Improve Your Portfolio’s Health,2017-09-08 22:53:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/v0JK55zhpU8/4-biotech-stocks-to-improve-your-portfolios-health-cm843236,InvestorPlace Stock Market News Stock Advice amp Trading Tips The pharmaceuticals and biotech industry has been blessed with good health so far this year The sector has recovered from the pricing controversy of 2016 and defied uncertainties surrounding President Trump s
LGND,LGND:US,BBG000BKF014,"Alnylam Shares Plunge on Patient Death, Dosing Suspended",2017-09-08 15:55:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dMaS-fS3ENA/alnylam-shares-plunge-on-patient-death-dosing-suspended-cm842932,Alnylam Pharmaceuticals Inc s ALNY shares plunged 15 7 on Thursday in response to a death event reported by the company in an open label extension phase II study on fitusiran Alnylam has stopped dosing in all ongoing studies on its hemophilia candidate fitusiran following the fatal
LGND,LGND:US,BBG000BKF014,"Lilly to Cut 3,500 Jobs to Invest in New Drugs and Growth",2017-09-08 15:55:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4ELjzSz_DaM/lilly-to-cut-3500-jobs-to-invest-in-new-drugs-and-growth-cm842928,Eli Lilly amp Company LLY announced plans on Thursday to reduce its global workforce by approximately 3 500 positions These initiatives are expected to amass annualized savings of approximately 500 million beginning 2018 The drug giant plans to invest the savings in new drugs and
LGND,LGND:US,BBG000BKF014,"Lilly to Cut 3,500 Jobs to Invest in New Drugs and Growth",2017-09-08 13:54:01 +0000,https://finance.yahoo.com/news/lilly-cut-3-500-jobs-135401853.html?.tsrc=rss,"Lilly (LLY) plans to reduce its global workforce by approximately 3,500 positions, which should save $500 million. Lilly plans to invest the savings in new drugs and overall growth of the company."
LGND,LGND:US,BBG000BKF014,"Alnylam Shares Plunge on Patient Death, Dosing Suspended",2017-09-08 13:53:01 +0000,https://finance.yahoo.com/news/alnylam-shares-plunge-patient-death-135301488.html?.tsrc=rss,"Alnylam (ALNY) announced suspension of dosing in all ongoing studies on its hemophilia candidate, fitusiran, following a patient&apos;s death in a phase II study."
LGND,LGND:US,BBG000BKF014,Ligand (LGND) Up 9.6% Since Earnings Report: Can It Continue?,2017-09-07 08:52:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vyVVd6g8Jc8/ligand-lgnd-up-96-since-earnings-report-can-it-continue-cm842035,It has been about a month since the last earnings report for Ligand Pharmaceuticals Incorporated LGND Shares have added about 9 6 in that time frame outperforming the market Will the recent positive trend continue leading up to the stock s next earnings release or is it due for a
LGND,LGND:US,BBG000BKF014,Ligand (LGND) Up 9.6% Since Earnings Report: Can It Continue?,2017-09-07 07:10:07 +0000,https://finance.yahoo.com/news/ligand-lgnd-9-6-since-071007600.html?.tsrc=rss,Ligand (LGND) reported earnings 30 days ago. What&apos;s next for the stock? We take a look at earnings estimates for some clues.
LGND,LGND:US,BBG000BKF014,Captisol-Enabled Prexasertib May Be Major Growth Driver for Ligand,2017-09-06 21:36:41 +0000,http://finance.yahoo.com/r/ac5a5145-cbe0-32ea-8be0-6775333230bf/captisol-enabled-prexasertib-may-prove-major-growth-driver-ligand-pharmaceuticals?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Eli Lilly’s (LLY) Captisol-enabled drug Prexasertib is currently being evaluated in multiple oncology indications such as head and neck cancer, small-cell lung cancer (or SCLC), and advanced metastatic ..."
LGND,LGND:US,BBG000BKF014,Brexanolone Could Strengthen Ligand’s Neurology Portfolio,2017-09-06 20:05:48 +0000,http://finance.yahoo.com/r/ade79c56-a851-3e24-b321-6a8805521087/brexanolone-expected-strengthen-ligand-pharmaceuticals-neurology-portfolio?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Sage Therapeutics is also exploring Brexanolone in moderate and severe post-partum depression (or PPD) patients in two separate Phase 3 trials.
LGND,LGND:US,BBG000BKF014,Sparsentan May Be Solid Near-Term Growth Driver for Ligand,2017-09-06 18:20:08 +0000,http://finance.yahoo.com/r/946f3152-eb21-387a-b1b0-67622ecf524c/sparsentan-may-prove-solid-near-term-growth-driver-ligand-pharmaceuticals?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"With Sparsentan, Retrophin and Ligand Pharmaceuticals could become major nephrology players similar to peers such as Amgen (AMGN), AstraZeneca (AZN), and Bristol-Myers Squibb (BMY)."
LGND,LGND:US,BBG000BKF014,Ligand (LGND) Diabetes Candidate Positive in Phase II Study,2017-09-06 15:56:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uHP3XhvvZQU/ligand-lgnd-diabetes-candidate-positive-in-phase-ii-study-cm841603,Ligand Pharmaceuticals Incorporated LGND announced positive top line results from a phase II study evaluating its diabetes candidate LGD 6972 The study achieved a statistically significant change in hemoglobin A1c HbA1c a measure of blood glucose from baseline after 12 weeks of
LGND,LGND:US,BBG000BKF014,Ligand (LGND) Diabetes Candidate Positive in Phase II Study,2017-09-06 14:03:02 +0000,https://finance.yahoo.com/news/ligand-lgnd-diabetes-candidate-positive-140302194.html?.tsrc=rss,"Ligand&apos;s (LGND) diabetes candidate, LGD-6972, demonstrated a change of statistical significance in blood glucose level (HbA1c) from baseline over a treatment period of 12 weeks."
LGND,LGND:US,BBG000BKF014,"Biotech Stock Roundup: Cellectis Down on Clinical Hold, Insmed Soars on Positive Data",2017-09-06 13:54:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Y3pWS9mQ1Ck/biotech-stock-roundup-cellectis-down-on-clinical-hold-insmed-soars-on-positive-data-cm841553,It was a relatively slow week for the biotech sector though key pipeline updates were provided by companies like Cellectis CLLS and Insmed INSM While Insmed skyrocketed on positive data on its lead pipeline candidate Cellectis was hit by a clinical hold on a couple of phase I
LGND,LGND:US,BBG000BKF014,Insmed Incorporated (INSM) Catches Eye: Stock Soars 119.6%,2017-09-06 13:54:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/D1WtCIObAEE/insmed-incorporated-insm-catches-eye-stock-soars-1196-cm841551,Insmed Incorporated INSM was a big mover last session as the company saw its shares rise nearly 120 on the day The move came on solid volume too with far more shares changing hands than in a normal session The stock picked up sharply from the near flat trend of 11 61 to 13 46 in the
LGND,LGND:US,BBG000BKF014,"Biotech Stock Roundup: Cellectis Down on Clinical Hold, Insmed Soars on Positive Data",2017-09-06 12:29:12 +0000,https://finance.yahoo.com/news/biotech-stock-roundup-cellectis-down-122912750.html?.tsrc=rss,Key highlights include pipeline updates from companies like Cellectis (CLLS) and Insmed. Insmed&apos;s shares skyrocketed on positive data from a late-stage study.
LGND,LGND:US,BBG000BKF014,"MDXG Revises Q3 Outlook, Two Down, One To Go For BLPH, TECH Opens Wallet",2017-09-06 02:12:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CyJAwP8WeIE/mdxg-revises-q3-outlook-two-down-one-to-go-for-blph-tech-opens-wallet-20170906-00050,"MDXG Revises Q3 Outlook, Two Down, One To Go For BLPH, TECH Opens Wallet"
LGND,LGND:US,BBG000BKF014,4 Biotech Stocks to Improve Your Portfolio's Health,2017-09-05 20:52:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xK-Nz0BrpNg/4-biotech-stocks-to-improve-your-portfolios-health-cm841215,The pharmaceuticals and biotech industry has been blessed with good health so far this year The sector has recovered from the pricing controversy of 2016 and defied uncertainties surrounding President Trump s proposed healthcare policy The NYSE ARCA Pharmaceutical Index has risen almost 9
LGND,LGND:US,BBG000BKF014,4 Biotech Stocks to Improve Your Portfolio&apos;s Health,2017-09-05 18:26:06 +0000,https://finance.yahoo.com/news/4-biotech-stocks-improve-portfolio-182606313.html?.tsrc=rss,"The biotech industry has posted a turnaround in the first half of the year, despite facing pricing issues in 2016."
LGND,LGND:US,BBG000BKF014,Analyst Makes The Case For Ligand As A 'Core' Holding,2017-09-05 12:49:59 +0000,https://finance.yahoo.com/news/analyst-makes-case-ligand-core-124959121.html?.tsrc=rss,"Analysts at H.C. Wainwright & Co. continue to see Ligand Pharmaceuticals Inc. (NASDAQ: LGND ) as a ""core long term holding"" for investors. The firm's Joseph Pantginis initiated coverage of the ..."
LGND,LGND:US,BBG000BKF014,Ligand Announces Top-Line Results from Phase 2 Study of LGD-6972 in Patients with Type 2 Diabetes,2017-09-05 12:00:00 +0000,https://finance.yahoo.com/news/ligand-announces-top-line-results-120000318.html?.tsrc=rss,"Ligand Pharmaceuticals Incorporated today announced positive top-line results from a Phase 2 clinical study evaluating the efficacy and safety of LGD-6972, as an adjunct to diet and exercise, in subjects with type 2 diabetes mellitus inadequately controlled on metformin monotherapy."
LGND,LGND:US,BBG000BKF014,Ligand Reports Phase 2 Study Results Of LGD-6972 In Patients With Type2 Diabetes,2017-09-05 08:16:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/K7Cw2qiJSMI/ligand-reports-phase-2-study-results-of-lgd6972-in-patients-with-type2-diabetes-20170905-00642,Ligand Reports Phase 2 Study Results Of LGD-6972 In Patients With Type2 Diabetes
LGND,LGND:US,BBG000BKF014,Baxdela Is Expected to Boost Ligand Pharmaceuticals’ Revenues,2017-09-04 11:37:21 +0000,http://finance.yahoo.com/r/6de08275-32ea-36cd-a13f-cb02d53a5bca/baxdela-expected-boost-ligand-pharmaceuticals-revenues-future-years?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"On June 19, 2017, Melinta Therapeutics announced that its drug, Baxdela, had secured regulatory approval from the FDA as a treatment option for adult patients suffering from acute bacterial skin and skin ..."
LGND,LGND:US,BBG000BKF014,See what the IHS Markit Score report has to say about Ligand Pharmaceuticals Inc.,2017-09-02 12:11:18 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-121118567.html?.tsrc=rss,"Index (PMI) data, output in the Healthcare sector is rising.  To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way."
LGND,LGND:US,BBG000BKF014,Amgen Gets EU Nod to Expand Hyperparathyroidism Drug Label,2017-09-01 17:51:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/W4SKhsccWS0/amgen-gets-eu-nod-to-expand-hyperparathyroidism-drug-label-cm840389,Amgen Inc AMGN announced that the European Commission has approved the marketing application for a pediatric formulation granules in capsule for opening of Mimpara for the treatment of secondary hyperparathyroidism sHPT With this approval the drug s label has been expanded to include
LGND,LGND:US,BBG000BKF014,Amgen Gets EU Nod to Expand Hyperparathyroidism Drug Label,2017-09-01 15:11:03 +0000,https://finance.yahoo.com/news/amgen-gets-eu-nod-expand-151103031.html?.tsrc=rss,The European Commission approves Amgen&apos;s (AMGN) marketing application for Mimpara&apos;s pediatric formulation to heal secondary hyperparathyroidism (HPT).
LGND,LGND:US,BBG000BKF014,Evomela’s Market Share Is Increasing in 2017,2017-09-01 14:38:08 +0000,http://finance.yahoo.com/r/a775b407-1d9b-3fd7-b0f1-5927b66b88cb/evomela-continues-witness-increase-market-share-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 2Q17, Evomela reported revenues of ~$10.1 million, which is the highest quarterly revenue figure reported by the drug since its commercial launch in 2016."
LGND,LGND:US,BBG000BKF014,Ligand Pharmaceuticals Projects Higher Average Royalty Rate for Promacta,2017-09-01 14:36:19 +0000,http://finance.yahoo.com/r/70f4dfde-a72a-3d41-a30a-aab47cfc003d/ligand-pharmaceuticals-projected-higher-average-royalty-rate-promacta-future-years?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Ligand Pharmaceuticals (LGND) receives royalties from Novartis on Promacta’s sales according to a tiered annual payment structure.
LGND,LGND:US,BBG000BKF014,Label Expansion Could Boost Promacta’s Revenues Going Forward,2017-09-01 13:09:01 +0000,http://finance.yahoo.com/r/2589af3e-e863-38e4-8285-787819ff750a/label-expansion-may-boost-promactas-revenues-future-years?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"To boost Promacta’s revenues, Novartis (NVS) is evaluating the potential of the drug in 35 ongoing clinical trials, mainly for oncology-related thrombocytopenia."
LGND,LGND:US,BBG000BKF014,Promacta: A Major Growth Driver for Ligand Pharmaceuticals in 2017,2017-09-01 13:06:33 +0000,http://finance.yahoo.com/r/2d1c81c2-feae-3ecf-8367-1cfe99d160ea/promacta-continues-major-growth-driver-ligand-pharmaceuticals-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Promacta was discovered by Ligand Pharmaceuticals (LGND) and GlaxoSmithKline (GSK) as a part of their thrombopoietin (or TPO) receptor agonist research collaboration.
LGND,LGND:US,BBG000BKF014,Ligand to Participate in Two Upcoming Investor Conferences,2017-09-01 13:00:00 +0000,https://finance.yahoo.com/news/ligand-participate-two-upcoming-investor-130000214.html?.tsrc=rss,Ligand Pharmaceuticals Incorporated announces that company executives are scheduled to participate in the following upcoming investor conferences:
LGND,LGND:US,BBG000BKF014,Ligand Pharmaceuticals Focuses on Increasing Returns for Shareholders,2017-09-01 11:36:41 +0000,http://finance.yahoo.com/r/47c644c8-feee-30ec-84c9-4d56b6218e1a/ligand-pharmaceuticals-focused-increasing-returns-shareholders-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Ligand Pharmaceuticals has developed a product portfolio that spans more than 700 patents offering varying degrees of protection to the assets.
LGND,LGND:US,BBG000BKF014,Kyprolis: A Major Growth Driver for Ligand Pharmaceuticals in 2017,2017-09-01 01:40:09 +0000,http://finance.yahoo.com/r/5df841fe-6789-3f22-aebf-1483f9f609ad/kyprolis-expected-prove-major-growth-driver-ligand-pharmaceuticals-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Royalties paid to Ligand Pharmaceuticals (LGND) based on the sales of Amgen’s (AMGN) Kyprolis are a major revenue driver for the company. In 2Q17, LGND earned royalties of ~$222 million on Kyprolis’ sales...."
LGND,LGND:US,BBG000BKF014,Technology Platforms and Research Programs Drive LGND’s Partnerships,2017-08-31 14:36:54 +0000,http://finance.yahoo.com/r/a65c2933-363a-3c61-8535-03c1949a40b3/technology-platforms-research-programs-drive-ligand-pharmaceuticals-partnerships-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Ligand Pharmaceuticals (LGND) has entered multiple fully funded partnerships by licensing its technology platforms such as OmniAb, Captisol, LTP Technology, and SUREtechnology Platform."
LGND,LGND:US,BBG000BKF014,Fully Funded Partnerships May Drive Growth for Ligand Pharmaceuticals,2017-08-31 13:07:08 +0000,http://finance.yahoo.com/r/72ebfca9-4d0b-33da-8a71-aafaf0f07c34/fully-funded-partnerships-may-drive-growth-ligand-pharmaceuticals-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Ligand Pharmaceuticals (LGND) expects its licensees to invest ~$2.0 billion for advancing more than 155 partnered research and development programs in 2017.
LGND,LGND:US,BBG000BKF014,Ligand Pharmaceuticals’ Shots-on-Goal Business Model,2017-08-31 11:37:38 +0000,http://finance.yahoo.com/r/763563e3-2882-3064-b2e4-ac756481c7e7/shots-goal-business-model-increased-capital-cost-efficiency-ligand-pharmaceuticals?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Ligand Pharmaceuticals (LGND) has developed a business model called Shots-on-Goal, which is based on fully funded partnerships."
LGND,LGND:US,BBG000BKF014,Top Ranked Momentum Stocks to Buy for August 30th,2017-08-30 15:54:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/11k3B56IqoQ/top-ranked-momentum-stocks-to-buy-for-august-30th-cm839267,Here are four stocks with buy rank and strong momentum characteristics for investors to consider today August 30th Tilly s Inc TLYS This apparel and footwear retailer has a Zacks Rank 2 Buy and witnessed the Zacks Consensus Estimate for its current year earnings rising 17 8 over
LGND,LGND:US,BBG000BKF014,Ligand Pharmaceuticals’ Net Profit Margins Could Rise in 2017,2017-08-30 14:37:45 +0000,http://finance.yahoo.com/r/a987389b-7567-3058-a078-4a931661421b/ligand-pharmaceuticals-may-report-solid-rise-net-profit-margins-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In its 2Q17 earnings conference call, Ligand Pharmaceuticals (LGND) projected its fiscal 2017 adjusted diluted earnings per share (or EPS) to be ~$2.93."
LGND,LGND:US,BBG000BKF014,Top Ranked Momentum Stocks to Buy for August 30th,2017-08-30 13:16:01 +0000,https://finance.yahoo.com/news/top-ranked-momentum-stocks-buy-131601579.html?.tsrc=rss,Top Ranked Momentum Stocks to Buy for August 30th
LGND,LGND:US,BBG000BKF014,Ligand Pharmaceuticals Expected to Report Robust Revenue Growth in 2017,2017-08-30 13:08:53 +0000,http://finance.yahoo.com/r/e979d88b-9329-3ab5-9bee-6e442bf4ec08/ligand-pharmaceuticals-expected-report-robust-revenue-growth-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"During its 2Q17 earnings conference call, Ligand Pharmaceuticals (LGND) updated its fiscal 2017 revenue guidance from $132 million to $133 million."
LGND,LGND:US,BBG000BKF014,Analysts’ Recommendations for Ligand Pharmaceuticals and Peers in 2017,2017-08-30 11:38:05 +0000,http://finance.yahoo.com/r/a3e078e3-9a65-3ea5-bdbf-a4f8f0ab25ce/analysts-recommendations-ligand-pharmaceuticals-peers-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 2Q17, Ligand Pharmaceuticals (LGND) reported revenues of ~$28.0 million, representing year-over-year growth of ~43.4%. LGND received ~$14.2 million in royalties, a year-over-year rise of 45.7%."
LGND,LGND:US,BBG000BKF014,3 Reasons Why Ligand Pharmaceuticals (LGND) is a Great Momentum Stock,2017-08-29 14:54:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/G31NvBGOxkQ/3-reasons-why-ligand-pharmaceuticals-lgnd-is-a-great-momentum-stock-cm838514,Many investors like to look for momentum in stocks but this can be very tough to define There is great debate regarding which metrics are the best to focus on in this regard and which are not really quality indicators of future performance Fortunately with our new style score system we
LGND,LGND:US,BBG000BKF014,3 Reasons Why Ligand Pharmaceuticals (LGND) is a Great Momentum Stock,2017-08-29 12:51:12 +0000,https://finance.yahoo.com/news/3-reasons-why-ligand-pharmaceuticals-125112107.html?.tsrc=rss,Momentum Stock Investors Will Love Ligand Pharmaceuticals (LGND) seeing its favorable price performance both in short and long term.
LGND,LGND:US,BBG000BKF014,Vertex's Cystic Fibrosis Combo Gets Priority Review in U.S.,2017-08-25 16:41:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/k1QgDXo3Fvg/vertexs-cystic-fibrosis-combo-gets-priority-review-in-us-cm837196,Vertex Pharmaceuticals Incorporated VRTX announced that its regulatory applications for tezacaftor ivacaftor Kalydeco combination have been accepted by the FDA and the European Medicines Agency EMA for review The regulatory applications have been filed to seek approval of Kalydeco
LGND,LGND:US,BBG000BKF014,See what the IHS Markit Score report has to say about Ligand Pharmaceuticals Inc.,2017-08-25 12:02:12 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120212423.html?.tsrc=rss,Ligand Pharmaceuticals Inc NASDAQ NMS:LGND
LGND,LGND:US,BBG000BKF014,4 Biotech Stocks to Add to your Portfolio Post Q2 Earnings,2017-08-22 14:10:02 +0000,https://finance.yahoo.com/news/4-biotech-stocks-add-portfolio-141002250.html?.tsrc=rss,Here is a look at four biotech stocks including Gilead (GILD) that topped estimates in Q2 and are witnessing upward estimate revisions for the current year.
LGND,LGND:US,BBG000BKF014,Ligand Appoints Dr. Nancy Gray to its Board of Directors,2017-08-21 13:00:00 +0000,https://finance.yahoo.com/news/ligand-appoints-dr-nancy-gray-130000218.html?.tsrc=rss,"Ligand Pharmaceuticals Incorporated announces the appointment of Nancy Ryan Gray, Ph.D. to the Company’s Board of Directors, effective today."
LGND,LGND:US,BBG000BKF014,Strength Seen in Myovant Sciences (MYOV): Stock Soars 16.1%,2017-08-18 15:43:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jpYM1FPdIa4/strength-seen-in-myovant-sciences-myov-stock-soars-161-cm833939,Myovant Sciences Ltd MYOV was a big mover last session as the company saw its shares rise over 16 on the day The move came on solid volume too with far more shares changing hands than in a normal session This stock which remained volatile and traded within the range of 9 93 12 04 in
LGND,LGND:US,BBG000BKF014,Ligand to Receive $2 Million from WuXi Biologics for Licensing Clinical-Stage anti-PD-1 Antibody Discovered Using the OmniAb® Technology,2017-08-18 13:00:00 +0000,https://finance.yahoo.com/news/ligand-receive-2-million-wuxi-130000488.html?.tsrc=rss,"Ligand Pharmaceuticals Incorporated announces that it will receive a $2 million payment from WuXi Biologics subsequent to their licensing of exclusive rights to the anti-PD-1 antibody GLS-010 to Arcus Biosciences in North America, Europe, Japan and certain other territories."
LGND,LGND:US,BBG000BKF014,Strength Seen in Myovant Sciences (MYOV): Stock Soars 16.1%,2017-08-18 12:58:12 +0000,https://finance.yahoo.com/news/strength-seen-myovant-sciences-myov-125812768.html?.tsrc=rss,"Myovant Sciences Ltd. (MYOV) was a big mover last session, as the company saw its shares rise over 16% on the day."
LGND,LGND:US,BBG000BKF014,See what the IHS Markit Score report has to say about Ligand Pharmaceuticals Inc.,2017-08-16 12:02:09 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120209010.html?.tsrc=rss,Ligand Pharmaceuticals Inc NASDAQ NMS:LGND
LGND,LGND:US,BBG000BKF014,Can Ligand's Captisol Deals Boost Growth in the Long Run?,2017-08-15 16:39:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/L-mwemjVgzw/can-ligands-captisol-deals-boost-growth-in-the-long-run-cm832301,On Aug 14 2017 we issued an updated report on Ligand Pharmaceuticals Incorporated LGND Ligand s Captisol formulation technology platform has allowed it to enter into partnerships with several leading drug companies like Novartis AG NVS Merck amp Co Inc MRK and Amgen Inc
LGND,LGND:US,BBG000BKF014,Can Ligand&apos;s Captisol Deals Boost Growth in the Long Run?,2017-08-15 14:09:02 +0000,https://finance.yahoo.com/news/ligand-apos-captisol-deals-boost-140902617.html?.tsrc=rss,"Ligand&apos;s (LGND) Captisol formulation technology platform allows it to partner with several leading drug companies, earning milestones and royalty payments from the same."
LGND,LGND:US,BBG000BKF014,Edited Transcript of LGND earnings conference call or presentation 9-May-17 8:30pm GMT,2017-08-13 02:15:53 +0000,https://finance.yahoo.com/news/edited-transcript-lgnd-earnings-conference-015229668.html?.tsrc=rss,Q1 2017 Ligand Pharmaceuticals Inc Earnings Call
LGND,LGND:US,BBG000BKF014,Edited Transcript of LGND earnings conference call or presentation 7-Aug-17 8:30pm GMT,2017-08-13 00:45:57 +0000,https://finance.yahoo.com/news/edited-transcript-lgnd-earnings-conference-234643811.html?.tsrc=rss,Q2 2017 Ligand Pharmaceuticals Inc Earnings Call
LGND,LGND:US,BBG000BKF014,"RK Capital Management, LLC Buys Electronics for Imaging Inc, Douglas Dynamics Inc, KBR Inc, ...",2017-08-12 10:34:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8XrhHdpT0QU/rk-capital-management-llc-buys-electronics-for-imaging-inc-douglas-dynamics-inc-kbr-inc-cm831271,RK Capital Management LLC New Purchases EFII PLOW KBR SNHY GMS TLGT Added Positions DCI TACO IBP EMKR ODFL DLX JRVR QTNA AIMC MANT Reduced Positions EXTR CCOI ROLL PATK JAZZ FORM JILL PENN LFUS CVTI Sold Out MMS LCII DY
LGND,LGND:US,BBG000BKF014,See what the IHS Markit Score report has to say about Ligand Pharmaceuticals Inc.,2017-08-11 12:01:47 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120147338.html?.tsrc=rss,"Index (PMI) data, output in the Healthcare sector is rising.  To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way."
LGND,LGND:US,BBG000BKF014,"Ligand (LGND) Q2 Earnings & Revenues Top, 2017 View Raised",2017-08-08 17:36:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Cbz3i1mBhf0/ligand-lgnd-q2-earnings-revenues-top-2017-view-raised-cm828893,Ligand Pharmaceuticals Incorporated LGND reported second quarter 2017 earnings of 54 cents per share including the after tax impact of stock based compensation expenses significantly up 157 1 from the year ago figure of 21 cents Earnings also beat the Zacks Consensus Estimate of 25 cents
LGND,LGND:US,BBG000BKF014,"Ligand (LGND) Q2 Earnings & Revenues Top, 2017 View Raised",2017-08-08 15:14:03 +0000,https://finance.yahoo.com/news/ligand-lgnd-q2-earnings-revenues-151403991.html?.tsrc=rss,Ligand&apos;s (LGND) earnings and revenues beat estimates. Total revenue also rises year over on the back of higher royalty benefits. The company ups its outlook for 2017.
LGND,LGND:US,BBG000BKF014,Ligand posts 2Q profit,2017-08-08 03:59:03 +0000,https://finance.yahoo.com/news/ligand-posts-2q-profit-201504203.html?.tsrc=rss,"The San Diego-based company said it had net income of 26 cents per share. Earnings, adjusted for one-time gains and costs, came to 67 cents per share. The drugmaker posted revenue of $28 million in the ..."
LGND,LGND:US,BBG000BKF014,Ligand Reports Second Quarter 2017 Financial Results,2017-08-07 20:01:00 +0000,https://finance.yahoo.com/news/ligand-reports-second-quarter-2017-200100646.html?.tsrc=rss,"Ligand Pharmaceuticals Incorporated today reported financial results for the three and six months ended June 30, 2017, and provided an operating forecast and program updates."
LGND,LGND:US,BBG000BKF014,Ligand Pharmaceuticals Inc Profit Rises 95% In Q2,2017-08-07 16:04:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xB9M3I2zYpU/ligand-pharmaceuticals-inc-profit-rises-95-in-q2-20170807-01059,Ligand Pharmaceuticals Inc Profit Rises 95% In Q2
LGND,LGND:US,BBG000BKF014,Ligand Pharmaceuticals Q2 17 Earnings Conference Call At 4:30 PM ET,2017-08-07 15:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pFkymdt_y60/ligand-pharmaceuticals-q2-17-earnings-conference-call-at-430-pm-et-20170807-00984,Ligand Pharmaceuticals Q2 17 Earnings Conference Call At 4:30 PM ET
LGND,LGND:US,BBG000BKF014,Investor Network: Ligand Pharmaceuticals Incorporated to Host Earnings Call,2017-08-07 10:40:00 +0000,https://finance.yahoo.com/news/investor-network-ligand-pharmaceuticals-incorporated-104000944.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / August 7, 2017 / Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will be discussing their earnings results in their Q2 Earnings Call to be held on Monday, August 07, 2017 ..."
LGND,LGND:US,BBG000BKF014,Can Ligand (LGND) Pull a Surprise This Earnings Season?,2017-08-01 22:55:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LKKTK5QUcAw/can-ligand-lgnd-pull-a-surprise-this-earnings-season-cm825337,Ligand Pharmaceuticals Incorporated LGND is scheduled to report second quarter 2017 results on Aug 7 after the market closes Ligand s earnings history has been disappointing as it missed expectations in all of the last four quarters The company delivered an average negative surprise
LGND,LGND:US,BBG000BKF014,Can Ligand (LGND) Pull a Surprise This Earnings Season?,2017-08-01 20:50:08 +0000,https://finance.yahoo.com/news/ligand-lgnd-pull-surprise-earnings-205008235.html?.tsrc=rss,"Milestone payment on Baxdela&apos;s approval in the U.S. leveraging Ligand&apos;s (LGND) Captisol formulation technology and partnerships with leading healthcare companies, might drive the company in Q2."
LGND,LGND:US,BBG000BKF014,Ligand to Report Second Quarter 2017 Results on August 7th,2017-07-20 20:01:00 +0000,https://finance.yahoo.com/news/ligand-report-second-quarter-2017-200100476.html?.tsrc=rss,"Ligand Pharmaceuticals Incorporated announced today plans to report second quarter 2017 financial results on August 7, 2017. Ligand’s CEO John Higgins, President and COO Matt Foehr and CFO Matt Korenberg will host the conference call."
LGND,LGND:US,BBG000BKF014,"Ligand Signs Agreement with Amgen, Grants Rights to Captisol",2017-07-18 17:04:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Gr4KXZBVDuw/ligand-signs-agreement-with-amgen-grants-rights-to-captisol-cm817609,Ligand Pharmaceuticals Incorporated LGND announced that it has signed a commercial license and supply agreement with Amgen Inc AMGN Per the deal Amgen was granted exclusive worldwide rights to use Ligand s Captisol technology for the development of its pipeline candidate AMG 330 for a
LGND,LGND:US,BBG000BKF014,Invest Like &quot;Royalty&quot; With These 3 Stocks,2017-07-18 17:03:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mS_oS_5HwfQ/invest-like-royalty-with-these-3-stocks-cm817576,Investors have been dealt an exceptional hand since March 2009 with all three major U S indexes more than tripling in value since their lows Considering that the stock market has historically returned about 7 annually inclusive of dividend reinvestment investors have been privy
LGND,LGND:US,BBG000BKF014,Invest Like &quot;Royalty&quot; With These 3 Stocks,2017-07-18 15:22:00 +0000,http://finance.yahoo.com/r/5fbbc128-3d90-38d0-8a00-a1711f703ce6/invest-like-royalty-with-these-3-stocks.aspx?yptr=yahoo&.tsrc=rss,High-margin royalty stocks could be a smart way to play a potentially pricey market.
LGND,LGND:US,BBG000BKF014,"Ligand Signs Agreement with Amgen, Grants Rights to Captisol",2017-07-18 14:37:02 +0000,https://finance.yahoo.com/news/ligand-signs-agreement-amgen-grants-143702355.html?.tsrc=rss,Ligand Pharmaceuticals Incorporated (LGND) announced that it has signed a commercial license and supply agreement with Amgen Inc. granting exclusive worldwide rights to use Ligand&apos;s Captisol technology for the development of AMG 330
LGND,LGND:US,BBG000BKF014,"FDA Nod For PBYI, ANIK Sees 23-26% Revenue Growth, CBAY Abuzz, RPRX Plunges",2017-07-18 03:42:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ehAY7mKbIFs/fda-nod-for-pbyi-anik-sees-2326-revenue-growth-cbay-abuzz-rprx-plunges-20170718-00099,"FDA Nod For PBYI, ANIK Sees 23-26% Revenue Growth, CBAY Abuzz, RPRX Plunges"
LGND,LGND:US,BBG000BKF014,"FDA Nod For PBYI, ANIK Sees 23-26% Revenue Growth, CBAY Abuzz, RPRX Plunges",2017-07-18 03:42:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/d6iX_VkeCJo/fda-nod-for-pbyi-anik-sees-2326%25-revenue-growth-cbay-abuzz-rprx-plunges-20170718-00099,"FDA Nod For PBYI, ANIK Sees 23-26% Revenue Growth, CBAY Abuzz, RPRX Plunges"
LGND,LGND:US,BBG000BKF014,Ligand Enters Into Commercial License and Supply Agreement with Amgen for Rights to Use Captisol in the Formulation of AMG 330,2017-07-17 13:00:00 +0000,https://finance.yahoo.com/news/ligand-enters-commercial-license-supply-130000825.html?.tsrc=rss,"Ligand Pharmaceuticals Incorporated today announced that it has entered into a commercial license and supply agreement with Amgen, granting rights to use Ligand’s Captisol technology in the formulation of AMG 330."
LGND,LGND:US,BBG000BKF014,3 Hot Stocks to Buy in July,2017-07-10 13:49:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CRyWsW4sxtM/3-hot-stocks-to-buy-in-july-cm813675,If you haven t noticed summer is officially in full swing thank you air conditioner and temperatures across the country are soaring But that s not the only thing that s been red hot this summer The stock market has also been practically unstoppable During the shortened session
LGND,LGND:US,BBG000BKF014,3 Hot Stocks to Buy in July,2017-07-10 11:41:00 +0000,http://finance.yahoo.com/r/40262e78-811f-3481-a8fa-73960f0ebac1/3-hot-stocks-to-buy-in-july.aspx?yptr=yahoo&.tsrc=rss,"A banking behemoth, a social media giant, and an under-the-radar biotech company appear to be sizzling deals this July."
LGND,LGND:US,BBG000BKF014,Ligand Gets Milestone Payment on Partner Drug FDA Approval,2017-06-21 23:22:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ktu6KYR0CSk/ligand-gets-milestone-payment-on-partner-drug-fda-approval-cm806592,Ligand Pharmaceuticals Incorporated LGND announced receipt of a milestone payment of 1 5 million after its partner Melinta Therapeutics pipeline candidate Baxdela delafloxacin was approved by the FDA Baxdela was approved to treat acute bacterial skin and skin structure infections
LGND,LGND:US,BBG000BKF014,Ligand Gets Milestone Payment on Partner Drug FDA Approval,2017-06-21 21:40:09 +0000,https://finance.yahoo.com/news/ligand-gets-milestone-payment-partner-214009508.html?.tsrc=rss,Ligand Pharmaceuticals Incorporated (LGND) announced receipt of a milestone payment of $1.5 million after its partner Melinta Therapeutics&apos; pipeline candidate Baxdela (delafloxacin) was approved by the FDA.
LGND,LGND:US,BBG000BKF014,Ligand’s Partner Melinta Therapeutics Announces U.S. FDA Approval of Baxdela™ (Delafloxacin) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI),2017-06-20 13:00:00 +0000,https://finance.yahoo.com/news/ligand-partner-melinta-therapeutics-announces-130000743.html?.tsrc=rss,"Ligand Pharmaceuticals Incorporated announces that partner Melinta Therapeutics, a privately held company focused on discovering, developing, and commercializing novel antibiotics to treat serious bacterial infections, announced yesterday that the U.S."
LGND,LGND:US,BBG000BKF014,Ligand Pharma Earns Milestone Payment On FDA Approval Of Baxdela - Quick Facts,2017-06-20 09:17:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QAwuwXif77Q/ligand-pharma-earns-milestone-payment-on-fda-approval-of-baxdela--quick-facts-20170620-00725,Ligand Pharma Earns Milestone Payment On FDA Approval Of Baxdela - Quick Facts
LGND,LGND:US,BBG000BKF014,Why Is Ligand Pharmaceuticals (LGND) Up 5.1% Since the Last Earnings Report?,2017-06-13 10:28:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WfzZsRXyNk8/why-is-ligand-pharmaceuticals-lgnd-up-51-since-the-last-earnings-report-cm802437,A month has gone by since the last earnings report for Ligand Pharmaceuticals Incorporated LGND Shares have added about 5 1 in that time frame outperforming the market Will the recent positive trend continue leading up to the stock s next earnings release or is it due for a
LGND,LGND:US,BBG000BKF014,Why Is Ligand Pharmaceuticals (LGND) Up 5.1% Since the Last Earnings Report?,2017-06-13 08:12:08 +0000,https://finance.yahoo.com/news/why-ligand-pharmaceuticals-lgnd-5-081208046.html?.tsrc=rss,Ligand Pharmaceuticals (LGND) reported earnings 30 days ago. What&apos;s next for the stock? We take a look at earnings estimates for some clues.
LGND,LGND:US,BBG000BKF014,Featured Company News - Viking Therapeutics' VK2809 Shows Encouraging Results in Non-Alcoholic Steatohepatitis,2017-06-08 12:15:00 +0000,https://finance.yahoo.com/news/featured-company-news-viking-therapeutics-121500591.html?.tsrc=rss,"Research Desk Line-up: Ligand Pharma Post Earnings Coverage LONDON, UK / ACCESSWIRE / June 8, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Viking ..."
LGND,LGND:US,BBG000BKF014,Key FDA Events to Watch Out for in Jun 2017,2017-06-05 14:04:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/A96XP2NidGQ/key-fda-events-to-watch-out-for-in-jun-2017-cm798552,The FDA which approved 22 treatments last year has given its approval to 21 drugs so far in 2017 including 3 in May Key approvals so far in 2017 include Regeneron Sanofi s Kevzara rheumatoid arthritis Roche s multiple sclerosis treatment Ocrevus Regeneron and Sanofi s eczema
LGND,LGND:US,BBG000BKF014,Key FDA Events to Watch Out for in Jun 2017,2017-06-05 11:47:11 +0000,https://finance.yahoo.com/news/key-fda-events-watch-jun-114711878.html?.tsrc=rss,Companies like Portola (PTLA) are awaiting key FDA decisions this month which could send their stocks soaring in case of a positive response.
LGND,LGND:US,BBG000BKF014,Ligand Enters into Worldwide OmniAb® Platform License Agreement with Surface Oncology,2017-06-01 13:00:00 +0000,https://finance.yahoo.com/news/ligand-enters-worldwide-omniab-platform-130000775.html?.tsrc=rss,"Ligand Pharmaceuticals Incorporated announces it has entered into a worldwide license agreement with Cambridge, Massachusetts-based Surface Oncology. Under the license, Surface will be able to use the OmniRat®, OmniMouse® and OmniFlic® platforms to discover fully human mono- and bispecific antibodies."
LGND,LGND:US,BBG000BKF014,"Ligand Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LGND-US : June 1, 2017",2017-06-01 12:42:40 +0000,http://finance.yahoo.com/r/dc45656c-fee3-350a-a9a3-196ba6143ced/ligand-pharmaceuticals-inc-breached-its-50-day-moving-average-in-a-bearish-manner-lgnd-us-june-1-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Ligand Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving ... Read more
<b>(Read more...)</b>"
LGND,LGND:US,BBG000BKF014,Ligand (LGND) Signs Licensing Deal with xCella Biosciences,2017-05-31 22:32:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JEzdVTEiPzw/ligand-lgnd-signs-licensing-deal-with-xcella-biosciences-cm797120,Ligand Pharmaceuticals Inc LGND announced it has entered into a worldwide license agreement with drug discovery company xCella Biosciences Inc under which xCella will use the former s OmniAb platform for the discovery of fully human mono and bispecific antibodies Note that OmniAb
LGND,LGND:US,BBG000BKF014,InPlay from Briefing.com,2017-05-31 21:58:03 +0000,https://finance.yahoo.com/news/inplay-briefing-com-115750752.html?.tsrc=rss,InPlay from Briefing.com
LGND,LGND:US,BBG000BKF014,Ligand Announces Aziyo Biologics Acquires Commercial Products from Partner CorMatrix,2017-05-31 21:35:00 +0000,https://finance.yahoo.com/news/ligand-announces-aziyo-biologics-acquires-213500012.html?.tsrc=rss,"Ligand Pharmaceuticals Incorporated announces it will receive $10 million from a contractually specified royalty rate buy-down following the sale by CorMatrix Cardiovascular, Inc."
LGND,LGND:US,BBG000BKF014,Ligand (LGND) Signs Licensing Deal with xCella Biosciences,2017-05-31 20:59:08 +0000,https://finance.yahoo.com/news/ligand-lgnd-signs-licensing-deal-205908437.html?.tsrc=rss,"Ligand Pharmaceuticals Incorporated (LGND) announces it has entered into a worldwide license agreement with drug discovery company xCella Biosciences, Inc."
LGND,LGND:US,BBG000BKF014,Ligand Enters Into Worldwide OmniAb® Platform License Agreement With xCella Biosciences,2017-05-30 13:00:00 +0000,https://finance.yahoo.com/news/ligand-enters-worldwide-omniab-platform-130000206.html?.tsrc=rss,"Ligand Pharmaceuticals Incorporated announces it has entered into a worldwide license agreement with Menlo Park, California-based xCella Biosciences, Inc. Under the license, xCella will be able to use the OmniRat®, OmniMouse® and OmniFlic® platforms to discover fully human mono- and bispecific antibodies."
LGND,LGND:US,BBG000BKF014,Biotech Stocks Facing FDA Decision In June,2017-05-25 05:32:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/a9bvKdScdD8/biotech-stocks-facing-fda-decision-in-june-20170525-00145,Biotech Stocks Facing FDA Decision In June
LGND,LGND:US,BBG000BKF014,"ETFs with exposure to Ligand Pharmaceuticals, Inc. : May 22, 2017",2017-05-22 17:51:09 +0000,http://finance.yahoo.com/r/84aca4a1-924c-3976-a93f-07cf9cd5e651/etfs-with-exposure-to-ligand-pharmaceuticals-inc-may-22-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Ligand Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to LGND-US. Comparing the performance and risk of Ligand Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
LGND,LGND:US,BBG000BKF014,Ligand to Participate in Two Upcoming Investor Conferences,2017-05-22 13:00:00 +0000,https://finance.yahoo.com/news/ligand-participate-two-upcoming-investor-130000314.html?.tsrc=rss,Ligand Pharmaceuticals Incorporated announces that company executives are scheduled to participate in the following upcoming investor conferences:
LGND,LGND:US,BBG000BKF014,"Ligand Pharmaceuticals, Inc. :LGND-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017",2017-05-19 14:03:53 +0000,http://finance.yahoo.com/r/b3de6523-de6c-37a8-a2c4-a7f707b21bab/ligand-pharmaceuticals-inc-lgnd-us-earnings-analysis-q1-2017-by-the-numbers-may-19-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis Ligand Pharmaceuticals, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Ligand Pharmaceuticals, Inc. – Amgen Inc., GTx, Inc., Spectrum Pharmaceuticals, Inc., Eli Lilly and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, Baxter International Inc., Pfizer Inc., GlaxoSmithKline ... Read more
<b>(Read more...)</b>"
LGND,LGND:US,BBG000BKF014,These 3 Stocks Look Expensive but Are Actually Cheap,2017-05-11 16:03:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zG3W0zxIBlQ/these-3-stocks-look-expensive-but-are-actually-cheap-cm787877,There s probably no fundamental metric that investors follow more closely than the price to earnings ratio Unfortunately this bare bones metric doesn t always tell you the full story about a company In fact some companies with currently unsightly P E ratios may look expensive
LGND,LGND:US,BBG000BKF014,These 3 Stocks Look Expensive but Are Actually Cheap,2017-05-11 14:43:00 +0000,http://finance.yahoo.com/r/0b7e02c8-28e9-33a9-bb98-5848e81aa773/these-3-stocks-look-expensive-but-are-actually-che.aspx?yptr=yahoo&.tsrc=rss,"Contrary to what their price-to-earnings ratios may suggest, these three stocks could be a great deal."
LGND,LGND:US,BBG000BKF014,Here's Why Organovo Holdings Stock Fell 5.2% In April,2017-05-11 12:03:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZkaNZiFOjOg/heres-why-organovo-holdings-stock-fell-52-in-april-cm787656,What happened Investors in Organovo Holdings NASDAQ ONVO 160 a company focused on 160 tissue engineering had a rough April The company s stock decline by 5 2 during the month 160 according to data from S amp P Global Market Intelligence So what It isn
LGND,LGND:US,BBG000BKF014,Edited Transcript of LGND earnings conference call or presentation 9-May-17 8:30pm GMT,2017-05-11 01:06:19 +0000,http://finance.yahoo.com/news/edited-transcript-lgnd-earnings-conference-015229668.html?.tsrc=rss,Q1 2017 Ligand Pharmaceuticals Inc Earnings Call
LGND,LGND:US,BBG000BKF014,Ligand Pharmaceuticals (LGND) Q1 Earnings Miss Estimates,2017-05-10 16:04:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Qt8gmm3tfkU/ligand-pharmaceuticals-lgnd-q1-earnings-miss-estimates-cm787223,Ligand Pharmaceuticals Incorporated LGND reported first quarter 2017 earnings of 31 cents per share including the impact of stock based compensation expenses down 32 5 from the year ago figure The bottom line also missed the Zacks Consensus Estimate of 55 cents per share
LGND,LGND:US,BBG000BKF014,Ligand Pharmaceuticals (LGND) Q1 Earnings Miss Estimates,2017-05-10 14:06:02 +0000,http://finance.yahoo.com/news/ligand-pharmaceuticals-lgnd-q1-earnings-140602736.html?.tsrc=rss,"Ligand Pharmaceuticals Incorporated (LGND) reported first-quarter 2017 earnings of 31 cents per share (including the impact of stock-based compensation expenses), down 32.5% from the year-ago figure."
LGND,LGND:US,BBG000BKF014,Ligand posts 1Q profit,2017-05-09 21:12:25 +0000,http://finance.yahoo.com/news/ligand-posts-1q-profit-211225254.html?.tsrc=rss,"The San Diego-based company said it had profit of 22 cents per share. Earnings, adjusted for one-time gains and costs, were 57 cents per share. The drugmaker posted revenue of $29.3 million in the period. ..."
LGND,LGND:US,BBG000BKF014,Ligand Reports First Quarter 2017 Financial Results,2017-05-09 20:01:00 +0000,http://finance.yahoo.com/news/ligand-reports-first-quarter-2017-200100929.html?.tsrc=rss,"Ligand Pharmaceuticals Incorporated today reported financial results for the three months ended March 31, 2017, and provided an operating forecast and program updates."
LGND,LGND:US,BBG000BKF014,Ligand Pharmaceuticals Inc Q1 Earnings Fall 7%,2017-05-09 17:58:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hvsq5I92ixE/ligand-pharmaceuticals-inc-q1-earnings-fall-7-20170509-01991,Ligand Pharmaceuticals Inc Q1 Earnings Fall 7%
LGND,LGND:US,BBG000BKF014,Investor Network: Ligand Pharmaceuticals Incorporated to Host Earnings Call,2017-05-09 17:15:00 +0000,http://finance.yahoo.com/news/investor-network-ligand-pharmaceuticals-incorporated-171500884.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / May 9, 2017 / Ligand Pharmaceuticals Incorporated (NASDAQ: LGND ) will be discussing their earnings results in their Q1 Earnings Call to be held May 9, 2017 at 4:30 PM Eastern ..."
LGND,LGND:US,BBG000BKF014,Ligand Pharmaceuticals Q1 17 Earnings Conference Call At 4:30 PM ET,2017-05-09 15:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Q_6n9L_eSew/ligand-pharmaceuticals-q1-17-earnings-conference-call-at-430-pm-et-20170509-01475,Ligand Pharmaceuticals Q1 17 Earnings Conference Call At 4:30 PM ET
LGND,LGND:US,BBG000BKF014,Can Ligand (LGND) Spring a Surprise this Earnings Season?,2017-05-04 16:15:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RhxvkGeYlAc/can-ligand-lgnd-spring-a-surprise-this-earnings-season-cm784212,Ligand Pharmaceuticals Incorporated LGND is scheduled to report first quarter 2017 results on May 9 after the market closes Ligand s earnings history has been disappointing as it missed expectations in three of the last four quarters and beat estimates in one Overall the company had
LGND,LGND:US,BBG000BKF014,Can Ligand (LGND) Spring a Surprise this Earnings Season?,2017-05-04 14:29:02 +0000,http://finance.yahoo.com/news/ligand-lgnd-spring-surprise-earnings-142902520.html?.tsrc=rss,"Ligand Pharmaceuticals Incorporated (LGND) is scheduled to report first-quarter 2017 results on May 9, after the market closes."
LGND,LGND:US,BBG000BKF014,"Notable Tuesday Option Activity: IAC, LGND, WATT",2017-05-02 20:28:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IFOJHCOfUg0/notable-tuesday-option-activity-iac-lgnd-watt-cm782992,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in IAC InterActiveCorp Symbol IAC where a total volume of 5 030 contracts has been traded thus far today a contract volume which is representative of approximately 503
LGND,LGND:US,BBG000BKF014,"Ligand Pharmaceuticals, Inc. – Value Analysis (NASDAQ:LGND) : April 27, 2017",2017-04-27 20:58:55 +0000,http://finance.yahoo.com/r/d27997dd-3d08-3a36-b41a-cfd9a35f2666/ligand-pharmaceuticals-inc-value-analysis-nasdaqlgnd-april-27-2017?yptr=yahoo&.tsrc=rss,"Categories:  Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Ligand Pharmaceuticals, Inc. a score of 47. Our analysis is based on comparing Ligand Pharmaceuticals, Inc. with the following peers – Amgen Inc., GTx, Inc., Spectrum Pharmaceuticals, Inc., Eli Lilly and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, Baxter International Inc., Pfizer Inc., GlaxoSmithKline plc Sponsored ... Read more
<b>(Read more...)</b>"
LGND,LGND:US,BBG000BKF014,"Ligand Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LGND-US : April 26, 2017",2017-04-26 12:40:10 +0000,http://finance.yahoo.com/r/c4d9fc54-7638-353a-bd0e-8667f94709f2/ligand-pharmaceuticals-inc-breached-its-50-day-moving-average-in-a-bullish-manner-lgnd-us-april-26-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Ligand Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving ... Read more
<b>(Read more...)</b>"
LGND,LGND:US,BBG000BKF014,LGND Makes Bullish Cross Above Critical Moving Average,2017-04-25 17:03:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6Zu621gXfuk/lgnd-makes-bullish-cross-above-critical-moving-average-cm778774,In trading on Tuesday shares of Ligand Pharmaceuticals Inc Symbol LGND crossed above their 200 day moving average of 107 65 changing hands as high as 108 93 per share Ligand Pharmaceuticals Inc shares are currently trading up about 3 5 on the day The chart below shows the one
LGND,LGND:US,BBG000BKF014,Ligand to Report First Quarter 2017 Results on May 9th,2017-04-13 13:00:00 +0000,http://finance.yahoo.com/news/ligand-report-first-quarter-2017-130000497.html?.tsrc=rss,"Ligand Pharmaceuticals Incorporated announced today plans to report first quarter 2017 financial results on May 9, 2017. Ligand’s CEO John Higgins, President and COO Matt Foehr and CFO Matt Korenberg will host the conference call."
LGND,LGND:US,BBG000BKF014,3 Stocks With Apple-Like Return Potential,2017-04-11 13:55:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CzsuwUigYu8/3-stocks-with-apple-like-return-potential-cm772537,Apple NASDAQ AAPL has delivered market smashing returns and is up more than 900 over the last 10 years Propelling those returns has been its ability to produce elite level revenue and earnings growth In fact it is one of only 15 stocks to grow cash flow at a 20 compound
LGND,LGND:US,BBG000BKF014,3 Stocks With Apple-Like Return Potential,2017-04-11 12:51:00 +0000,http://finance.yahoo.com/r/d2d3dd8f-ba24-3227-a432-ffa4688fcfd2/3-stocks-with-apple-like-return-potential.aspx?yptr=yahoo&.tsrc=rss,"We think this biotech royalty company, e-commerce enhancer, and oil company (yes, oil company!) can all deliver Apple-like returns in the years ahead."
LGND,LGND:US,BBG000BKF014,"Ligand Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LGND-US : April 10, 2017",2017-04-10 12:14:11 +0000,http://finance.yahoo.com/r/ffd04e25-4dd3-35c7-9fb2-c557de7296c2/ligand-pharmaceuticals-inc-breached-its-50-day-moving-average-in-a-bullish-manner-lgnd-us-april-10-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Ligand Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving ... Read more
<b>(Read more...)</b>"
LGND,LGND:US,BBG000BKF014,Ligand Enters Commercial License and Supply Agreements with Marinus Pharmaceuticals for Captisol-Enabled Ganaxolone,2017-04-05 13:00:00 +0000,http://finance.yahoo.com/news/ligand-enters-commercial-license-supply-130000792.html?.tsrc=rss,"Ligand Pharmaceuticals Incorporated today announced that it has entered into commercial License and Supply Agreements with Marinus Pharmaceuticals, Inc., granting rights to use Ligand’s Captisol in the formulation of its intravenous ganaxolone."
LGND,LGND:US,BBG000BKF014,"9:03 am Ligand Pharma announces that an affiliate of Johnson & Johnson (<a href=""/q?s=jnj"" name=""jnj"">JNJ</a>) subsidiary Janssen has filed an IND for an antibody discovered using Ligand's OmniAb technology; IND filing results in a $1 mln ",2017-03-28 13:03:00 +0000,http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#lgnd,"9:03 am Ligand Pharma announces that an affiliate of Johnson & Johnson (<a href=""/q?s=jnj"" name=""jnj"">JNJ</a>) subsidiary Janssen has filed an IND for an antibody discovered using Ligand's OmniAb technology; IND filing results in a $1 mln "
LGND,LGND:US,BBG000BKF014,Ligand Announces Licensing Partner Janssen Has Filed an IND for an Antibody Discovered Using the OmniAb® Technology,2017-03-28 13:00:00 +0000,http://finance.yahoo.com/news/ligand-announces-licensing-partner-janssen-130000304.html?.tsrc=rss,"Ligand Pharmaceuticals Incorporated announces that CNA Development LLC, an affiliate of Janssen Pharmaceuticals, Inc. has filed an IND for an antibody discovered using Ligand’s OmniAb technology."
LGND,LGND:US,BBG000BKF014,Ligand Announces Licensing Partner Janssen Has Filed an IND for an Antibody Discovered Using the OmniAb® Technology,2017-03-28 13:00:00 +0000,http://finance.yahoo.com/news/ligand-announces-licensing-partner-janssen-130000304.html,"[Business Wire] - Ligand Pharmaceuticals Incorporated announces that CNA Development LLC, an affiliate of Janssen Pharmaceuticals, Inc. has filed an IND for an antibody discovered using Ligand’s OmniAb technology."
LGND,LGND:US,BBG000BKF014,3 Least Risky Biotech Stocks on the Market,2017-03-28 12:59:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qJJLEJ_9Fj4/3-least-risky-biotech-stocks-on-the-market-cm766316,Biotech stocks are notoriously risky investments But not every biotech carries as much risk as others Three biotech stocks could be the least risky of all Celgene NASDAQ CELG Ligand Pharmaceuticals NASDAQ LGND and Gilead Sciences NASDAQ GILD Here s why
LGND,LGND:US,BBG000BKF014,"Ligand Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LGND-US : March 28, 2017",2017-03-28 12:08:47 +0000,http://www.capitalcube.com/blog/index.php/ligand-pharmaceuticals-inc-breached-its-50-day-moving-average-in-a-bullish-manner-lgnd-us-march-28-2017/,"Ligand Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LGND-US : March 28, 2017"
LGND,LGND:US,BBG000BKF014,"Ligand Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LGND-US : March 28, 2017",2017-03-28 12:08:47 +0000,http://finance.yahoo.com/r/62cf324b-6736-384d-bc4d-e3bc9efaaed9/ligand-pharmaceuticals-inc-breached-its-50-day-moving-average-in-a-bullish-manner-lgnd-us-march-28-2017?yptr=yahoo&.tsrc=rss,"Categories:   ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Ligand Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving ... Read more    
<b>(Read more...)</b>"
LGND,LGND:US,BBG000BKF014,3 Least Risky Biotech Stocks on the Market,2017-03-28 11:23:00 +0000,https://www.fool.com/investing/2017/03/28/3-least-risky-biotech-stocks-on-the-market.aspx,3 Least Risky Biotech Stocks on the Market
LGND,LGND:US,BBG000BKF014,3 Least Risky Biotech Stocks on the Market,2017-03-28 11:23:00 +0000,http://finance.yahoo.com/r/017b5972-f746-3e6d-bbe2-054a8a10dcf7/3-least-risky-biotech-stocks-on-the-market.aspx?yptr=yahoo&.tsrc=rss,"Why Celgene, Ligand Pharmaceuticals, and Gilead Sciences don't look as risky as many biotech stocks."
LGND,LGND:US,BBG000BKF014,3 Stocks to Invest in Healthcare,2017-03-26 19:58:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bbUpCnFCLyI/3-stocks-to-invest-in-healthcare-cm765688,If you re looking to invest in the healthcare sector there are a lot of choices And those choices span quite a few industries So when we asked three of our top healthcare contributors to name three of the best stocks to invest in healthcare it s not surprising that their
LGND,LGND:US,BBG000BKF014,3 Stocks to Invest in Healthcare,2017-03-26 18:03:00 +0000,http://finance.yahoo.com/r/42c76b4c-3019-30f8-a873-b9be6c8aa854/3-stocks-to-invest-in-healthcare.aspx?yptr=yahoo&.tsrc=rss,"Masimo, CVS Health, and Ligand Pharmaceuticals stand out as great healthcare stock picks for long-term investors."
LGND,LGND:US,BBG000BKF014,3 Stocks to Invest in Healthcare,2017-03-26 18:03:00 +0000,https://www.fool.com/investing/2017/03/26/3-stocks-to-invest-in-healthcare.aspx,3 Stocks to Invest in Healthcare
LGND,LGND:US,BBG000BKF014,VKTX: Results from Phase 2 Trial of VK5211 in Hip Fracture in mid-2017,2017-03-24 15:45:00 +0000,http://finance.yahoo.com/news/vktx-results-phase-2-trial-154500349.html,VKTX: Results from Phase 2 Trial of VK5211 in Hip Fracture in mid-2017
LGND,LGND:US,BBG000BKF014,Ligand Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for LGND,2017-03-11 00:10:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CrHPJRT5Jz8/ligand-pharmaceuticals-breaks-above-200-day-moving-average-bullish-for-lgnd-cm759323,In trading on Friday shares of Ligand Pharmaceuticals Inc Symbol LGND crossed above their 200 day moving average of 109 46 changing hands as high as 109 59 per share Ligand Pharmaceuticals Inc shares are currently trading up about 0 9 on the day The chart below shows the one
LGND,LGND:US,BBG000BKF014,"PJP, AKRX, LGND, MYL: ETF Outflow Alert",2017-03-09 17:14:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cEFuGIuUzyE/pjp-akrx-lgnd-myl-etf-outflow-alert-cm758566,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the PowerShares Dynamic Pharmaceuticals Portfolio Symbol PJP where we have detected an approximate 56 8 million dollar outflow that s a 6 7 decrease week over
LGND,LGND:US,BBG000BKF014,Ligand to Participate in Upcoming Investor Conference,2017-03-09 13:00:00 +0000,http://finance.yahoo.com/news/ligand-participate-upcoming-investor-conference-130000191.html?.tsrc=rss,Ligand Pharmaceuticals Incorporated announces that company executives are scheduled to participate in the following upcoming investor conference:
LGND,LGND:US,BBG000BKF014,Ligand to Participate in Upcoming Investor Conference,2017-03-09 13:00:00 +0000,http://finance.yahoo.com/news/ligand-participate-upcoming-investor-conference-130000191.html,[Business Wire] - Ligand Pharmaceuticals Incorporated announces that company executives are scheduled to participate in the following upcoming investor conference:
LGND,LGND:US,BBG000BKF014,New Strong Sell Stocks for March 7th,2017-03-07 16:15:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3ZBzkWuR0Ws/new-strong-sell-stocks-for-march-7th-cm757230,Here are 5 stocks added to the Zacks Rank 5 Strong Sell List today Ambarella Inc AMBA develops video compression and image processing semiconductors The Zacks Consensus Estimate for its current year earnings has been revised 61 6 downward over the last 30 days Consolidated
LGND,LGND:US,BBG000BKF014,New Strong Sell Stocks for March 7th,2017-03-07 14:12:02 +0000,http://finance.yahoo.com/news/strong-sell-stocks-march-7th-141202814.html?.tsrc=rss,Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
LGND,LGND:US,BBG000BKF014,New Strong Sell Stocks for March 7th,2017-03-07 14:12:02 +0000,http://finance.yahoo.com/news/strong-sell-stocks-march-7th-141202814.html,New Strong Sell Stocks for March 7th
LGND,LGND:US,BBG000BKF014,"Ligand Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LGND-US : March 7, 2017",2017-03-07 12:18:46 +0000,http://finance.yahoo.com/r/eac37343-b105-3951-803d-2e627701347b/ligand-pharmaceuticals-inc-breached-its-50-day-moving-average-in-a-bullish-manner-lgnd-us-march-7-2017?yptr=yahoo&.tsrc=rss,"Categories:   ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Ligand Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving ... Read more    
<b>(Read more...)</b>"
LGND,LGND:US,BBG000BKF014,"Ligand Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LGND-US : March 7, 2017",2017-03-07 12:18:46 +0000,http://www.capitalcube.com/blog/index.php/ligand-pharmaceuticals-inc-breached-its-50-day-moving-average-in-a-bullish-manner-lgnd-us-march-7-2017/,"Ligand Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LGND-US : March 7, 2017"
LGND,LGND:US,BBG000BKF014,"LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Other Events",2017-03-06 13:30:23 +0000,http://biz.yahoo.com/e/170306/lgnd8-k.html,"LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Other Events"
LGND,LGND:US,BBG000BKF014,LIGAND PHARMACEUTICALS INC Financials,2017-03-03 18:04:13 +0000,http://finance.yahoo.com/q/is?s=lgnd,LIGAND PHARMACEUTICALS INC Financials
LGND,LGND:US,BBG000BKF014,"LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Other Events",2017-03-03 14:05:35 +0000,http://biz.yahoo.com/e/170303/lgnd8-k.html,"LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Other Events"
LGND,LGND:US,BBG000BKF014,"Noteworthy Thursday Option Activity: LGND, LXRX, REGN",2017-03-02 22:13:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TtdIQOZ2mas/noteworthy-thursday-option-activity-lgnd-lxrx-regn-cm755650,Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Ligand Pharmaceuticals Inc Symbol LGND where a total of 1 488 contracts have traded so far representing approximately 148 800 underlying shares That amounts to about 43 9 of LGND
LGND,LGND:US,BBG000BKF014,"Health Care Sector Update for 03/01/2017: LGND,DVAX,IPXL",2017-03-01 18:51:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qrpYWxuCJtY/health-care-sector-update-for-03012017-lgnddvaxipxl-cm754984,Top Health Care StocksTop Health Care Stocks JNJ 1 55 JNJ 1 55 PFE 0 99 PFE 0 99 MRK 1 09 MRK 1 09 ABT 0 96 ABT 0 96 AMGN 1 31 AMGN 1 31 Health care stocks were following the broader U S markets higher with the NYSE Health Care Index gaining almost 0 7 while shares of health
LGND,LGND:US,BBG000BKF014,"Ligand Pharmaceuticals, Inc. :LGND-US: Earnings Analysis: 2016 By the Numbers : March 1, 2017",2017-03-01 17:34:34 +0000,http://finance.yahoo.com/r/df1fd3e1-94c0-356d-bff4-e2768d252476/ligand-pharmaceuticals-inc-lgnd-us-earnings-analysis-2016-by-the-numbers-march-1-2017?yptr=yahoo&.tsrc=rss,"Categories:   Yahoo Finance Get free summary analysis Ligand Pharmaceuticals, Inc. reports financial results for the year ended December 31, 2016. We analyze the earnings along side the following peers of Ligand Pharmaceuticals, Inc. – Amgen Inc., Eli Lilly and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, Baxter International Inc., Pfizer Inc., GlaxoSmithKline plc Sponsored ADR and Johnson ... Read more    
<b>(Read more...)</b>"
LGND,LGND:US,BBG000BKF014,"Ligand Pharmaceuticals, Inc. :LGND-US: Earnings Analysis: 2016 By the Numbers : March 1, 2017",2017-03-01 17:34:34 +0000,http://www.capitalcube.com/blog/index.php/ligand-pharmaceuticals-inc-lgnd-us-earnings-analysis-2016-by-the-numbers-march-1-2017/,"Ligand Pharmaceuticals, Inc. :LGND-US: Earnings Analysis: 2016 By the Numbers : March 1, 2017"
LGND,LGND:US,BBG000BKF014,Ligand Provides Highlights from Today’s Analyst Day Event,2017-02-28 21:10:00 +0000,http://finance.yahoo.com/news/ligand-provides-highlights-today-analyst-211000182.html?.tsrc=rss,"At an Analyst Day event held today in New York City, Ligand Pharmaceuticals Incorporated reviewed the recent progress of its business, its revenue growth opportunities and its portfolio of partnered assets and unpartnered development programs."
LGND,LGND:US,BBG000BKF014,Ligand Provides Highlights from Today’s Analyst Day Event,2017-02-28 21:10:00 +0000,http://finance.yahoo.com/news/ligand-provides-highlights-today-analyst-211000182.html,"[Business Wire] - At an Analyst Day event held today in New York City, Ligand Pharmaceuticals Incorporated reviewed the recent progress of its business, its revenue growth opportunities and its portfolio of partnered assets and unpartnered development programs."
LGND,LGND:US,BBG000BKF014,Ligand Expands License with Sermonix to Include Worldwide Rights for Oral Lasofoxifene,2017-02-28 21:01:00 +0000,http://finance.yahoo.com/news/ligand-expands-license-sermonix-worldwide-210100820.html?.tsrc=rss,Ligand Pharmaceuticals Incorporated announces that it has expanded its license with Sermonix Pharmaceuticals to include worldwide rights to develop and commercialize oral lasofoxifene.
LGND,LGND:US,BBG000BKF014,Ligand Expands License with Sermonix to Include Worldwide Rights for Oral Lasofoxifene,2017-02-28 21:01:00 +0000,http://finance.yahoo.com/news/ligand-expands-license-sermonix-worldwide-210100820.html,[Business Wire] - Ligand Pharmaceuticals Incorporated announces that it has expanded its license with Sermonix Pharmaceuticals to include worldwide rights to develop and commercialize oral lasofoxifene.
LGND,LGND:US,BBG000BKF014,6 Stocks on the Move With Unusual Volume,2017-02-28 15:40:00 +0000,https://www.thestreet.com/story/14018054/1/6-stocks-on-the-move-with-unusual-volume.html?puc=yahoo&cm_ven=YAHOO,6 Stocks on the Move With Unusual Volume
LGND,LGND:US,BBG000BKF014,6 Stocks on the Move With Unusual Volume,2017-02-28 15:40:00 +0000,http://finance.yahoo.com/r/42feb3cc-ad95-3f43-a284-f18f34ce103e/6-stocks-on-the-move-with-unusual-volume.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Here's a technical look at how to trade a number of stocks rising with unusual volume flow.
LGND,LGND:US,BBG000BKF014,"LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits",2017-02-28 15:00:56 +0000,http://biz.yahoo.com/e/170228/lgnd8-k.html,"LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits"
LGND,LGND:US,BBG000BKF014,"Sermonix Pharmaceuticals Secures Worldwide Rights to Oral Lasofoxifene From Ligand Pharmaceuticals, Expanding From U.S., Japan",2017-02-28 13:23:42 +0000,http://finance.yahoo.com/news/sermonix-pharmaceuticals-secures-worldwide-rights-132342277.html?.tsrc=rss,"Sermonix Pharmaceuticals LLC, a privately held biotechnology company focused on the development and commercialization of female-specific oncology products, today announced it licensed worldwide rights ..."
LGND,LGND:US,BBG000BKF014,"Sermonix Pharmaceuticals Secures Worldwide Rights to Oral Lasofoxifene From Ligand Pharmaceuticals, Expanding From U.S., Japan",2017-02-28 13:23:42 +0000,http://finance.yahoo.com/news/sermonix-pharmaceuticals-secures-worldwide-rights-132342277.html,"[Marketwired] - Sermonix Pharmaceuticals LLC, a privately held biotechnology company focused on the development and commercialization of female-specific oncology products, today announced it licensed worldwide rights ..."
LGND,LGND:US,BBG000BKF014,"LIGAND PHARMACEUTICALS INC Files SEC form 10-K, Annual Report",2017-02-28 12:39:56 +0000,http://biz.yahoo.com/e/170228/lgnd10-k.html,"LIGAND PHARMACEUTICALS INC Files SEC form 10-K, Annual Report"
LGND,LGND:US,BBG000BKF014,Ligand Pharmaceuticals Analyst Day At 10:00 AM ET,2017-02-28 08:59:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yNPdWpX5BJQ/ligand-pharmaceuticals-analyst-day-at-1000-am-et-20170228-00915,Ligand Pharmaceuticals Analyst Day At 10:00 AM ET
LGND,LGND:US,BBG000BKF014,"LJPC Climbs 76%, VTVT On Track, Eventful October Awaits ACRX, ATRS",2017-02-28 02:26:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bxhUUyzujKE/ljpc-climbs-76-vtvt-on-track-eventful-october-awaits-acrx-atrs-20170228-00116,"LJPC Climbs 76%, VTVT On Track, Eventful October Awaits ACRX, ATRS"
LGND,LGND:US,BBG000BKF014,"LJPC Climbs 76%, VTVT On Track, Eventful October Awaits ACRX, ATRS",2017-02-28 02:26:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2eHuZviu5dE/ljpc-climbs-76-vtvt-on-track-eventful-october-awaits-acrx-atrs-20170228-00115,"LJPC Climbs 76%, VTVT On Track, Eventful October Awaits ACRX, ATRS"
LGND,LGND:US,BBG000BKF014,"Ligand Pharmaceuticals, Inc. :LGND-US: Earnings Analysis: Q4, 2016 By the Numbers : February 27, 2017",2017-02-27 15:32:13 +0000,http://finance.yahoo.com/r/ecce914e-9b80-36f3-a07f-173f189952e7/ligand-pharmaceuticals-inc-lgnd-us-earnings-analysis-q4-2016-by-the-numbers-february-27-2017?yptr=yahoo&.tsrc=rss,"Categories:   Yahoo Finance Get free summary analysis Ligand Pharmaceuticals, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Ligand Pharmaceuticals, Inc. – Amgen Inc., Eli Lilly and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, Baxter International Inc., Pfizer Inc., GlaxoSmithKline plc Sponsored ADR and Johnson ... Read more    
<b>(Read more...)</b>"
LGND,LGND:US,BBG000BKF014,"Ligand Pharmaceuticals, Inc. :LGND-US: Earnings Analysis: Q4, 2016 By the Numbers : February 27, 2017",2017-02-27 15:32:13 +0000,http://www.capitalcube.com/blog/index.php/ligand-pharmaceuticals-inc-lgnd-us-earnings-analysis-q4-2016-by-the-numbers-february-27-2017/,"Ligand Pharmaceuticals, Inc. :LGND-US: Earnings Analysis: Q4, 2016 By the Numbers : February 27, 2017"
LGND,LGND:US,BBG000BKF014,Enrollment Completed in Ligand’s Phase 2 Trial of LGD-6972 in Type 2 Diabetes,2017-02-27 14:00:00 +0000,http://finance.yahoo.com/news/enrollment-completed-ligand-phase-2-140000176.html,"[Business Wire] - Ligand Pharmaceuticals Incorporated announces the completion of enrollment in the Company’s Phase 2 clinical trial with its novel, small-molecule glucagon receptor antagonist LGD-6972 for the treatment of type 2 diabetes mellitus ."
LGND,LGND:US,BBG000BKF014,Enrollment Completed in Ligand’s Phase 2 Trial of LGD-6972 in Type 2 Diabetes,2017-02-27 14:00:00 +0000,http://finance.yahoo.com/news/enrollment-completed-ligand-phase-2-140000176.html?.tsrc=rss,"Ligand Pharmaceuticals Incorporated announces the completion of enrollment in the Company’s Phase 2 clinical trial with its novel, small-molecule glucagon receptor antagonist LGD-6972 for the treatment of type 2 diabetes mellitus ."
LGND,LGND:US,BBG000BKF014,Oversold Conditions For Ligand Pharmaceuticals,2017-02-24 18:49:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jb-MvdSZMBA/oversold-conditions-for-ligand-pharmaceuticals-cm752932,Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which measures momentum on
LGND,LGND:US,BBG000BKF014,"Ligand (LGND) Q4 Earnings Down Y/Y, Revenues Miss Estimates",2017-02-24 16:51:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YhErBjxW2FQ/ligand-lgnd-q4-earnings-down-yy-revenues-miss-estimates-cm752780,Ligand Pharmaceuticals Incorporated LGND reported fourth quarter 2016 earnings of 50 cents per share including the impact of stock based compensation expense down 11 1 from the year ago figure The Ligand stock underperformed the Zacks classified Medical Biomed Genetics industry year
LGND,LGND:US,BBG000BKF014,Sum Up The Parts: PJP Could Be Worth $70,2017-02-24 15:51:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PCsd_Fyp6ZI/sum-up-the-parts-pjp-could-be-worth-70-cm752723,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For
LGND,LGND:US,BBG000BKF014,"Ligand (LGND) Q4 Earnings Down Y/Y, Revenues Miss Estimates",2017-02-24 14:52:02 +0000,http://finance.yahoo.com/news/ligand-lgnd-q4-earnings-down-145202819.html?.tsrc=rss,"Ligand Pharmaceuticals Incorporated (LGND) reported fourth-quarter 2016 earnings of 50 cents per share (including the impact of stock-based compensation expense), down 11.1% from the year-ago figure."
LGND,LGND:US,BBG000BKF014,"Ligand (LGND) Q4 Earnings Down Y/Y, Revenues Miss Estimates",2017-02-24 14:52:02 +0000,http://finance.yahoo.com/news/ligand-lgnd-q4-earnings-down-145202819.html,"Ligand (LGND) Q4 Earnings Down Y/Y, Revenues Miss Estimates"
LGND,LGND:US,BBG000BKF014,Edited Transcript of LGND earnings conference call or presentation 23-Feb-17 9:30pm GMT,2017-02-24 05:34:14 +0000,http://finance.yahoo.com/news/edited-transcript-lgnd-earnings-conference-053414437.html?.tsrc=rss,Q4 2016 Ligand Pharmaceuticals Inc Earnings Call
LGND,LGND:US,BBG000BKF014,Edited Transcript of LGND earnings conference call or presentation 23-Feb-17 9:30pm GMT,2017-02-24 05:34:14 +0000,http://finance.yahoo.com/news/edited-transcript-lgnd-earnings-conference-053414437.html,Edited Transcript of LGND earnings conference call or presentation 23-Feb-17 9:30pm GMT
LGND,LGND:US,BBG000BKF014,Ligand reports 4Q loss,2017-02-23 22:13:22 +0000,http://finance.yahoo.com/news/ligand-reports-4q-loss-221322387.html?.tsrc=rss,"On a per-share basis, the San Diego-based company said it had a loss of 15 cents. Earnings, adjusted for non-recurring costs and stock option expense, were 74 cents per share. The drugmaker posted revenue ..."
LGND,LGND:US,BBG000BKF014,Ligand reports 4Q loss,2017-02-23 22:13:22 +0000,http://sg.finance.yahoo.com/news/ligand-reports-4q-loss-221322324.html,Ligand reports 4Q loss
LGND,LGND:US,BBG000BKF014,"LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition",2017-02-23 21:08:14 +0000,http://biz.yahoo.com/e/170223/lgnd8-k.html,"LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition"
LGND,LGND:US,BBG000BKF014,Ligand Reports Fourth Quarter and Full Year 2016 Financial Results,2017-02-23 21:01:00 +0000,http://finance.yahoo.com/news/ligand-reports-fourth-quarter-full-210100367.html?.tsrc=rss,"Ligand Pharmaceuticals Incorporated today reported financial results for the three and 12 months ended December 31, 2016, and provided an operating forecast and program updates."
LGND,LGND:US,BBG000BKF014,Ligand Reports Fourth Quarter and Full Year 2016 Financial Results,2017-02-23 21:01:00 +0000,http://finance.yahoo.com/news/ligand-reports-fourth-quarter-full-210100367.html,"[Business Wire] - Ligand Pharmaceuticals Incorporated today reported financial results for the three and 12 months ended December 31, 2016, and provided an operating forecast and program updates."
LGND,LGND:US,BBG000BKF014,Ligand Pharmaceuticals Inc Reports 31% Increase In Q4 Bottom Line,2017-02-23 16:07:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HqzloMP4hvk/ligand-pharmaceuticals-inc-reports-31-increase-in-q4-bottom-line-20170223-01625,Ligand Pharmaceuticals Inc Reports 31% Increase In Q4 Bottom Line
LGND,LGND:US,BBG000BKF014,Ligand Pharmaceuticals Q4 16 Earnings Conference Call At 4:30 PM ET,2017-02-23 14:59:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aEdFeT7-LS8/ligand-pharmaceuticals-q4-16-earnings-conference-call-at-430-pm-et-20170223-01457,Ligand Pharmaceuticals Q4 16 Earnings Conference Call At 4:30 PM ET
LGND,LGND:US,BBG000BKF014,Three Stocks Ripe For Bottom Fishing,2017-02-23 14:45:00 +0000,http://finance.yahoo.com/r/0271c588-fa97-3fa1-b77e-a94c02b4b2a6/three-stocks-ripe-bottom-fishing-nptn-lgnd-nptn-lgnd-five.aspx?partner=YahooSA&yptr=yahoo&.tsrc=rss,Recent laggards should benefit when market players take profits on their top performing positions and seek out lower-risk buying opportunities.
LGND,LGND:US,BBG000BKF014,Q4 2016 Ligand Pharmaceuticals Inc Earnings Release - Before Market Open,2017-02-23 12:07:04 +0000,http://biz.yahoo.com/research/earncal/20170223.html?t=lgnd,Q4 2016 Ligand Pharmaceuticals Inc Earnings Release - Before Market Open
LGND,LGND:US,BBG000BKF014,"Drug Stocks Q4 Earnings Slated for Feb 23: BMRN, ICPT & More",2017-02-22 15:12:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KcgF6FkWn34/drug-stocks-q4-earnings-slated-for-feb-23-bmrn-icpt-more-cm751080,The fourth quarter earnings season is drawing to a close with results from 411 S amp P 500 members or 82 2 of the index s total membership already out as of Feb 22 2017 according to the latest Earnings Preview report Total earnings for these 411 index members were up 8 from the year
LGND,LGND:US,BBG000BKF014,"Drug Stocks Q4 Earnings Slated for Feb 23: BMRN, ICPT & More",2017-02-22 13:29:01 +0000,http://finance.yahoo.com/news/drug-stocks-q4-earnings-slated-132901558.html,"Drug Stocks Q4 Earnings Slated for Feb 23: BMRN, ICPT & More"
LGND,LGND:US,BBG000BKF014,"Forget Alexion, Buy these 4 Biotech Stocks Instead",2017-02-20 14:53:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wCRPpf18LR0/forget-alexion-buy-these-4-biotech-stocks-instead-cm750186,New Haven CT based Alexion Pharmaceuticals Inc s ALXN fourth quarter results were mixed with the company reporting in line earnings while revenues were just shy of expectations Alexion s guidance for 2017 also fell short of expectations Although flagship drug Soliris will continue
LGND,LGND:US,BBG000BKF014,"Forget Alexion, Buy these 4 Biotech Stocks Instead",2017-02-20 12:52:12 +0000,http://finance.yahoo.com/news/forget-alexion-buy-4-biotech-125212478.html,"Forget Alexion, Buy these 4 Biotech Stocks Instead"
LGND,LGND:US,BBG000BKF014,"Ligand Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LGND-US : February 17, 2017",2017-02-17 12:54:43 +0000,http://www.capitalcube.com/blog/index.php/ligand-pharmaceuticals-inc-breached-its-50-day-moving-average-in-a-bullish-manner-lgnd-us-february-17-2017/,"Ligand Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LGND-US : February 17, 2017"
LGND,LGND:US,BBG000BKF014,3 Biotechs With Tremendously Promising Pipelines,2017-02-16 19:39:43 +0000,http://www.fool.com/investing/2017/02/15/3-biotechs-with-tremendously-promising-pipelines.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Biotechs With Tremendously Promising Pipelines
LGND,LGND:US,BBG000BKF014,Ligand (LGND) Q4 Earnings: Will the Stock Pull a Surprise?,2017-02-16 14:58:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YTrr4g81MyA/ligand-lgnd-q4-earnings-will-the-stock-pull-a-surprise-cm748921,Ligand Pharmaceuticals Incorporated LGND is scheduled to report fourth quarter 2016 results on Feb 23 after the market closes Ligand s earnings history is mixed as it missed expectations in two of the last four quarters Overall the company had an average negative surprise of 5 01 in
LGND,LGND:US,BBG000BKF014,Ligand (LGND) Q4 Earnings: Will the Stock Pull a Surprise?,2017-02-16 13:29:01 +0000,http://finance.yahoo.com/news/ligand-lgnd-q4-earnings-stock-132901053.html,Ligand (LGND) Q4 Earnings: Will the Stock Pull a Surprise?
LGND,LGND:US,BBG000BKF014,3 Biotechs With Tremendously Promising Pipelines,2017-02-15 22:55:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ItTAfMVDYlQ/3-biotechs-with-tremendously-promising-pipelines-cm748613,Research and development is the lifeblood of biotech companies The potential for new drugs also serves as a primary factor driving biotech stocks higher and higher That s been the case for Celgene NASDAQ CELG Ionis Pharmaceuticals NASDAQ IONS and
LGND,LGND:US,BBG000BKF014,"Dr. Christel Iffland Joins Ligand as Vice President, Antibody Technologies, Expands Team Focused on OmniAb Drug Discovery Platform",2017-02-14 21:30:00 +0000,http://finance.yahoo.com/news/dr-christel-iffland-joins-ligand-213000902.html,"[Business Wire] - Ligand Pharmaceuticals Incorporated announces the appointment of Christel Iffland, Ph.D. as a Vice President of Antibody Technologies."
LGND,LGND:US,BBG000BKF014,Reminder: Ligand to Host Analyst Day on February 28th in New York City,2017-02-13 21:30:00 +0000,http://finance.yahoo.com/news/reminder-ligand-host-analyst-day-213000224.html,"[Business Wire] - Ligand Pharmaceuticals Incorporated will host an Analyst Day on Tuesday, February 28, 2017 from 10:00 a.m. to 11:30 a.m. Eastern time in New York City at the Andaz 5th Avenue, 485 5th Avenue at East 41st Street."
LGND,LGND:US,BBG000BKF014,"The Zacks Analyst Blog Highlights: Celgene, Exelixis, Ligand Pharmaceuticals and RedHill Biopharma",2017-02-08 16:23:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/F_jkw37SB0Q/the-zacks-analyst-blog-highlights-celgene-exelixis-ligand-pharmaceuticals-and-redhill-biopharma-cm744841,For Immediate Release Chicago IL February 08 2017 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
LGND,LGND:US,BBG000BKF014,"The Zacks Analyst Blog Highlights: Celgene, Exelixis, Ligand Pharmaceuticals and RedHill Biopharma",2017-02-08 14:30:02 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-celgene-143002999.html,"The Zacks Analyst Blog Highlights: Celgene, Exelixis, Ligand Pharmaceuticals and RedHill Biopharma"
LGND,LGND:US,BBG000BKF014,4 Drug Stocks that are Broker Favorites,2017-02-07 14:21:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0k8TXEOm584/4-drug-stocks-that-are-broker-favorites-cm744131,Pharma and biotech stocks have been under pressure for quite a while now mainly due to the drug pricing issue biotech stocks especially have been under intense pressure given President Donald Trump s comments regarding the drug industry getting away with murder At a recent meeting
LGND,LGND:US,BBG000BKF014,4 Drug Stocks that are Broker Favorites,2017-02-07 12:41:12 +0000,http://finance.yahoo.com/news/4-drug-stocks-broker-favorites-124112242.html,4 Drug Stocks that are Broker Favorites
LGND,LGND:US,BBG000BKF014,"Ligand Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LGND-US : February 1, 2017",2017-02-01 12:30:50 +0000,http://www.capitalcube.com/blog/index.php/ligand-pharmaceuticals-inc-breached-its-50-day-moving-average-in-a-bullish-manner-lgnd-us-february-1-2017/,"Ligand Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LGND-US : February 1, 2017"
LGND,LGND:US,BBG000BKF014,3 Biotech Stocks I'd Buy Right Now,2017-01-30 20:12:41 +0000,http://www.fool.com/investing/2017/01/29/3-biotech-stocks-id-buy-right-now.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Biotech Stocks I'd Buy Right Now
LGND,LGND:US,BBG000BKF014,3 Biotech Stocks I'd Buy Right Now,2017-01-29 21:30:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gVzdPgzxHQg/3-biotech-stocks-id-buy-right-now-cm739905,Conflicting statements from the Trump administration have made owning biotech stocks feel like a roller coaster ride in recent weeks but there are a few stocks I d happily buy and hold despite the sway of political uncertainty Shares of Ligand Pharmaceuticals NASDAQ LGND
LGND,LGND:US,BBG000BKF014,"LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers",2017-01-27 21:06:24 +0000,http://biz.yahoo.com/e/170127/lgnd8-k.html,"LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers"
LGND,LGND:US,BBG000BKF014,Ligand to Host Analyst Day on February 28th in New York City,2017-01-24 21:30:00 +0000,http://finance.yahoo.com/news/ligand-host-analyst-day-february-213000779.html,"[Business Wire] - Ligand Pharmaceuticals Incorporated will host an Analyst Day on Tuesday, February 28, 2017 from 10:00 a.m. to 11:30 a.m. Eastern time in New York City."
LGND,LGND:US,BBG000BKF014,Ligand to Report Fourth Quarter and Full Year 2016 Results on February 23rd,2017-01-23 21:30:00 +0000,http://finance.yahoo.com/news/ligand-report-fourth-quarter-full-213000039.html,"[Business Wire] - Ligand Pharmaceuticals Incorporated announced today plans to report fourth quarter and full year 2016 financial results on February 23, 2017. Ligand’s CEO John Higgins, President and COO Matt Foehr and CFO Matt Korenberg will host the conference call."
LGND,LGND:US,BBG000BKF014,"Notable Wednesday Option Activity: RGR, RAD, LGND",2017-01-18 21:38:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/G0DHhAZ9tCs/notable-wednesday-option-activity-rgr-rad-lgnd-cm735065,Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Sturm Ruger amp Co Inc Symbol RGR where a total of 1 675 contracts have traded so far representing approximately 167 500 underlying shares That amounts to about 51 7 of RGR
LGND,LGND:US,BBG000BKF014,"LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure",2017-01-18 21:19:57 +0000,http://biz.yahoo.com/e/170118/lgnd8-k.html,"LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure"
LGND,LGND:US,BBG000BKF014,"Lemelson Capital Management Announces 2016 Performance Results for The Amvona Fund, LP",2017-01-18 15:30:00 +0000,http://finance.yahoo.com/news/lemelson-capital-management-announces-2016-153000383.html,"[PR Newswire] - MARLBOROUGH, Mass., Jan. 18, 2017 /PRNewswire/ -- Lemelson Capital Management, LLC, a private investment management firm, today announced performance results for its flagship Amvona Fund, LP. For 2016, ..."
LGND,LGND:US,BBG000BKF014,"Ligand Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LGND-US : January 18, 2017",2017-01-18 14:51:14 +0000,http://www.capitalcube.com/blog/index.php/ligand-pharmaceuticals-inc-breached-its-50-day-moving-average-in-a-bearish-manner-lgnd-us-january-18-2017/,"Ligand Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LGND-US : January 18, 2017"
LGND,LGND:US,BBG000BKF014,EQUITY NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm,2017-01-13 16:55:00 +0000,http://finance.yahoo.com/news/equity-notice-lundin-law-pc-165500237.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / January 13, 2017 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Ligand Pharmaceuticals Incorporated (""Ligand"" or the ""Company"") ..."
LGND,LGND:US,BBG000BKF014,"UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders of Ligand Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017",2017-01-13 15:46:00 +0000,http://finance.yahoo.com/news/upcoming-deadline-levi-korsinsky-llp-154600807.html,"[Business Wire] - The following statement is being issued by Levi & Korsinsky, LLP:"
LGND,LGND:US,BBG000BKF014,SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm,2017-01-12 14:56:00 +0000,http://finance.yahoo.com/news/shareholder-alert-khang-khang-llp-145600892.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / January 12, 2017 / Khang & Khang LLP (the ""Firm"") announces the filing of a class action lawsuit against Ligand Pharmaceuticals Incorporated (""Ligand"" or the ..."
LGND,LGND:US,BBG000BKF014,Deadline in Lawsuit for Investors in shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) announced by Shareholders Foundation,2017-01-11 18:20:00 +0000,http://finance.yahoo.com/news/deadline-lawsuit-investors-shares-ligand-182000510.html,"[GlobeNewswire] - SAN DIEGO, Jan. 11, 2017-- The Shareholders Foundation, Inc. announces that a deadline is coming up on January 17, 2017 in the lawsuit that was filed for certain investors in NASDAQ: LGND shares over alleged ..."
LGND,LGND:US,BBG000BKF014,"DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ligand Pharmaceuticals Incorporated (LGND) and Lead Plaintiff Deadline: January 17, 2017",2017-01-11 15:15:00 +0000,http://finance.yahoo.com/news/deadline-alert-bronstein-gewirtz-grossman-151500299.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / January 11, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Ligand Pharmaceuticals Incorporated (""Ligand"" ..."
LGND,LGND:US,BBG000BKF014,INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm,2017-01-10 15:56:00 +0000,http://finance.yahoo.com/news/investor-notice-lundin-law-pc-155600245.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / January 10, 2017 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Ligand Pharmaceuticals Incorporated (""Ligand"" or the ""Company"") ..."
LGND,LGND:US,BBG000BKF014,"LGND SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Ligand Pharmaceuticals Inc. and a Lead Plaintiff Deadline of January 17, 2017",2017-01-09 18:08:00 +0000,http://finance.yahoo.com/news/lgnd-shareholder-alert-law-offices-180800665.html,[Business Wire] - The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of California on behalf of investors who purchased Ligand Pharmaceuticals Inc.
LGND,LGND:US,BBG000BKF014,Immunomedics Announces Reconstituted Board of Directors and Leadership Succession Plan,2017-01-09 11:00:00 +0000,http://finance.yahoo.com/news/immunomedics-announces-reconstituted-board-directors-110000433.html,"[GlobeNewswire] - --Appoints Four New, Highly Qualified Independent Directors: Jason Aryeh, Dr. Geoffrey Cox, Robert Forrester and Bob Oliver--–. --Announces Chairman and CEO Succession Plans--–."
LGND,LGND:US,BBG000BKF014,"DEADLINE ALERT: Brower Piven Reminds Investors Of The January 17, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess of $100,000 From Investment In Ligand Pharmaceuticals Incorporated To Contact The Firm",2017-01-07 11:00:00 +0000,http://finance.yahoo.com/news/deadline-alert-brower-piven-reminds-110000526.html,"[Business Wire] - The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of California on behalf of purchasers of Ligand Pharmaceuticals Incorporated securities during the period between November 9, 2015 and November 14, 2016, inclusive ."
LGND,LGND:US,BBG000BKF014,INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm,2017-01-06 19:49:00 +0000,http://finance.yahoo.com/news/investor-alert-khang-khang-llp-194900094.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / January 6, 2017 / Khang & Khang LLP (the ""Firm"") announces the filing of a class action lawsuit against Ligand Pharmaceuticals Incorporated (""Ligand"" or the ..."
LGND,LGND:US,BBG000BKF014,"DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ligand Pharmaceuticals Incorporated (LGND) and Lead Plaintiff Deadline: January 17, 2017",2017-01-06 15:19:00 +0000,http://finance.yahoo.com/news/deadline-alert-bronstein-gewirtz-grossman-151900822.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / January 6, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Ligand Pharmaceuticals Incorporated (""Ligand"" ..."
LGND,LGND:US,BBG000BKF014,LGND LOSS ALERT: Rosen Law Firm Reminds Ligand Pharmaceuticals Incorporated Investors of Important January 17 Deadline in Class Action Filed by Firm - LGND,2017-01-05 18:53:32 +0000,http://finance.yahoo.com/news/lgnd-loss-alert-rosen-law-185332917.html,"[GlobeNewswire] - NEW YORK, Jan. 05, 2017-- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Ligand Pharmaceuticals Incorporated securities from November 9, 2015 through November 14, 2016, both dates ..."
LGND,LGND:US,BBG000BKF014,"Ligand Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LGND-US : January 5, 2017",2017-01-05 13:16:47 +0000,http://www.capitalcube.com/blog/index.php/ligand-pharmaceuticals-inc-breached-its-50-day-moving-average-in-a-bullish-manner-lgnd-us-january-5-2017/,"Ligand Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LGND-US : January 5, 2017"
LGND,LGND:US,BBG000BKF014,SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm,2017-01-05 09:55:00 +0000,http://finance.yahoo.com/news/shareholder-notice-lundin-law-pc-095500570.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / January 5, 2017 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Ligand Pharmaceuticals Incorporated (""Ligand"" or the ""Company"") ..."
LGND,LGND:US,BBG000BKF014,"Bragar Eagel & Squire, P.C. Reminds Investors of a Class Action Lawsuit Against Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and the Lead Plaintiff Deadline of January 17, 2017",2017-01-04 22:30:00 +0000,http://finance.yahoo.com/news/bragar-eagel-squire-p-c-223000796.html,"[Business Wire] - Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Southern District of California on behalf of all persons or entities who acquired Ligand Pharmaceuticals Incorporated securities between November 9, 2015 and November 14, 2016 ."
LGND,LGND:US,BBG000BKF014,"LGND INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Ligand Pharmaceuticals Inc. and a Lead Plaintiff Deadline of January 17, 2017",2017-01-04 18:12:00 +0000,http://finance.yahoo.com/news/lgnd-investor-alert-law-offices-181200838.html,"[PR Newswire] - NEW YORK, Jan. 4, 2017 /PRNewswire/ -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of California on behalf of investors ..."
LGND,LGND:US,BBG000BKF014,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ligand Pharmaceuticals Incorporated (LGND) and Lead Plaintiff Deadline: January 17, 2017",2017-01-04 15:17:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-151700097.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / January 4, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Ligand Pharmaceuticals Incorporated (""Ligand"" ..."
LGND,LGND:US,BBG000BKF014,EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm,2016-12-30 02:20:00 +0000,http://finance.yahoo.com/news/equity-alert-khang-khang-llp-022000314.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / December 29, 2016 / Khang & Khang LLP (the ""Firm"") announces the filing of a class action lawsuit against Ligand Pharmaceuticals Incorporated (""Ligand"" or ..."
LGND,LGND:US,BBG000BKF014,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ligand Pharmaceuticals Incorporated (LGND) and Lead Plaintiff Deadline: January 17, 2017",2016-12-29 15:10:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-151000788.html,"[GlobeNewswire] - NEW YORK, Dec. 29, 2016-- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Ligand Pharmaceuticals Incorporated and certain ..."
LGND,LGND:US,BBG000BKF014,INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm,2016-12-27 22:29:00 +0000,http://finance.yahoo.com/news/investor-notice-lundin-law-pc-222900710.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / December 27, 2016 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Ligand Pharmaceuticals Incorporated (""Ligand"" or the ""Company"") ..."
LGND,LGND:US,BBG000BKF014,"SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Ligand Pharmaceuticals Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017",2016-12-27 17:25:00 +0000,http://finance.yahoo.com/news/shareholder-alert-levi-korsinsky-llp-172500182.html,"[Business Wire] - The following statement is being issued by Levi & Korsinsky, LLP:"
LGND,LGND:US,BBG000BKF014,"Ligand Pharmaceuticals, Inc. – Value Analysis (NASDAQ:LGND) : December 27, 2016",2016-12-27 15:59:06 +0000,http://www.capitalcube.com/blog/index.php/ligand-pharmaceuticals-inc-value-analysis-nasdaqlgnd-december-27-2016/,"Ligand Pharmaceuticals, Inc. – Value Analysis (NASDAQ:LGND) : December 27, 2016"
LGND,LGND:US,BBG000BKF014,4 Biotech Stocks to Buy in January,2016-12-27 13:52:18 +0000,http://www.fool.com/investing/2016/12/26/4-biotech-stocks-to-buy-in-january.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,4 Biotech Stocks to Buy in January
LGND,LGND:US,BBG000BKF014,4 Biotech Stocks to Buy in January,2016-12-26 14:58:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NflNs50fciM/4-biotech-stocks-to-buy-in-january-cm726063,When an entire sector goes on sale it tends to create bargains There s no doubt that the biotech sector has the blue light special flashing right now as it has massively underperformed the S amp P 500 year to date Knowing that we asked a team of healthcare contributors
LGND,LGND:US,BBG000BKF014,Ligand (LGND) Signs Licensing Deals with Ono and Novartis,2016-12-23 15:00:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ahqDxrRBxGA/ligand-lgnd-signs-licensing-deals-with-ono-and-novartis-cm725582,Ligand Pharmaceuticals Incorporated LGND announced that it has entered into a worldwide license agreement with Ono Pharmaceutical Co Ltd under which Ono will use its OmniAb platform for the discovery of fully human mono and bispecific antibodies Note that OmniAb includes
LGND,LGND:US,BBG000BKF014,Ligand (LGND) Signs Licensing Deals with Ono and Novartis,2016-12-23 13:14:01 +0000,http://finance.yahoo.com/news/ligand-lgnd-signs-licensing-deals-131401776.html,Ligand (LGND) Signs Licensing Deals with Ono and Novartis
LGND,LGND:US,BBG000BKF014,"Ligand Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LGND-US : December 23, 2016",2016-12-23 12:39:36 +0000,http://www.capitalcube.com/blog/index.php/ligand-pharmaceuticals-inc-breached-its-50-day-moving-average-in-a-bearish-manner-lgnd-us-december-23-2016/,"Ligand Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LGND-US : December 23, 2016"
LGND,LGND:US,BBG000BKF014,Health Care Sector Update for 12/22/2016: LGND,2016-12-22 14:37:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hSNL23CIG4Y/health-care-sector-update-for-12222016-lgnd-cm725029,Top Health care stocks Top Health care stocks JNJ flatJNJ flat PFE 0 2 PFE 0 2 ABT flatABT flat MRK 0 2 MRK 0 2 AMGN flatAMGN flat Health care shares were mainly unchanged in pre market trade on Thursday Health care shares were mainly unchanged in pre market trade on Thursday
LGND,LGND:US,BBG000BKF014,Ligand Enters Commercial License and Supply Agreements for Captisol®-enabled trametinib,2016-12-22 14:15:00 +0000,http://finance.yahoo.com/news/ligand-enters-commercial-license-supply-141500600.html,"[Business Wire] - Ligand Pharmaceuticals Incorporated announces it has entered into global license and supply agreements with Novartis for the development and commercialization of a Captisol-enabled oral liquid formulation of trametinib, a kinase inhibitor currently indicated as a single agent or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600 mutation...."
LGND,LGND:US,BBG000BKF014,"Ligand Enters into Worldwide OmniAb® Platform License Agreement with ONO PHARMACEUTICAL CO., LTD.",2016-12-22 13:30:00 +0000,http://finance.yahoo.com/news/ligand-enters-worldwide-omniab-platform-133000968.html,"[Business Wire] - Ligand Pharmaceuticals Incorporated announces it has entered into a worldwide license agreement with ONO PHARMACEUTICAL CO., LTD. . Under the license, ONO will be able to use the OmniRat®, OmniMouse® and OmniFlic® platforms to discover fully human mono- and bispecific antibodies."
LGND,LGND:US,BBG000BKF014,Ligand In License And Supply Deals With Novartis For Captisol-enabled Trametinib,2016-12-22 10:21:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BVsBe5cZ4u0/ligand-in-license-and-supply-deals-with-novartis-for-captisolenabled-trametinib-20161222-00442,Ligand In License And Supply Deals With Novartis For Captisol-enabled Trametinib
LGND,LGND:US,BBG000BKF014,Ligand In License And Supply Deals With Novartis For Captisol-enabled Trametinib,2016-12-22 10:21:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ghrsas8nk-w/ligand-in-license-and-supply-deals-with-novartis-for-captisolenabled-trametinib-20161222-00443,Ligand In License And Supply Deals With Novartis For Captisol-enabled Trametinib
LGND,LGND:US,BBG000BKF014,"ONO Enters Into Worldwide OmniAb® Platform License Agreement With Ligand Pharmaceuticals, Inc. (34.6KB)",2016-12-22 06:12:07 +0000,http://www.publicnow.com/view/FC21DAC7E1B41583CAEC566BDA002AEA079EF4AB,"[at noodls] - December 22, 2016 ONO Enters Into Worldwide OmniAb® Platform License Agreement With Ligand Pharmaceuticals, Inc. ONO PHARMACEUTICAL CO., LTD (Osaka, Japan; President, Representative Director and CEO, Gyo ..."
LGND,LGND:US,BBG000BKF014,SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm,2016-12-21 22:33:00 +0000,http://finance.yahoo.com/news/shareholder-notice-lundin-law-pc-223300588.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / December 21, 2016 / Lundin Law PC , a shareholder rights firm announces a class action lawsuit against Ligand Pharmaceuticals Incorporated (""Ligand"" or the ""Company"") ..."
LGND,LGND:US,BBG000BKF014,Lantern Foundation Founder Urges Senate Committee to Commence Investigation into Ligand Pharmaceuticals,2016-12-21 19:00:00 +0000,http://finance.yahoo.com/news/lantern-foundation-founder-urges-senate-190000005.html,"[PR Newswire] - MARLBOROUGH, Mass., Dec. 21, 2016 /PRNewswire/ -- Rev. Fr. Emmanuel Lemelson, the founder and president of the Lantern Foundation, a U.S.-based non-profit foundation, today released a letter he has provided ..."
LGND,LGND:US,BBG000BKF014,EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Ligand Pharmaceuticals Incorporated - LGND,2016-12-21 18:02:11 +0000,http://finance.yahoo.com/news/equity-alert-rosen-law-firm-180211482.html,"[GlobeNewswire] - NEW YORK, Dec. 21, 2016-- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Ligand Pharmaceuticals Incorporated securities from ..."
LGND,LGND:US,BBG000BKF014,SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm,2016-12-21 16:58:00 +0000,http://finance.yahoo.com/news/shareholder-alert-khang-khang-llp-165800590.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / December 21, 2016 / Khang & Khang LLP (the ""Firm"") announces the filing of a class action lawsuit against Ligand Pharmaceuticals Incorporated (""Ligand"" or ..."
LGND,LGND:US,BBG000BKF014,"LGND SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Ligand Pharmaceuticals Inc. and a Lead Plaintiff Deadline of January 17, 2017",2016-12-21 15:14:00 +0000,http://finance.yahoo.com/news/lgnd-shareholder-alert-law-offices-151400365.html,[Business Wire] - The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of California on behalf of investors who purchased Ligand Pharmaceuticals Inc.
LGND,LGND:US,BBG000BKF014,INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm,2016-12-20 23:06:00 +0000,http://finance.yahoo.com/news/investor-notice-lundin-law-pc-230600881.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / December 20, 2016 / Lundin Law PC , a shareholder rights firm announces a class action lawsuit against Ligand Pharmaceuticals Incorporated (""Ligand"" or the ""Company"") ..."
LGND,LGND:US,BBG000BKF014,"SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Ligand Pharmaceuticals Incorporated To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit – LGND",2016-12-20 19:04:38 +0000,http://finance.yahoo.com/news/shareholder-alert-brower-piven-encourages-190438293.html,"[GlobeNewswire] - STEVENSON, Md., Dec. 20, 2016-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court ..."
LGND,LGND:US,BBG000BKF014,INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm,2016-12-20 16:10:00 +0000,http://finance.yahoo.com/news/investor-alert-khang-khang-llp-161000259.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / December 20, 2016 / Khang & Khang LLP (the ""Firm"") announces the filing of a class action lawsuit against Ligand Pharmaceuticals Incorporated (""Ligand"" or ..."
LGND,LGND:US,BBG000BKF014,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ligand Pharmaceuticals Incorporated (LGND) and Lead Plaintiff Deadline: January 17, 2017",2016-12-20 15:16:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-151600123.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / December 20, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Ligand Pharmaceuticals Incorporated (""Ligand"" ..."
LGND,LGND:US,BBG000BKF014,SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm,2016-12-16 17:58:00 +0000,http://finance.yahoo.com/news/shareholder-notice-lundin-law-pc-175800172.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / December 16, 2016 / Lundin Law PC , a shareholder rights firm announces a class action lawsuit against Ligand Pharmaceuticals Incorporated (""Ligand"" or the ""Company"") ..."
LGND,LGND:US,BBG000BKF014,"LGND INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Ligand Pharmaceuticals Inc. and a Lead Plaintiff Deadline of January 17, 2017",2016-12-16 16:28:50 +0000,http://finance.yahoo.com/news/lgnd-investor-alert-law-offices-162850729.html,"[GlobeNewswire] - NEW YORK, Dec. 16, 2016-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of California on behalf of investors who purchased ..."
LGND,LGND:US,BBG000BKF014,Why Ligand Pharmaceuticals (LGND) Stock Might be a Great Pick,2016-12-16 14:59:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jWsgZD8Va80/why-ligand-pharmaceuticals-lgnd-stock-might-be-a-great-pick-cm722466,One stock that might be an intriguing choice for investors right now is Ligand Pharmaceuticals Incorporated LGND This is because this security in the Medical Biomedical Genetics space is seeing solid earnings estimate revision activity and is in great company from a Zacks Industry
LGND,LGND:US,BBG000BKF014,Why Ligand Pharmaceuticals (LGND) Stock Might be a Great Pick,2016-12-16 13:33:01 +0000,http://finance.yahoo.com/news/why-ligand-pharmaceuticals-lgnd-stock-133301745.html,Why Ligand Pharmaceuticals (LGND) Stock Might be a Great Pick
LGND,LGND:US,BBG000BKF014,SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm,2016-12-15 16:53:00 +0000,http://finance.yahoo.com/news/shareholder-alert-khang-khang-llp-165300278.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / December 15, 2016 / Khang & Khang LLP (the ""Firm"") announces the filing of a class action lawsuit against Ligand Pharmaceuticals Incorporated (""Ligand"" or ..."
LGND,LGND:US,BBG000BKF014,"SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ligand Pharmaceuticals Incorporated (LGND) and Lead Plaintiff Deadline: January 17, 2017",2016-12-15 15:14:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-151400389.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / December 15, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Ligand Pharmaceuticals Incorporated (""Ligand"" ..."
LGND,LGND:US,BBG000BKF014,"Notable Wednesday Option Activity: LGND, TER, OSTK",2016-12-14 17:56:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kk02hFyur54/notable-wednesday-option-activity-lgnd-ter-ostk-cm721431,Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Ligand Pharmaceuticals Inc Symbol LGND where a total of 2 543 contracts have traded so far representing approximately 254 300 underlying shares That amounts to about 88 of LGND
LGND,LGND:US,BBG000BKF014,EQUITY NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm,2016-12-14 16:32:00 +0000,http://finance.yahoo.com/news/equity-notice-lundin-law-pc-163200233.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / December 14, 2016 / Lundin Law PC , a shareholder rights firm announces a class action lawsuit against Ligand Pharmaceuticals Incorporated (""Ligand"" or the ""Company"") ..."
LGND,LGND:US,BBG000BKF014,3 Top Growth Stocks to Buy in 2017,2016-12-14 15:58:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/y2cmW06jb3w/3-top-growth-stocks-to-buy-in-2017-cm721269,Image source Getty Images The year may have begun as bad as investors could have imagined with all three major U S indexes losing at least 10 by mid February But with just three weeks to go before the end of 2016 all three indexes have pushed to new all time highs As we
LGND,LGND:US,BBG000BKF014,LIGAND PHARMACEUTICALS INVESTOR REMINDER: Hagens Berman Reminds Ligand Pharmaceuticals Investors of Securities Class Action Lead Plaintiff Deadline,2016-12-14 14:30:00 +0000,http://finance.yahoo.com/news/ligand-pharmaceuticals-investor-reminder-hagens-143000751.html,"[GlobeNewswire] - SAN FRANCISCO, Dec. 14, 2016-- Hagens Berman Sobol Shapiro LLP reminds investors in Ligand Pharmaceuticals, Inc. of the January 17, 2017 Lead Plaintiff deadline.. If you purchased or otherwise acquired ..."
LGND,LGND:US,BBG000BKF014,3 Top Growth Stocks to Buy in 2017,2016-12-14 14:03:11 +0000,http://www.fool.com/investing/2016/12/14/3-top-growth-stocks-to-buy-in-2017.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Top Growth Stocks to Buy in 2017
LGND,LGND:US,BBG000BKF014,INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm,2016-12-12 21:18:00 +0000,http://finance.yahoo.com/news/investor-alert-khang-khang-llp-211800313.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / December 12, 2016 / Khang & Khang LLP (the ""Firm"") announces the filing of a class action lawsuit against Ligand Pharmaceuticals Incorporated (""Ligand"" or ..."
LGND,LGND:US,BBG000BKF014,"INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Ligand Pharmaceuticals Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 – LGND",2016-12-12 16:08:18 +0000,http://finance.yahoo.com/news/investor-alert-levi-korsinsky-llp-160818126.html,"[GlobeNewswire] - NEW YORK, Dec. 12, 2016-- The following statement is being issued by Levi & Korsinsky, LLP:. To: All persons or entities who purchased or otherwise acquired securities of Ligand Pharmaceuticals Inc. between ..."
LGND,LGND:US,BBG000BKF014,The Best Healthcare Stocks for 2017,2016-12-11 12:34:34 +0000,http://www.fool.com/investing/2016/12/10/the-best-healthcare-stocks-for-2017.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,The Best Healthcare Stocks for 2017
LGND,LGND:US,BBG000BKF014,The Best Healthcare Stocks for 2017,2016-12-10 13:56:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2IJvoQU3ZHg/the-best-healthcare-stocks-for-2017-cm719711,Although 2016 hasn t been the greatest year for healthcare stocks in general another year is around the corner and with it come new opportunities Here s why Celgene NASDAQ CELG Ligand Pharmaceuticals NASDAQ LGND and UnitedHealth Group NYSE UNH stand out as
LGND,LGND:US,BBG000BKF014,INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm,2016-12-07 21:55:00 +0000,http://finance.yahoo.com/news/investor-notice-lundin-law-pc-215500737.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / December 7, 2016 / Lundin Law PC , a shareholder rights firm announces a class action lawsuit against Ligand Pharmaceuticals Incorporated (""Ligand"" or the ""Company"") ..."
LGND,LGND:US,BBG000BKF014,"SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Ligand Pharmaceuticals Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 - LGND",2016-12-07 15:54:00 +0000,http://finance.yahoo.com/news/shareholder-alert-levi-korsinsky-llp-155400866.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / December 7, 2016 / The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Ligand Pharmaceuticals ..."
LGND,LGND:US,BBG000BKF014,SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm,2016-12-06 16:52:00 +0000,http://finance.yahoo.com/news/shareholder-alert-khang-khang-llp-165200905.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / December 6, 2017 / Khang & Khang LLP (the ""Firm"") announces the filing of a class action lawsuit against Ligand Pharmaceuticals Incorporated (""Ligand"" or the ..."
LGND,LGND:US,BBG000BKF014,"SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Ligand Pharmaceuticals Incorporated (LGND) and Lead Plaintiff Deadline: January 17, 2017",2016-12-06 15:09:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-150900602.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / December 6, 2016 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Ligand Pharmaceuticals Incorporated (""Ligand"" ..."
LGND,LGND:US,BBG000BKF014,SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm,2016-12-05 22:00:00 +0000,http://finance.yahoo.com/news/shareholder-notice-lundin-law-pc-220000487.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / December 5, 2016 / Lundin Law PC , a shareholder rights firm announces a class action lawsuit against Ligand Pharmaceuticals Incorporated (""Ligand"" or the ""Company"") ..."
LGND,LGND:US,BBG000BKF014,LGND NOTICE: Rosen Law Firm Reminds Ligand Pharmaceuticals Incorporated Investors of Important Deadline in Class Action Filed by Firm - LGND,2016-12-05 21:30:00 +0000,http://finance.yahoo.com/news/lgnd-notice-rosen-law-firm-213000943.html,"[Business Wire] - Rosen Law Firm, a global investor rights law firm, reminds purchasers of Ligand Pharmaceuticals Incorporated securities from November 9, 2015 through November 14, 2016, both dates inclusive of the important January 17, 2017 lead plaintiff deadline in the class action filed by the firm."
LGND,LGND:US,BBG000BKF014,Ligand Pharmaceuticals Inc. (LGND): Hedge Fund Sentiment Unchanged,2016-12-05 11:45:53 +0000,http://www.insidermonkey.com/blog/ligand-pharmaceuticals-inc-lgnd-hedge-fund-sentiment-unchanged-497782/,Ligand Pharmaceuticals Inc. (LGND): Hedge Fund Sentiment Unchanged
LGND,LGND:US,BBG000BKF014,INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm,2016-12-01 22:43:00 +0000,http://finance.yahoo.com/news/investor-alert-khang-khang-llp-224300833.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / December 1, 2016 / Khang & Khang LLP (the ""Firm"") announces the filing of a class action lawsuit against Ligand Pharmaceuticals Incorporated (""Ligand"" or the ..."
LGND,LGND:US,BBG000BKF014,"Lifshitz & Miller Law Firm Announces Investigation of Adeptus Health Inc., Avid Technology, Inc., Cempra, Inc., Clovis Oncology, Inc., Impax Laboratories, Inc., Ligand Pharmaceuticals Incorporated, Pattern Energy Group Inc. and Kandi Techno",2016-12-01 16:44:00 +0000,http://finance.yahoo.com/news/lifshitz-miller-law-firm-announces-164400841.html,"[PR Newswire] - NEW YORK, Dec.1, 2016 /PRNewswire/ -- Adeptus Health Inc. (ADPT) Lifshitz & Miller announces investigation on behalf of ADPT investors concerning whether ADPT adequately disclosed its billing practices, ..."
LGND,LGND:US,BBG000BKF014,"INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Ligand Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 -- LGND",2016-11-30 17:10:58 +0000,http://finance.yahoo.com/news/investor-alert-levi-korsinsky-llp-171058782.html,"[Marketwired] - The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Ligand Pharmaceuticals Inc. between November 9, 2015 and ..."
LGND,LGND:US,BBG000BKF014,INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm,2016-11-29 23:35:00 +0000,http://finance.yahoo.com/news/investor-notice-lundin-law-pc-233500920.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / November 29, 2016 / Lundin Law PC , a shareholder rights firm announces a class action lawsuit against Ligand Pharmaceuticals Incorporated (""Ligand"" or the ""Company"") ..."
LGND,LGND:US,BBG000BKF014,Robbins Arroyo LLP: Ligand Pharmaceuticals Incorporated (LGND) Misled Shareholders According to a Recently Filed Class Action,2016-11-29 19:12:00 +0000,http://finance.yahoo.com/news/robbins-arroyo-llp-ligand-pharmaceuticals-191200217.html,[Business Wire] - Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against Ligand Pharmaceuticals Incorporated in the U.S. District Court for the Southern District of California.
LGND,LGND:US,BBG000BKF014,Lawsuit for Investors in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) over alleged Violations of Securities Laws announced by Shareholders Foundation,2016-11-29 18:35:00 +0000,http://finance.yahoo.com/news/lawsuit-investors-ligand-pharmaceuticals-inc-183500757.html,"[GlobeNewswire] - SAN DIEGO, Nov. 29, 2016-- The Shareholders Foundation, Inc. announces that a lawsuit was filed in California on behalf of certain purchasers of shares of Ligand Pharmaceuticals Inc. over alleged Securities ..."
LGND,LGND:US,BBG000BKF014,IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm,2016-11-29 17:36:00 +0000,http://finance.yahoo.com/news/important-shareholder-alert-khang-khang-173600513.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / November 29, 2016 / Khang & Khang LLP (the ""Firm"") announces the filing of a class action lawsuit against Ligand Pharmaceuticals Incorporated (""Ligand"" or ..."
LGND,LGND:US,BBG000BKF014,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Ligand Pharmaceuticals Incorporated (LGND) and Lead Plaintiff Deadline: January 17, 2017",2016-11-29 15:05:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-150500094.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / November 29, 2016 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Ligand Pharmaceuticals Incorporated (""Ligand"" ..."
LGND,LGND:US,BBG000BKF014,SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm,2016-11-27 11:15:00 +0000,http://finance.yahoo.com/news/shareholder-notice-lundin-law-pc-111500741.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / November 28, 2016 / Lundin Law PC , a shareholder rights firm announces a class action lawsuit against Ligand Pharmaceuticals Incorporated (""Ligand"" or the ""Company"") ..."
LGND,LGND:US,BBG000BKF014,"SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Ligand Pharmaceuticals Incorporated To Contact Brower Piven Before The Lead Plaintiff D",2016-11-27 11:00:00 +0000,http://finance.yahoo.com/news/shareholder-alert-brower-piven-notifies-110000314.html,"[GlobeNewswire] - STEVENSON, Md., Nov. 27, 2016-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court ..."
LGND,LGND:US,BBG000BKF014,INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm,2016-11-25 20:32:00 +0000,http://finance.yahoo.com/news/investor-alert-lundin-law-pc-203200648.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / November 25, 2016 / Lundin Law PC , a shareholder rights firm announces a class action lawsuit against Ligand Pharmaceuticals Incorporated (""Ligand"" or the ""Company"") ..."
LGND,LGND:US,BBG000BKF014,"LGND SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Ligand Pharmaceuticals Inc. and a Lead Plaintiff Deadline of January 17, 2017",2016-11-25 16:00:00 +0000,http://finance.yahoo.com/news/lgnd-shareholder-alert-law-offices-160000937.html,"[GlobeNewswire] - NEW YORK, Nov. 25, 2016-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of California on behalf of investors who purchased ..."
LGND,LGND:US,BBG000BKF014,SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm,2016-11-23 16:19:00 +0000,http://finance.yahoo.com/news/shareholder-alert-khang-khang-llp-161900841.html,"[Business Wire] - Khang & Khang LLP announces the filing of a class action lawsuit against Ligand Pharmaceuticals Incorporated . Investors, who purchased or otherwise acquired shares between November 9, 2015 and November 14, 2016 inclusive , are encouraged to contact the Firm in advance of the January 17, 2017 lead plaintiff motion deadline."
LGND,LGND:US,BBG000BKF014,"LIGAND PHARMACEUTICALS INVESTOR ALERT: Hagens Berman Alerts Ligand Pharmaceuticals Investors to Accounting Restatements, Securities Class Action, and Lead Plaintiff Deadline",2016-11-23 14:30:00 +0000,http://finance.yahoo.com/news/ligand-pharmaceuticals-investor-alert-hagens-143000696.html,"[GlobeNewswire] - SAN FRANCISCO, Nov. 23, 2016-- Hagens Berman Sobol Shapiro LLP alerts investors in Ligand Pharmaceuticals, Inc. to the securities class action filed in the U.S. District Court for the Southern District ..."
LGND,LGND:US,BBG000BKF014,Ligand's Partner Retrophin Provides New Data on Sparsentan,2016-11-22 22:20:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Xe4Z5Amc_PY/ligands-partner-retrophin-provides-new-data-on-sparsentan-cm712661,Ligand Pharmaceuticals Incorporated s LGND partner Retrophin Inc RTRX announced additional positive data results from the phase II DUET study on sparsentan for the treatment of focal segmental glomerulosclerosis FSGS The data was presented at the American Society of Nephrology Kidney
LGND,LGND:US,BBG000BKF014,LGND LOSS ALERT: Rosen Law Firm Reminds Ligand Pharmaceuticals Incorporated Investors of Important Deadline in Class Action Filed by Firm- LGND,2016-11-22 19:08:00 +0000,http://finance.yahoo.com/news/lgnd-loss-alert-rosen-law-190800190.html,"[PR Newswire] - NEW YORK, Nov. 22, 2016 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Ligand Pharmaceuticals Incorporated securities (NASDAQ: LGND) of the important January 17, ..."
LGND,LGND:US,BBG000BKF014,Ligand's Partner Retrophin Provides New Data on Sparsentan,2016-11-22 14:02:02 +0000,http://finance.yahoo.com/news/ligands-partner-retrophin-provides-data-140202477.html,Ligand's Partner Retrophin Provides New Data on Sparsentan
LGND,LGND:US,BBG000BKF014,IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm,2016-11-21 19:05:00 +0000,http://finance.yahoo.com/news/important-shareholder-alert-lundin-law-190500866.html,"[Business Wire] - Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Ligand Pharmaceuticals Incorporated concerning possible violations of federal securities laws between November 9, 2015 and November 14, 2016 inclusive ."
LGND,LGND:US,BBG000BKF014,"SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Ligand Pharmaceuticals Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 – LGND",2016-11-21 18:19:29 +0000,http://finance.yahoo.com/news/shareholder-alert-levi-korsinsky-llp-181929907.html,"[GlobeNewswire] - NEW YORK, Nov. 21, 2016-- The following statement is being issued by Levi & Korsinsky, LLP:. To: All persons or entities who purchased or otherwise acquired securities of Ligand Pharmaceuticals Inc. between ..."
LGND,LGND:US,BBG000BKF014,SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm,2016-11-21 16:24:00 +0000,http://finance.yahoo.com/news/shareholder-alert-goldberg-law-pc-162400687.html,"[Business Wire] - Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Ligand Pharmaceuticals Incorporated ."
LGND,LGND:US,BBG000BKF014,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Ligand Pharmaceuticals Incorporated (LGND) and Lead Plaintiff Deadline: January 17, 2017",2016-11-21 15:10:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-151000700.html,"[GlobeNewswire] - NEW YORK, Nov. 21, 2016-- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Ligand Pharmaceuticals Incorporated and certain ..."
LGND,LGND:US,BBG000BKF014,Ligand Partner Retrophin Reports Additional Positive Data from Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis at ASN Kidney Week 2016,2016-11-21 12:30:00 +0000,http://finance.yahoo.com/news/ligand-partner-retrophin-reports-additional-123000037.html,"[Business Wire] - Ligand Pharmaceuticals Incorporated partner Retrophin, Inc. today announced additional results from the Phase 2 DUET study of sparsentan for the treatment of focal segmental glomerulosclerosis , a rare kidney disorder without an FDA-approved pharmacologic treatment that often leads to end-stage renal disease."
LGND,LGND:US,BBG000BKF014,INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm,2016-11-19 02:11:00 +0000,http://finance.yahoo.com/news/investor-alert-khang-khang-llp-021100420.html,"[Business Wire] - Khang & Khang LLP announces the filing of a class action lawsuit against Ligand Pharmaceuticals Incorporated . Investors, who purchased or otherwise acquired shares between November 9, 2015 and November 14, 2016 inclusive , are encouraged to contact the Firm in advance of the January 17, 2017 lead plaintiff motion deadline."
LGND,LGND:US,BBG000BKF014,"Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Encourages Investors to Contact the Firm",2016-11-18 21:30:00 +0000,http://finance.yahoo.com/news/bragar-eagel-squire-p-c-213000029.html,"[Business Wire] - Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of California on behalf of all persons or entities who acquired Ligand Pharmaceuticals Incorporated securities between November 9, 2015 and November 14, 2016 ."
LGND,LGND:US,BBG000BKF014,IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm,2016-11-18 16:36:00 +0000,http://finance.yahoo.com/news/important-investor-alert-lundin-law-163600446.html,"[Business Wire] - Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Ligand Pharmaceuticals Incorporated concerning possible violations of federal securities laws between November 9, 2015 and November 14, 2016 inclusive ."
LGND,LGND:US,BBG000BKF014,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Ligand Pharmaceuticals Incorporated (LGND) and Lead Plaintiff Deadline: January 17, 2017",2016-11-18 15:20:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-152000511.html,"[PR Newswire] - NEW YORK, Nov. 18, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Ligand Pharmaceuticals Incorporated ..."
LGND,LGND:US,BBG000BKF014,INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm,2016-11-18 02:34:00 +0000,http://finance.yahoo.com/news/investor-alert-goldberg-law-pc-023400220.html,"[Business Wire] - Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Ligand Pharmaceuticals Incorporated ."
LGND,LGND:US,BBG000BKF014,EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Ligand Pharmaceuticals Incorporated - LGND,2016-11-18 00:52:00 +0000,http://finance.yahoo.com/news/equity-alert-rosen-law-firm-005200098.html,"[Business Wire] - Rosen Law Firm, a global investor rights law firm, announces that it has filed a class action lawsuit on behalf of purchasers of Ligand Pharmaceuticals Incorporated securities from November 9, 2015 through November 14, 2016, both dates inclusive ."
LGND,LGND:US,BBG000BKF014,INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm,2016-11-17 15:54:00 +0000,http://finance.yahoo.com/news/investor-alert-khang-khang-llp-155400754.html,[Business Wire] - Khang & Khang LLP announces that it is investigating claims against Ligand Pharmaceuticals Incorporated concerning possible violations of federal securities laws.
LGND,LGND:US,BBG000BKF014,LIGAND PHARMACEUTICALS INVESTOR ALERT: Hagens Berman is Investigating Ligand Pharmaceuticals' Accounting Restatements and Possible Securities Law Violations,2016-11-17 14:30:00 +0000,http://finance.yahoo.com/news/ligand-pharmaceuticals-investor-alert-hagens-143000446.html,"[PR Newswire] - SAN FRANCISCO, Nov. 17, 2016 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) to the firm's investigation into improper accounting ..."
LGND,LGND:US,BBG000BKF014,INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Ligand Pharmaceuticals Incorporated and Advises Investors with Losses to Contact the Firm,2016-11-16 17:02:00 +0000,http://finance.yahoo.com/news/investor-alert-goldberg-law-pc-170200629.html,"[Business Wire] - Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Ligand Pharmaceuticals Incorporated concerning possible violations of federal securities laws."
LGND,LGND:US,BBG000BKF014,EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Ligand Pharmaceuticals Incorporated,2016-11-16 15:51:00 +0000,http://finance.yahoo.com/news/equity-alert-rosen-law-firm-155100695.html,"[Business Wire] - Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Ligand Pharmaceuticals Incorporated resulting from allegations that Ligand may have issued materially misleading business information to the investing public."
LGND,LGND:US,BBG000BKF014,IMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of Ligand Pharmaceuticals Incorporated and Advises Investors with Losses to Contact the Firm,2016-11-16 11:45:00 +0000,http://finance.yahoo.com/news/important-investor-alert-lundin-law-114500643.html,"[Business Wire] - Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Ligand Pharmaceuticals Incorporated concerning possible violations of federal securities laws."
LGND,LGND:US,BBG000BKF014,Ligand Pharmaceuticals Inc. Investigated For Securities Fraud By Block & Leviton After Announcing Restatement Of Financial Results,2016-11-16 00:06:00 +0000,http://finance.yahoo.com/news/ligand-pharmaceuticals-inc-investigated-securities-000600428.html,"[PR Newswire] - BOSTON, Nov. 15, 2016 /PRNewswire/ -- Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, is investigating whether Ligand Pharmaceuticals Inc. (LGND) and certain of its officers and directors violated federal securities laws following the news that the Company has restated several quarters of recent financial results. If you have recently purchased or otherwise acquired Ligand securities and have questions about your legal rights or possess information relevant to this investigation, please contact attorneys Steven Harte or Bradley Vettraino at (617) 398-5600 or by email at steven@blockesq.com or bradley@blockesq.com."
LGND,LGND:US,BBG000BKF014,SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm,2016-11-15 21:37:00 +0000,http://finance.yahoo.com/news/shareholder-alert-khang-khang-llp-213700803.html,[Business Wire] - Khang & Khang LLP announces that it is investigating claims against Ligand Pharmaceuticals Incorporated concerning possible violations of federal securities laws.
LGND,LGND:US,BBG000BKF014,Harwood Feffer LLP Announces Investigation of Ligand Pharmaceuticals Incorporated,2016-11-15 20:44:00 +0000,http://finance.yahoo.com/news/harwood-feffer-llp-announces-investigation-204400513.html,"[PR Newswire] - NEW YORK, Nov. 15, 2016 /PRNewswire/ -- Harwood Feffer LLP ( www.hfesq.com ) is investigating potential claims against the board of directors of Ligand Pharmaceuticals Incorporated (""Ligand"" ..."
LGND,LGND:US,BBG000BKF014,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Ligand Pharmaceuticals Incorporated (LGND)",2016-11-15 20:08:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-200800051.html,"[PR Newswire] - NEW YORK, Nov. 15, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ligand Pharmaceuticals Incorporated (""Ligand"" ..."
LGND,LGND:US,BBG000BKF014,SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Ligand Pharmaceuticals Incorporated and Advises Investors with Losses to Contact the Firm,2016-11-15 17:39:00 +0000,http://finance.yahoo.com/news/shareholder-alert-goldberg-law-pc-173900309.html,"[Business Wire] - Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Ligand Pharmaceuticals Incorporated concerning possible violations of federal securities laws."
LGND,LGND:US,BBG000BKF014,"SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Violations of Federal Securities Laws by Certain Officers and Directors of Ligand Pharmaceuticals, Inc.",2016-11-15 16:51:00 +0000,http://finance.yahoo.com/news/shareholder-alert-levi-korsinsky-llp-165100025.html,"[Business Wire] - Levi & Korsinsky announces it has commenced an investigation of Ligand Pharmaceuticals, Inc. concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors."
LGND,LGND:US,BBG000BKF014,"LIGAND PHARMACEUTICALS INC Files SEC form 10-Q/A, Quarterly Report",2016-11-15 11:07:35 +0000,http://biz.yahoo.com/e/161115/lgnd10-q_a.html,"LIGAND PHARMACEUTICALS INC Files SEC form 10-Q/A, Quarterly Report"
LGND,LGND:US,BBG000BKF014,"LIGAND PHARMACEUTICALS INC Files SEC form 10-K/A, Annual Report",2016-11-15 11:06:22 +0000,http://biz.yahoo.com/e/161115/lgnd10-k_a.html,"LIGAND PHARMACEUTICALS INC Files SEC form 10-K/A, Annual Report"
LGND,LGND:US,BBG000BKF014,IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Ligand Pharmaceuticals Incorporated and Advises Investors with Losses to Contact the Firm,2016-11-15 05:56:00 +0000,http://finance.yahoo.com/news/important-shareholder-alert-lundin-law-055600374.html,IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Ligand Pharmaceuticals Incorporated and Advises Investors with Losses to Contact the Firm
LGND,LGND:US,BBG000BKF014,"LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Non-Reliance on Previou",2016-11-14 22:49:21 +0000,http://biz.yahoo.com/e/161114/lgnd8-k.html,"LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Non-Reliance on Previou"
LGND,LGND:US,BBG000BKF014,"ETFs with exposure to Ligand Pharmaceuticals, Inc. : November 14, 2016",2016-11-14 18:48:02 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-ligand-pharmaceuticals-inc-november-14-2016/,"ETFs with exposure to Ligand Pharmaceuticals, Inc. : November 14, 2016"
LGND,LGND:US,BBG000BKF014,"Ligand Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LGND-US : November 11, 2016",2016-11-11 12:10:35 +0000,http://www.capitalcube.com/blog/index.php/ligand-pharmaceuticals-inc-breached-its-50-day-moving-average-in-a-bullish-manner-lgnd-us-november-11-2016/,"Ligand Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LGND-US : November 11, 2016"
LGND,LGND:US,BBG000BKF014,"Ligand Pharmaceuticals, Inc. :LGND-US: Earnings Analysis: Q3, 2016 By the Numbers : November 10, 2016",2016-11-10 15:32:52 +0000,http://www.capitalcube.com/blog/index.php/ligand-pharmaceuticals-inc-lgnd-us-earnings-analysis-q3-2016-by-the-numbers-november-10-2016/,"Ligand Pharmaceuticals, Inc. :LGND-US: Earnings Analysis: Q3, 2016 By the Numbers : November 10, 2016"
LGND,LGND:US,BBG000BKF014,3 Top Healthcare Stocks to Own If Donald Trump Becomes President,2016-11-06 21:47:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sbwXM8KB3SI/3-top-healthcare-stocks-to-own-if-donald-trump-becomes-president-cm704609,Just a few days ago FiveThirtyEight baseball columnist Rob Arthur wrote that the Chicago Cubs had a smaller chance of winning the World Series than Donald Trump had for winning the presidency Now the Cubs are champions And Trump has a reasonably good shot at winning also What
LGND,LGND:US,BBG000BKF014,"Ligand (LGND) Q3 Earnings Down Y/Y, Lowers '16 Guidance",2016-11-04 12:06:12 +0000,http://finance.yahoo.com/news/ligand-lgnd-q3-earnings-down-120612571.html,"Ligand (LGND) Q3 Earnings Down Y/Y, Lowers '16 Guidance"
LGND,LGND:US,BBG000BKF014,Ligand Pharmaceuticals is Now Oversold (LGND),2016-11-03 22:07:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FyJBhsHo2T4/ligand-pharmaceuticals-is-now-oversold-lgnd-cm703670,Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which measures momentum on
LGND,LGND:US,BBG000BKF014,Ligand misses 3Q revenue forecasts,2016-11-03 21:23:30 +0000,http://sg.finance.yahoo.com/news/ligand-misses-3q-revenue-forecasts-212330225.html,Ligand misses 3Q revenue forecasts
LGND,LGND:US,BBG000BKF014,"LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition",2016-11-03 20:06:26 +0000,http://biz.yahoo.com/e/161103/lgnd8-k.html,"LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition"
LGND,LGND:US,BBG000BKF014,Ligand Reports Third Quarter 2016 Financial Results,2016-11-03 20:01:00 +0000,http://finance.yahoo.com/news/ligand-reports-third-quarter-2016-200100220.html,"[Business Wire] - Ligand Pharmaceuticals Incorporated today reported financial results for the three and nine months ended September 30, 2016, and provided an operating forecast and program updates."
LGND,LGND:US,BBG000BKF014,Ligand Pharmaceuticals Inc Reveals 12% Gain In Q3 Earnings,2016-11-03 16:04:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ui--CrPJWV0/ligand-pharmaceuticals-inc-reveals-12-gain-in-q3-earnings-20161103-00796,Ligand Pharmaceuticals Inc Reveals 12% Gain In Q3 Earnings
LGND,LGND:US,BBG000BKF014,Ligand Pharmaceuticals Q3 16 Earnings Conference Call At 4:30 PM ET,2016-11-03 15:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lQFzY4YhCDM/ligand-pharmaceuticals-q3-16-earnings-conference-call-at-430-pm-et-20161103-01311,Ligand Pharmaceuticals Q3 16 Earnings Conference Call At 4:30 PM ET
LGND,LGND:US,BBG000BKF014,Q3 2016 Ligand Pharmaceuticals Inc Earnings Release - Before Market Open,2016-11-03 11:07:07 +0000,http://biz.yahoo.com/research/earncal/20161103.html?t=lgnd,Q3 2016 Ligand Pharmaceuticals Inc Earnings Release - Before Market Open
LGND,LGND:US,BBG000BKF014,Ligand (LGND) Q3 Earnings: Is the Stock Likely to Disappoint?,2016-10-28 14:35:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/P6XKleSpxLk/ligand-lgnd-q3-earnings-is-the-stock-likely-to-disappoint-cm700217,Ligand Pharmaceuticals Incorporated LGND is scheduled to report third quarter 2016 results on Nov 3 after the market closes Ligand has an impressive track record with its earnings surpassing expectations in three of the trailing four quarters delivering an average positive surprise
LGND,LGND:US,BBG000BKF014,Ligand (LGND) Q3 Earnings: Is the Stock Likely to Disappoint?,2016-10-28 13:22:01 +0000,http://finance.yahoo.com/news/ligand-lgnd-q3-earnings-stock-132201642.html,Ligand (LGND) Q3 Earnings: Is the Stock Likely to Disappoint?
LGND,LGND:US,BBG000BKF014,Ligand Partner Melinta Therapeutics Submits NDA for Baxdela,2016-10-25 22:24:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HNlZ2OxTG5Q/ligand-partner-melinta-therapeutics-submits-nda-for-baxdela-cm698250,Ligand Pharmaceuticals Incorporated LGND said its partner Melinta Therapeutics a private pharma company has submitted New Drug Applications NDAs to the FDA for its pipeline candidate Baxdela delafloxacin to treat serious bacterial infections Ligand Pharma and Melinta Therapeutics
LGND,LGND:US,BBG000BKF014,Ligand Partner Melinta Therapeutics Submits NDA for Baxdela,2016-10-25 20:32:08 +0000,http://finance.yahoo.com/news/ligand-partner-melinta-therapeutics-submits-203208669.html,Ligand Partner Melinta Therapeutics Submits NDA for Baxdela
LGND,LGND:US,BBG000BKF014,"INO Slips On Clinical Hold, MRK Gets FDA Nod, Be All Ears For AKAO",2016-10-25 03:29:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-zhnSBzNTVg/ino-slips-on-clinical-hold-mrk-gets-fda-nod-be-all-ears-for-akao-20161025-00106,"INO Slips On Clinical Hold, MRK Gets FDA Nod, Be All Ears For AKAO"
LGND,LGND:US,BBG000BKF014,Ligand Partner Melinta Therapeutics Submits Baxdela New Drug Application for Hospital-Treated Skin Infections,2016-10-24 13:21:00 +0000,http://finance.yahoo.com/news/ligand-partner-melinta-therapeutics-submits-132100275.html,"[Business Wire] - Ligand Pharmaceuticals Incorporated partner Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today that it has submitted New Drug Applications to the U.S."
LGND,LGND:US,BBG000BKF014,Ligand Announces Third Quarter 2016 Earnings Release Date and Participation in the Stephens Fall Investment Conference,2016-10-13 13:00:00 +0000,http://finance.yahoo.com/news/ligand-announces-third-quarter-2016-130000108.html,"[Business Wire] - Ligand Pharmaceuticals Incorporated announced today plans to report third quarter 2016 financial results on November 3, 2016. Ligand’s CEO John Higgins, President and COO Matt Foehr and CFO Matt Korenberg will host the conference call."
LGND,LGND:US,BBG000BKF014,"FDA Says No To Nicox, Lundbeck''s Persistence Pays Off, It''s A Win For LPCN",2016-10-10 04:21:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FOusswuex7E/fda-says-no-to-nicox-lundbecks-persistence-pays-off-its-a-win-for-lpcn-20161010-00080,"FDA Says No To Nicox, Lundbeck''s Persistence Pays Off, It''s A Win For LPCN"
LGND,LGND:US,BBG000BKF014,Ligand Partner Lundbeck Receives FDA Approval of Carnexiv™ (carbamazepine) Injection as Intravenous Short-Term Replacement Therapy for Certain Seizure Types,2016-10-07 22:17:00 +0000,http://finance.yahoo.com/news/ligand-partner-lundbeck-receives-fda-221700797.html,[Business Wire] - Ligand Pharmaceuticals Incorporated partner Lundbeck announced today that the U.S. Food and Drug Administration has approved Carnexiv™ injection as a short-term replacement therapy for oral carbamazepine formulations in adults with certain seizure types when oral administration is temporarily not feasible.
LGND,LGND:US,BBG000BKF014,New Strong Sell Stocks for October 5th,2016-10-05 14:47:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GeiU9A9JzZc/new-strong-sell-stocks-for-october-5th-cm689010,Here are 5 stocks added to the Zacks Rank 5 Strong Sell List today 160 160 160 Vulcan Materials Company VMC is a leading producer of construction aggregates a major producer of asphalt mix cement and concrete The Zacks Consensus Estimate for its current year earnings has
LGND,LGND:US,BBG000BKF014,3 Top Biotech Stocks to Buy in October,2016-10-03 19:13:02 +0000,http://www.fool.com/investing/2016/10/02/3-top-biotech-stocks-to-buy-in-october.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Top Biotech Stocks to Buy in October
LGND,LGND:US,BBG000BKF014,3 Top Biotech Stocks to Buy in October,2016-10-02 20:42:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KBVGAIpI0zk/3-top-biotech-stocks-to-buy-in-october-cm687545,Image source Getty Images The biotech industry is on pace for a down year The First Trust NYSE Arca Biotech ETF NYSEMKT FBT an exchange traded fund that holds a broad portfolio of biotech stocks has descended by double digits since the start of 2016 badly lagging the S amp
LGND,LGND:US,BBG000BKF014,Is It Too Late to Get In on This Millionaire-Maker Stock?,2016-10-01 13:44:05 +0000,http://www.fool.com/investing/2016/09/30/is-it-too-late-to-get-in-on-this-millionaire-maker.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Is It Too Late to Get In on This Millionaire-Maker Stock?
LGND,LGND:US,BBG000BKF014,Is It Too Late to Get In on This Millionaire-Maker Stock?,2016-09-30 15:23:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nfr9EG4KMUw/is-it-too-late-to-get-in-on-this-millionaire-maker-stock-cm687085,Image source Getty Images If you d invested in Ligand Pharmaceuticals NASDAQ LGND on the first trading day of 2011 then you would have lucked into an 11 bagger Not bad LGND data by YCharts While I m cherry picking the data to make
LGND,LGND:US,BBG000BKF014,Amgen's Multiple Myeloma Drug Kyprolis Fails in Phase III,2016-09-28 13:23:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3NQdgB3XjL4/amgens-multiple-myeloma-drug-kyprolis-fails-in-phase-iii-cm685765,Biotech major Amgen Inc AMGN announced that its multiple myeloma drug Kyprolis did not meet the primary endpoint in a phase III head to head CLARION study with Velcade The CLARION study n 955 compared Kyprolis carfilzomib in combination with melphalan and prednisone with
LGND,LGND:US,BBG000BKF014,Amgen's Multiple Myeloma Drug Kyprolis Fails in Phase III,2016-09-28 11:10:11 +0000,http://finance.yahoo.com/news/amgens-multiple-myeloma-drug-kyprolis-111011365.html,Amgen's Multiple Myeloma Drug Kyprolis Fails in Phase III
LGND,LGND:US,BBG000BKF014,Here's Why Ligand Pharmaceuticals Inc Is Plunging Today,2016-09-27 22:22:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IZGTDV3l-Wg/heres-why-ligand-pharmaceuticals-inc-is-plunging-today-cm685656,Image source Getty What Shares of Ligand Pharmaceuticals NASDAQ LGND an owner of royalty assets in the healthcare space are falling by more than 13 as of 3 30 p m EDT in response to its partner Amgen NASDAQ AMGN reporting disappointing clinical
LGND,LGND:US,BBG000BKF014,Ligand Pharmaceuticals Enters Oversold Territory (LGND),2016-09-27 22:20:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aHB1y4E9aPY/ligand-pharmaceuticals-enters-oversold-territory-lgnd-cm685650,Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which measures momentum on
LGND,LGND:US,BBG000BKF014,Here's Why Ligand Pharmaceuticals Inc Is Plunging Today,2016-09-27 20:26:00 +0000,http://www.fool.com/investing/2016/09/27/heres-why-ligand-pharmaceuticals-inc-is-plunging-t.aspx?source=yahoo-2-news&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2-news,Here's Why Ligand Pharmaceuticals Inc Is Plunging Today
LGND,LGND:US,BBG000BKF014,Amgen's Multiple Myeloma Drug Bumbles Key Test Vs. Blockbuster Velcade,2016-09-27 20:23:03 +0000,http://www.investors.com/news/technology/amgens-multiple-myeloma-drug-bumbles-key-test-vs-blockbuster-velcade/,Amgen's Multiple Myeloma Drug Bumbles Key Test Vs. Blockbuster Velcade
LGND,LGND:US,BBG000BKF014,Shares of Ligand plunge 12% after Amgen drug misses study goal,2016-09-27 20:22:26 +0000,http://www.cnbc.com/id/103973093?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=103973093,Shares of Ligand plunge 12% after Amgen drug misses study goal
LGND,LGND:US,BBG000BKF014,Kite Pharma Reports Favorable Data from Lymphoma Study,2016-09-27 16:24:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rdGfddAUwhU/kite-pharma-reports-favorable-data-from-lymphoma-study-cm685355,Kite Pharma Inc KITE announced encouraging top line data from a pre planned interim analysis of a pivotal phase II portion of the ZUMA 1 study on its lead pipeline candidate KTE C19 an anti CD19 CAR based therapy The candidate is being evaluated for the treatment of patients
LGND,LGND:US,BBG000BKF014,GW Pharma Attains 52-Week High on Positive Epidiolex Data,2016-09-27 15:25:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MAwZrVF65pg/gw-pharma-attains-52-week-high-on-positive-epidiolex-data-cm685319,GW Pharmaceuticals plc s GWPH shares are riding high after the company reported third consecutive positive phase III data on its lead cannabinoid pipeline candidate Epidiolex so far this year The company announced data from the second pivotal phase III study on Epidiolex for the treatment
LGND,LGND:US,BBG000BKF014,Analysts Forecast 14% Upside For IYH,2016-09-27 15:23:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sG_pQgaEPlA/analysts-forecast-14-upside-for-iyh-cm685262,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
LGND,LGND:US,BBG000BKF014,"Ligand Pharmaceuticals, Inc. – Value Analysis (NASDAQ:LGND) : September 27, 2016",2016-09-27 14:47:49 +0000,http://www.capitalcube.com/blog/index.php/ligand-pharmaceuticals-inc-value-analysis-nasdaqlgnd-september-27-2016/,"Ligand Pharmaceuticals, Inc. – Value Analysis (NASDAQ:LGND) : September 27, 2016"
LGND,LGND:US,BBG000BKF014,Kite Pharma Reports Favorable Data from Lymphoma Study,2016-09-27 14:28:02 +0000,http://finance.yahoo.com/news/kite-pharma-reports-favorable-data-142802085.html,Kite Pharma Reports Favorable Data from Lymphoma Study
LGND,LGND:US,BBG000BKF014,"Regeneron, Sanofi Skin Disease Drug Under Priority Review",2016-09-26 22:21:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/831enhIiZ_M/regeneron-sanofi-skin-disease-drug-under-priority-review-cm684876,Regeneron Pharmaceuticals Inc REGN and partner Sanofi SNY received encouraging news after their biologics license application for experimental skin disease treatment dupilumab was accepted for priority review by the FDA The companies are looking to get dupilumab approved for the
LGND,LGND:US,BBG000BKF014,3 Top Biotech Stocks to Buy on Sale,2016-09-26 20:25:44 +0000,http://www.fool.com/investing/2016/09/26/3-top-biotech-stocks-to-buy-on-sale.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Top Biotech Stocks to Buy on Sale
LGND,LGND:US,BBG000BKF014,"Regeneron, Sanofi Skin Disease Drug Under Priority Review",2016-09-26 19:55:07 +0000,http://finance.yahoo.com/news/regeneron-sanofi-skin-disease-drug-195507937.html,"Regeneron, Sanofi Skin Disease Drug Under Priority Review"
LGND,LGND:US,BBG000BKF014,"Endo Appoints New CEO, Keeps Q3 & '16 View, Stock Jumps",2016-09-26 17:22:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wkZLH-s-hxM/endo-appoints-new-ceo-keeps-q3-16-view-stock-jumps-cm684619,Ireland domiciled specialty pharmaceutical company Endo International plc s ENDP shares soared 15 5 after the company announced that its board of directors has appointed Paul V Campanelli as the new President and Chief Executive Officer CEO Campanelli will replace Rajiv De
LGND,LGND:US,BBG000BKF014,"Endo Appoints New CEO, Keeps Q3 & '16 View, Stock Jumps",2016-09-26 15:12:03 +0000,http://finance.yahoo.com/news/endo-appoints-ceo-keeps-q3-151203647.html,"Endo Appoints New CEO, Keeps Q3 & '16 View, Stock Jumps"
LGND,LGND:US,BBG000BKF014,3 Top Biotech Stocks to Buy on Sale,2016-09-26 14:24:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9snXci0A7dY/3-top-biotech-stocks-to-buy-on-sale-cm684420,Image source Getty Images Investors looking for growth opportunities often like what they find in the biotech sector Unfortunately biotech stocks frequently come with valuations that are either sky high or highly speculative The good news though is that there are some
LGND,LGND:US,BBG000BKF014,"Ligand Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LGND-US : September 26, 2016",2016-09-26 12:49:35 +0000,http://www.capitalcube.com/blog/index.php/ligand-pharmaceuticals-inc-breached-its-50-day-moving-average-in-a-bearish-manner-lgnd-us-september-26-2016/,"Ligand Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LGND-US : September 26, 2016"
LGND,LGND:US,BBG000BKF014,Teva Reports Positive Phase III Tardive Dyskinesia Data,2016-09-23 18:24:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Bs1ITqCBVBA/teva-reports-positive-phase-iii-tardive-dyskinesia-data-cm683737,Teva Pharmaceutical Industries Ltd TEVA announced encouraging top line data from the second phase III study AIM TD on SD 809 deutetrabenazine which is being evaluated for the treatment of tardive dyskinesia TD The randomized double blinded placebo controlled parallel
LGND,LGND:US,BBG000BKF014,Ligand Inks CNS License Agreement with Seelos Therapeutics,2016-09-23 16:24:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KqImjmGfCyo/ligand-inks-cns-license-agreement-with-seelos-therapeutics-cm683846,Ligand Pharmaceuticals Incorporated LGND announced that it has granted licensing rights to four of its pipeline programs to Seelos Therapeutics Inc a New York based private biopharmaceutical company The four programs target various central nervous system CNS respiratory and pain
LGND,LGND:US,BBG000BKF014,Ligand Inks CNS License Agreement with Seelos Therapeutics,2016-09-23 14:03:02 +0000,http://finance.yahoo.com/news/ligand-inks-cns-license-agreement-140302454.html,Ligand Inks CNS License Agreement with Seelos Therapeutics
LGND,LGND:US,BBG000BKF014,Teva Reports Positive Phase III Tardive Dyskinesia Data,2016-09-23 13:33:01 +0000,http://finance.yahoo.com/news/teva-reports-positive-phase-iii-133301225.html,Teva Reports Positive Phase III Tardive Dyskinesia Data
LGND,LGND:US,BBG000BKF014,"LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers",2016-09-22 20:06:56 +0000,http://biz.yahoo.com/e/160922/lgnd8-k.html,"LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers"
LGND,LGND:US,BBG000BKF014,"Health Care Sector Update for 09/22/2016: LGND,AVXL,BLUE",2016-09-22 19:40:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tdIuSTIBwls/health-care-sector-update-for-09222016-lgndavxlblue-cm683387,Top Health Care StocksTop Health Care Stocks JNJ 0 44 JNJ 0 44 PFE 0 31 PFE 0 31 MRK 0 74 MRK 0 74 ABT 0 53 ABT 0 53 AMGN 0 77 AMGN 0 77 Health care stocks were increasing today with the NYSE Health Care Index rising about 0 7 while shares of health care companies in the S amp
LGND,LGND:US,BBG000BKF014,5 Stocks With Amazon-Like Growth Potential,2016-09-22 16:45:00 +0000,http://www.fool.com/investing/2016/09/22/5-stocks-with-amazon-like-growth-potential.aspx?source=yahoo-2-news&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2-news,5 Stocks With Amazon-Like Growth Potential
LGND,LGND:US,BBG000BKF014,Ligand Licenses Four Programs to Seelos Therapeutics,2016-09-22 13:00:00 +0000,http://finance.yahoo.com/news/ligand-licenses-four-programs-seelos-130000450.html,"[Business Wire] - Ligand Pharmaceuticals Incorporated announces the licensing of rights to four programs to Seelos Therapeutics, Inc., a newly formed biopharmaceutical company focused on central nervous system , respiratory and other disorders."
LGND,LGND:US,BBG000BKF014,Ligand (LGND) Inks Deal with TeneoBio for OmniAb Technology,2016-09-19 16:23:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uBjkB99nFjA/ligand-lgnd-inks-deal-with-teneobio-for-omniab-technology-cm681320,Ligand Pharmaceuticals Incorporated LGND announced that it has entered into a worldwide license agreement with California based TeneoBio Inc Under the deal TeneoBio will utilize OmniFlic technology from Ligand s OmniAb platform for the discovery of fully human bispecific antibodies
LGND,LGND:US,BBG000BKF014,Ligand (LGND) Inks Deal with TeneoBio for OmniAb Technology,2016-09-19 14:26:02 +0000,http://finance.yahoo.com/news/ligand-lgnd-inks-deal-teneobio-142602520.html,Ligand (LGND) Inks Deal with TeneoBio for OmniAb Technology
LGND,LGND:US,BBG000BKF014,"ETF’s with exposure to Ligand Pharmaceuticals, Inc. : September 19, 2016",2016-09-19 14:20:24 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-ligand-pharmaceuticals-inc-september-19-2016/,"ETF’s with exposure to Ligand Pharmaceuticals, Inc. : September 19, 2016"
LGND,LGND:US,BBG000BKF014,Novartis Reports Positive Phase II Data on Migraine Drug,2016-09-16 17:21:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Rf14IKck64I/novartis-reports-positive-phase-ii-data-on-migraine-drug-cm680501,Novartis AG NVS announced results from a phase II study on migraine candidate AMG334 Data from the study were presented at the fifth European Headache and Migraine Trust International Congress EHMTIC in Glasgow Scotland The study enrolled 667 patients who had a mean baseline
LGND,LGND:US,BBG000BKF014,Epizyme Receives Milestone from Glaxo for Lymphoma Drug,2016-09-16 15:22:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aOSodPnkzRM/epizyme-receives-milestone-from-glaxo-for-lymphoma-drug-cm680516,Epizyme Inc EPZM announced that the company has earned a milestone payment worth 6 million from GlaxoSmithKline GSK The payment was triggered by Glaxo s initiation of a phase I study on GSK3326595 formerly EPZ015938 The company initiated a phase I dose escalation study to
LGND,LGND:US,BBG000BKF014,"Ligand Enters OmniAb® License Agreement with TeneoBio, Inc.",2016-09-16 13:00:00 +0000,http://finance.yahoo.com/news/ligand-enters-omniab-license-agreement-130000459.html,"[Business Wire] - Ligand Pharmaceuticals Incorporated announces it has entered into a worldwide license agreement with Menlo Park, CA-based TeneoBio, Inc. Under the license, TeneoBio will be able to use the OmniFlic® technology from the OmniAb® platform to discover fully human bispecific antibodies to be developed for the treatment of various diseases, with an initial focus on therapeutics for cancer, autoimmunity, ..."
LGND,LGND:US,BBG000BKF014,"Commit To Purchase Ligand Pharmaceuticals At $100, Earn 10.8% Annualized Using Options",2016-09-15 17:15:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EwZXpy-dpEA/commit-to-purchase-ligand-pharmaceuticals-at-100-earn-108-annualized-using-options-cm680085,Investors considering a purchase of Ligand Pharmaceuticals Inc Symbol LGND shares but cautious about paying the going market price of 115 04 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is
LGND,LGND:US,BBG000BKF014,Roche Ocrevus Positive in Phase III Multiple Sclerosis Trials,2016-09-15 16:20:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cuosqG2U-Zo/roche-ocrevus-positive-in-phase-iii-multiple-sclerosis-trials-cm680054,Roche Holdings RHHBY announced that new analyses from three phase III studies on its multiple sclerosis candidate Ocrevus will be presented at the 32nd congress of the European Committee for Treatment and Research in Multiple Sclerosis ECTRIMS scheduled for Sep 14 17 in London England
LGND,LGND:US,BBG000BKF014,Shire's Immunodeficiency Treatment Cuvitru Gets FDA Approval,2016-09-15 15:20:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BIZWfLDezhw/shires-immunodeficiency-treatment-cuvitru-gets-fda-approval-cm679960,Shire plc SHPG announced that the FDA has granted approval for Cuvitru Immune Globulin Subcutaneous Human 20 Solution for the treatment of adult and pediatric patients with primary immunodeficiency PI Note that PI affects six million people globally and comprises 300 genetic
LGND,LGND:US,BBG000BKF014,Ligand (LGND) Commences Phase II Type II Diabetes Study,2016-09-14 13:22:01 +0000,http://finance.yahoo.com/news/ligand-lgnd-commences-phase-ii-132201048.html,Ligand (LGND) Commences Phase II Type II Diabetes Study
LGND,LGND:US,BBG000BKF014,5 Biotech Stocks That Are Broker Favorites,2016-09-13 13:43:01 +0000,http://finance.yahoo.com/news/5-biotech-stocks-broker-favorites-134301108.html,5 Biotech Stocks That Are Broker Favorites
LGND,LGND:US,BBG000BKF014,Ligand Initiates Phase 2 Trial with LGD-6972 in Type 2 Diabetes,2016-09-13 12:30:00 +0000,http://finance.yahoo.com/news/ligand-initiates-phase-2-trial-123000481.html,[Business Wire] - Ligand Pharmaceuticals Incorporated announces the initiation of a Phase 2 clinical trial with the Company’s glucagon receptor antagonist LGD-6972 for the treatment of type 2 diabetes mellitus .
LGND,LGND:US,BBG000BKF014,4 Top Stocks on Track to Double Their Sales and Profits by 2019,2016-09-13 11:39:37 +0000,http://www.fool.com/investing/2016/09/13/4-top-stocks-on-track-to-double-their-sales-and-pr.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,4 Top Stocks on Track to Double Their Sales and Profits by 2019
LGND,LGND:US,BBG000BKF014,Ligand Pharma Initiates Phase 2 Trial For LGD-6972 - Quick Facts,2016-09-13 08:38:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ee0VsKixUvI/ligand-pharma-initiates-phase-2-trial-for-lgd6972--quick-facts-20160913-00491,Ligand Pharma Initiates Phase 2 Trial For LGD-6972 - Quick Facts
LGND,LGND:US,BBG000BKF014,Ligand Pharma To Present At Rodman & Renshaw Conference; Webcast At 9:10 AM ET,2016-09-13 08:10:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KC8mpG5kWqQ/ligand-pharma-to-present-at-rodman--renshaw-conference-webcast-at-910-am-et-20160913-00434,Ligand Pharma To Present At Rodman & Renshaw Conference; Webcast At 9:10 AM ET
LGND,LGND:US,BBG000BKF014,Ligand Pharma To Present At Morgan Stanley Global Conference; Webcast At 9:55 AM,2016-09-12 08:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8pvrXvFqqpQ/ligand-pharma-to-present-at-morgan-stanley-global-conference-webcast-at-955-am-20160912-00503,Ligand Pharma To Present At Morgan Stanley Global Conference; Webcast At 9:55 AM
LGND,LGND:US,BBG000BKF014,Ligand Pharma To Present At Morgan Stanley Global Conference; Webcast At 9:55 AM,2016-09-12 08:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MxyX3V13siM/ligand-pharma-to-present-at-morgan-stanley-global-conference-webcast-at-955-am-20160912-00504,Ligand Pharma To Present At Morgan Stanley Global Conference; Webcast At 9:55 AM
LGND,LGND:US,BBG000BKF014,Ligand/Retrophin Rare Disease Drug Positive in Phase II,2016-09-08 11:37:11 +0000,http://finance.yahoo.com/news/ligand-retrophin-rare-disease-drug-113711042.html,Ligand/Retrophin Rare Disease Drug Positive in Phase II
LGND,LGND:US,BBG000BKF014,LGND Makes Bullish Cross Above Critical Moving Average,2016-09-07 22:16:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ecOTF6IvKqE/lgnd-makes-bullish-cross-above-critical-moving-average-cm675914,In trading on Wednesday shares of Ligand Pharmaceuticals Inc Symbol LGND crossed above their 200 day moving average of 110 87 changing hands as high as 116 90 per share Ligand Pharmaceuticals Inc shares are currently trading up about 5 6 on the day The chart below shows the one
LGND,LGND:US,BBG000BKF014,"Retrophin, Ligand Pharma Jump As Rare-Disease Drug Hits In Trial",2016-09-07 20:28:28 +0000,http://www.investors.com/news/technology/retrophin-ligand-pharma-jump-as-rare-disease-drug-hits-in-trial/,"Retrophin, Ligand Pharma Jump As Rare-Disease Drug Hits In Trial"
LGND,LGND:US,BBG000BKF014,Why Shares of Retrophin Inc Are Soaring Today,2016-09-07 17:19:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/R9w3PaNjXxo/why-shares-of-retrophin-inc-are-soaring-today-cm675729,Image source Getty Images What happened Shares of Retrophin Inc NASDAQ RTRX 160 are off to the races today up 38 as of 10 30 a m ET after the company reported results from an important phase 2 clinical trial So what Retrophin released positive top line results
LGND,LGND:US,BBG000BKF014,Why Shares of Retrophin Inc Are Soaring Today,2016-09-07 15:36:47 +0000,http://www.fool.com/investing/2016/09/07/why-shares-of-retrophin-inc-are-soaring-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Shares of Retrophin Inc Are Soaring Today
LGND,LGND:US,BBG000BKF014,Ligand Partner Retrophin Announces Positive Top-Line Results from Phase 2 DUET Study of Sparsentan in Patients with Focal Segmental Glomerulosclerosis,2016-09-07 13:25:00 +0000,http://finance.yahoo.com/news/ligand-partner-retrophin-announces-positive-132500104.html,"[Business Wire] - Ligand Pharmaceuticals Incorporated partner Retrophin, Inc. today announced positive top-line results from the Phase 2 DUET study of sparsentan for the treatment of focal segmental glomerulosclerosis , a rare kidney disorder without an approved pharmacologic treatment that often leads to end-stage renal disease."
LGND,LGND:US,BBG000BKF014,Retrophin Reports Positive Top-line Results From Sparsentan Phase 2 DUET Study,2016-09-07 09:39:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vlhsaJLRGyc/retrophin-reports-positive-topline-results-from-sparsentan-phase-2-duet-study-20160907-00707,Retrophin Reports Positive Top-line Results From Sparsentan Phase 2 DUET Study
LGND,LGND:US,BBG000BKF014,Retrophin Reports Positive Top-line Results From Sparsentan Phase 2 DUET Study,2016-09-07 09:39:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/b3ipGGBuUIU/retrophin-reports-positive-topline-results-from-sparsentan-phase-2-duet-study-20160907-00710,Retrophin Reports Positive Top-line Results From Sparsentan Phase 2 DUET Study
LGND,LGND:US,BBG000BKF014,Ligand to Participate in Two Upcoming Investor Conferences,2016-09-02 13:00:00 +0000,http://finance.yahoo.com/news/ligand-participate-two-upcoming-investor-130000690.html,[Business Wire] - Ligand Pharmaceuticals Incorporated announces that company executives are scheduled to participate in the following upcoming investor conferences:
LGND,LGND:US,BBG000BKF014,Intec Pharma reports Q2 results,2016-09-01 10:23:05 +0000,http://www.publicnow.com/view/B10DAE69286E302564C5A53CDC1A747FA5BD4226,"[at noodls] - Intec Pharma Ltd. (Nasdaq: NTEC), a late stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, reports financial results for the three ..."
LGND,LGND:US,BBG000BKF014,"LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements an",2016-08-26 12:32:38 +0000,http://biz.yahoo.com/e/160826/lgnd8-k.html,"LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements an"
LGND,LGND:US,BBG000BKF014,"ETF’s with exposure to Ligand Pharmaceuticals, Inc. : August 24, 2016",2016-08-24 16:05:58 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-ligand-pharmaceuticals-inc-august-24-2016/,"ETF’s with exposure to Ligand Pharmaceuticals, Inc. : August 24, 2016"
LGND,LGND:US,BBG000BKF014,These 3 Stocks Are Up Over 700% in the Last 5 Years,2016-08-23 22:46:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nufLIipwc5s/these-3-stocks-are-up-over-700-in-the-last-5-years-cm669257,"Image source  Getty Images.  Home runs are fun to watch in baseball, but they're even more exciting in investing. Multi baggers    that is, investments that gain over 100%"
LGND,LGND:US,BBG000BKF014,These 3 Stocks Are Up Over 700% in the Last 5 Years,2016-08-23 21:07:00 +0000,http://www.fool.com/investing/2016/08/23/these-3-stocks-are-up-over-700-in-the-last-5-years.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,These 3 Stocks Are Up Over 700% in the Last 5 Years
LGND,LGND:US,BBG000BKF014,Ligand Pharmaceuticals (LGND) Is in Oversold Territory: What's Next?,2016-08-19 15:49:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4drbaWTRZ7I/ligand-pharmaceuticals-lgnd-is-in-oversold-territory-whats-next-cm667729,"Ligand Pharmaceuticals IncorporatedLGND has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. And for technical investors there is some hope when"
LGND,LGND:US,BBG000BKF014,Ligand Pharmaceuticals (LGND) Is in Oversold Territory: What's Next?,2016-08-19 13:34:01 +0000,http://finance.yahoo.com/news/ligand-pharmaceuticals-lgnd-oversold-territory-133401382.html,Ligand Pharmaceuticals (LGND) Is in Oversold Territory: What's Next?
LGND,LGND:US,BBG000BKF014,Ligand Pharmaceuticals (LGND) Shares Cross Below 200 DMA,2016-08-17 21:57:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7vjPWabwfNo/ligand-pharmaceuticals-lgnd-shares-cross-below-200-dma-cm666556,"In trading on Wednesday, shares of Ligand Pharmaceuticals Inc (Symbol LGND) crossed below their 200 day moving average of $110.06, changing hands as low as $109.00 per share. Ligand Pharmaceuticals Inc shares are currently trading down about 1.7% on"
LGND,LGND:US,BBG000BKF014,We Did The Math PTH Can Go To $54,2016-08-17 21:56:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oztct2XJWoM/we-did-the-math-pth-can-go-to-54-cm666376,"Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12 month forward target price, and computed the weighted average"
LGND,LGND:US,BBG000BKF014,4 Top Biotech Stocks That Can Be Purchased on the Cheap This Summer,2016-08-16 18:54:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MyXXrmZlDag/4-top-biotech-stocks-that-can-be-purchased-on-the-cheap-this-summer-cm665738,"Image source  Getty Images.  U.S stocks have been taken for a wild ride in 2016, but at least most long term investors can relish the fact that despite the volatility, the broader market"
LGND,LGND:US,BBG000BKF014,VKTX: Data From Phase 2 Studies of VK2809 for Hypercholersterolemia and VK5211 for Hip Fracture to be Reported in 2Q17,2016-08-16 16:00:00 +0000,http://finance.yahoo.com/news/vktx-data-phase-2-studies-160000402.html,VKTX: Data From Phase 2 Studies of VK2809 for Hypercholersterolemia and VK5211 for Hip Fracture to be Reported in 2Q17
LGND,LGND:US,BBG000BKF014,4 Top Biotech Stocks That Can Be Purchased on the Cheap This Summer,2016-08-16 12:18:00 +0000,http://www.fool.com/investing/2016/08/16/4-top-biotech-stocks-that-can-be-purchased-on-the.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,4 Top Biotech Stocks That Can Be Purchased on the Cheap This Summer
LGND,LGND:US,BBG000BKF014,"Results from Phase 1 Trials with Ligand’s LGD-6972 in Type 2 Diabetes Mellitus Published in Diabetes, Obesity and Metabolism",2016-08-15 13:00:00 +0000,http://finance.yahoo.com/news/results-phase-1-trials-ligand-130000707.html,"[Business Wire] - Ligand Pharmaceuticals Incorporated announces that results from two Phase 1 clinical trials with LGD-6972, the company’s investigational glucagon receptor antagonist, were published online in the August issue of the journal Diabetes, Obesity and Metabolism."
LGND,LGND:US,BBG000BKF014,"Zacks.com featured highlights: Ligand Pharmaceuticals, Ormat Technologies, Activision Blizzard, Boise Cascade and Ubiquiti Networks",2016-08-12 15:56:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_KUitwbG8SU/zackscom-featured-highlights-ligand-pharmaceuticals-ormat-technologies-activision-blizzard-boise-cascade-and-ubiquiti-networks-cm664686,"For Immediate Release Chicago, IL August 12, 2016 Stocks in this week's article include Ligand Pharmaceuticals Inc. ( LGND ), Ormat Technologies, Inc. ( ORA ), Activision Blizzard, Inc. ( ATVI ), Boise Cascade Company ( BCC ) and"
LGND,LGND:US,BBG000BKF014,"Zacks.com featured highlights: Ligand Pharmaceuticals, Ormat Technologies, Activision Blizzard, Boise Cascade and Ubiquiti Networks",2016-08-12 13:30:01 +0000,http://finance.yahoo.com/news/zacks-com-featured-highlights-ligand-133001870.html,"Zacks.com featured highlights: Ligand Pharmaceuticals, Ormat Technologies, Activision Blizzard, Boise Cascade and Ubiquiti Networks"
LGND,LGND:US,BBG000BKF014,"Ligand Pharmaceuticals Still Offers Double-Digits Upside, Vetr Crowd Says",2016-08-11 18:33:33 +0000,http://finance.yahoo.com/news/ligand-pharmaceuticals-still-offers-double-183333682.html,"Ligand Pharmaceuticals Still Offers Double-Digits Upside, Vetr Crowd Says"
LGND,LGND:US,BBG000BKF014,5 Stocks to Play Momentum the Driehaus Way,2016-08-11 15:54:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4aSWckx-5zU/5-stocks-to-play-momentum-the-driehaus-way-cm664076,"Momentum strategies that have the potential to offer healthy returns have always been the on radar of investors with a high risk appetite. The principle is ""buy high and sell higher."" Richard Driehaus is a pioneer investor who created"
LGND,LGND:US,BBG000BKF014,5 Stocks to Play Momentum the Driehaus Way,2016-08-11 13:53:01 +0000,http://finance.yahoo.com/news/5-stocks-play-momentum-driehaus-135301418.html,5 Stocks to Play Momentum the Driehaus Way
LGND,LGND:US,BBG000BKF014,"ETF’s with exposure to Ligand Pharmaceuticals, Inc. : August 9, 2016",2016-08-09 17:48:47 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-ligand-pharmaceuticals-inc-august-9-2016/,"ETF’s with exposure to Ligand Pharmaceuticals, Inc. : August 9, 2016"
LGND,LGND:US,BBG000BKF014,"Inovio (INO) Q2 Loss in Line with Estimates, Revenues Top",2016-08-09 15:37:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/66tdMq0-Qts/inovio-ino-q2-loss-in-line-with-estimates-revenues-top-cm662519,"Inovio Pharmaceuticals, Inc.INO reported a loss of 26 cents per share in the second quarter of 2016, in line with the Zacks Consensus Estimate but wider than the year ago loss of 9 cents. Inovio Pharmaceuticals Inc. (INO) Street"
LGND,LGND:US,BBG000BKF014,Licensing Agreements Drive Ligand Pharmaceuticals Inc. 13% Higher in July,2016-08-09 12:38:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/x79qdvr1LIs/licensing-agreements-drive-ligand-pharmaceuticals-inc-13-higher-in-july-cm662098,"Image source  Getty Images.  What  Shares of Ligand Pharmaceuticals (NASDAQ  LGND) , an acquirer of royalty assets in the biotech space, surged 13% in July, according to data from S&P Global"
LGND,LGND:US,BBG000BKF014,"Ligand Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LGND-US : August 9, 2016",2016-08-09 12:15:19 +0000,http://www.capitalcube.com/blog/index.php/ligand-pharmaceuticals-inc-breached-its-50-day-moving-average-in-a-bearish-manner-lgnd-us-august-9-2016/,"Ligand Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LGND-US : August 9, 2016"
LGND,LGND:US,BBG000BKF014,Endocyte (ECYT) Q2 Loss Wider than Expected (Revised),2016-08-09 11:16:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9edhoNESOy4/endocyte-ecyt-q2-loss-wider-than-expected-revised-cm662242,"Endocyte, Inc.ECYT reported a second quarter 2016 loss of 33 cents per share, wider than both the Zacks Consensus Estimate of a loss of 26 cents and the year ago loss of 25 cents. On the other hand, the"
LGND,LGND:US,BBG000BKF014,"Ligand Pharmaceuticals, Inc. :LGND-US: Earnings Analysis: Q2, 2016 By the Numbers : August 8, 2016",2016-08-08 17:00:58 +0000,http://www.capitalcube.com/blog/index.php/ligand-pharmaceuticals-inc-lgnd-us-earnings-analysis-q2-2016-by-the-numbers-august-8-2016/,"Ligand Pharmaceuticals, Inc. :LGND-US: Earnings Analysis: Q2, 2016 By the Numbers : August 8, 2016"
LGND,LGND:US,BBG000BKF014,Ligand Pharma downgraded by Deutsche Bank,2016-08-05 17:02:06 +0000,http://finance.yahoo.com/q/ud?s=LGND,Ligand Pharma downgraded by Deutsche Bank
LGND,LGND:US,BBG000BKF014,Edited Transcript of LGND earnings conference call or presentation 4-Aug-16 1:00pm GMT,2016-08-05 15:29:26 +0000,http://finance.yahoo.com/news/edited-transcript-lgnd-earnings-conference-152926562.html,Edited Transcript of LGND earnings conference call or presentation 4-Aug-16 1:00pm GMT
LGND,LGND:US,BBG000BKF014,"Ligand (LGND) Q2 Earnings Decline Y/Y, Maintains View",2016-08-05 12:56:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XfReTytZpok/ligand-lgnd-q2-earnings-decline-yy-maintains-view-cm660902,"Ligand Pharmaceuticals IncorporatedLGND reported second quarter 2016 earnings of 30 cents per share (including the impact of stock based compensation expense), well below the year ago earnings of $1.67 per share. Excluding the impact of non cash stock based"
LGND,LGND:US,BBG000BKF014,"Ligand (LGND) Q2 Earnings Decline Y/Y, Maintains View",2016-08-05 10:48:10 +0000,http://finance.yahoo.com/news/ligand-lgnd-q2-earnings-decline-104810265.html,"Ligand (LGND) Q2 Earnings Decline Y/Y, Maintains View"
LGND,LGND:US,BBG000BKF014,"Ligand (LGND) Beats Q2 Earnings, Revenues Up Y/Y",2016-08-04 16:01:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fBjLzL05wFs/ligand-lgnd-beats-q2-earnings-revenues-up-yy-cm660411,"La Jolla, CA based Ligand Pharmaceuticals IncorporatedLGND is a biotechnology company with a focus on drug discovery, reformulation and partnering. Ligand's Captisol formulation technology has allowed it to enter into several licensing deals with companies like Amgen and Novartis"
LGND,LGND:US,BBG000BKF014,"Ligand (LGND) Beats Q2 Earnings, Revenues Up Y/Y",2016-08-04 13:41:01 +0000,http://finance.yahoo.com/news/ligand-lgnd-beats-q2-earnings-134101673.html,"Ligand (LGND) Beats Q2 Earnings, Revenues Up Y/Y"
LGND,LGND:US,BBG000BKF014,"LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition",2016-08-04 13:08:38 +0000,http://biz.yahoo.com/e/160804/lgnd8-k.html,"LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition"
LGND,LGND:US,BBG000BKF014,Ligand reports 2Q loss,2016-08-04 13:03:34 +0000,http://sg.finance.yahoo.com/news/ligand-reports-2q-loss-130334270.html,Ligand reports 2Q loss
LGND,LGND:US,BBG000BKF014,Ligand Reports Second Quarter 2016 Financial Results,2016-08-04 12:00:00 +0000,http://finance.yahoo.com/news/ligand-reports-second-quarter-2016-120000859.html,"[Business Wire] - Ligand Pharmaceuticals Incorporated today reported financial results for the three and six months ended June 30, 2016, and provided an operating forecast and program updates."
LGND,LGND:US,BBG000BKF014,Q2 2016 Ligand Pharmaceuticals Inc Earnings Release - Before Market Open,2016-08-04 11:07:03 +0000,http://biz.yahoo.com/research/earncal/20160804.html?t=lgnd,Q2 2016 Ligand Pharmaceuticals Inc Earnings Release - Before Market Open
LGND,LGND:US,BBG000BKF014,Ligand Pharmaceuticals Inc Earnings Fall 72% In Q2,2016-08-04 08:02:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IKFkxF0fUzA/ligand-pharmaceuticals-inc-earnings-fall-72-in-q2-20160804-00589,Ligand Pharmaceuticals Inc Earnings Fall 72% In Q2
LGND,LGND:US,BBG000BKF014,Ligand Pharmaceuticals  Q2 16 Earnings Conference Call At 9:00 AM ET,2016-08-04 08:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MA4TCr6cXX8/ligand-pharmaceuticals--q2-16-earnings-conference-call-at-900-am-et-20160804-00566,Ligand Pharmaceuticals  Q2 16 Earnings Conference Call At 9:00 AM ET
LGND,LGND:US,BBG000BKF014,2 Biotech Funds Leading Nascent Bull Market: Which Is Right For You?,2016-08-02 20:09:55 +0000,http://www.investors.com/etfs-and-funds/etfs/2-etfs-leading-the-new-biotech-bull-market-which-is-right-for-you/,2 Biotech Funds Leading Nascent Bull Market: Which Is Right For You?
LGND,LGND:US,BBG000BKF014,Ligand (LGND) Q2 Earnings: What's in Store for the Stock?,2016-08-02 12:56:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ko3lOur36bQ/ligand-lgnd-q2-earnings-whats-in-store-for-the-stock-cm658631,"Ligand Pharmaceuticals IncorporatedLGND is scheduled to report second quarter 2016 results on Aug 4 before the market opens. In the last reported quarter, Ligand had posted a positive earnings surprise of 67.39%. Let's see how things are shaping up"
LGND,LGND:US,BBG000BKF014,Ligand (LGND) Q2 Earnings: What's in Store for the Stock?,2016-08-02 11:18:11 +0000,http://finance.yahoo.com/news/ligand-lgnd-q2-earnings-whats-111811180.html,Ligand (LGND) Q2 Earnings: What's in Store for the Stock?
LGND,LGND:US,BBG000BKF014,Are Biotechs Finally Making A Comeback? Here Are 5 Must-Watch Names,2016-08-01 21:02:54 +0000,http://www.investors.com/news/technology/are-biotechs-finally-making-a-comeback-here-are-5-must-watch-names/,Are Biotechs Finally Making A Comeback? Here Are 5 Must-Watch Names
LGND,LGND:US,BBG000BKF014,These Top Biotech Stocks Are Leading The Industry's Rebound,2016-08-01 18:51:54 +0000,http://finance.yahoo.com/video/top-biotech-stocks-leading-industrys-185154754.html,These Top Biotech Stocks Are Leading The Industry's Rebound
LGND,LGND:US,BBG000BKF014,Ligand Announces Multi-Program LTP Technology Licensing Agreement with Nucorion Pharmaceuticals,2016-07-29 12:30:00 +0000,http://au.finance.yahoo.com/news/ligand-announces-multi-program-ltp-123000602.html,"[Business Wire] - SAN DIEGO--(BUSINESSWIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - News) announces the signing of a license agreement for three programs utilizing Ligand’s LTP (Liver Targeting Prodrug) technology with Nucorion Pharmaceuticals, Inc., a venture-funded biotechnology company focused on developing anti-cancer and anti-viral agents initially directed to China. Ligand’s LTP technology is a novel prodrug technology platform designed to selectively deliver a range of active pharmaceutical agents to the liver."
LGND,LGND:US,BBG000BKF014,Ligand Pharmaceuticals Reaches Analyst Target Price,2016-07-21 15:14:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0Ie0Du_xuCk/ligand-pharmaceuticals-reaches-analyst-target-price-cm652544,"In recent trading, shares of Ligand Pharmaceuticals Inc (Symbol LGND) have crossed above the average analyst 12 month target price of $134.40, changing hands for $135.12 share. When a stock reaches the target an analyst has set, the analyst"
LGND,LGND:US,BBG000BKF014,Ligand Pharmaceuticals (LGND) Jumps: Stock Rises 5.5%,2016-07-21 14:17:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uyApUDuru58/ligand-pharmaceuticals-lgnd-jumps-stock-rises-55-cm652490,"Ligand Pharmaceuticals IncorporatedLGND was a big mover last session, as its shares rose almost 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the"
LGND,LGND:US,BBG000BKF014,3 Biotech Stocks for Conservative Investors,2016-07-17 21:09:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/H8nEd3BB7YI/3-biotech-stocks-for-conservative-investors-cm650280,"Image source  Getty Images.  The biotechnology industry is chock full of risky stocks, but that doesn't mean conservative investors should ignore it entirely. You might be surprised to find that more than a"
LGND,LGND:US,BBG000BKF014,The 3 Most Unbelievably Undervalued Healthcare Stocks,2016-07-13 13:54:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/b_FpfhQNyZ4/the-3-most-unbelievably-undervalued-healthcare-stocks-cm648464,"Image source  Getty Images.  It's been a volatile first half of the year for the stock market, but the healthcare sector has really stood out as an underperformer. Specifically, drugmakers have taken it"
LGND,LGND:US,BBG000BKF014,Here's Why SAGE Therapeutics Inc. Is Surging Today,2016-07-12 17:50:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pDnZshRjsvg/heres-why-sage-therapeutics-inc-is-surging-today-cm648109,Image source  Getty Images.  What   It's a great day to be an investor in SAGE Therapeutics (NASDAQ  SAGE) . Shares of the clinical stage biotech are up more than 37% as
LGND,LGND:US,BBG000BKF014,Ligand (LGND) Signs Deal with Gilead for OmniAb Technology,2016-07-11 16:49:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MbOo2rIjw4E/ligand-lgnd-signs-deal-with-gilead-for-omniab-technology-cm647224,"Ligand Pharmaceuticals IncorporatedLGND announced that it has entered into a worldwide license agreement with Gilead Sciences, Inc. GILD , under which the latter will use the OmniRat, OmniMouse and OmniFlic technologies for the discovery of fully human mono and"
LGND,LGND:US,BBG000BKF014,Ligand Receives $4 Million from Expansion of Two OmniAb® License Agreements,2016-06-30 20:02:00 +0000,http://au.finance.yahoo.com/news/ligand-receives-4-million-expansion-200200538.html,"[Business Wire] - SAN DIEGO--(BUSINESSWIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - News) announces that two recent events relating to its OmniAb platform generated $4 million in combined payments due to Ligand. In exercising its option, an OmniAb licensee broadened its access to the OmniAb platform by adding OmniFlic®, a transgenic rat technology with a fixed light chain used to generate bispecific antibodies. The option exercise triggered a payment to Ligand."
LGND,LGND:US,BBG000BKF014,3 Biotech Stocks to Buy on Sale Right Now,2016-06-29 21:50:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/02GYgOQ7uP0/3-biotech-stocks-to-buy-on-sale-right-now-cm642916,Image source  Getty Images.  Don't wait until next year  there are stocks you can buy right now that should give you exceptional returns over the long run. Three of them are in
LGND,LGND:US,BBG000BKF014,Ligand tops 1Q revenue forecasts,2016-05-04 10:21:17 +0000,http://sg.finance.yahoo.com/news/ligand-tops-1q-revenue-forecasts-102117920.html,Ligand tops 1Q revenue forecasts
LGND,LGND:US,BBG000BKF014,Ligand Announces First Quarter 2016 Earnings Reporting Date and Participation in Four Upcoming Investor Conferences,2016-04-22 13:00:00 +0000,http://uk.finance.yahoo.com/news/ligand-announces-first-quarter-2016-130000580.html,Ligand Announces First Quarter 2016 Earnings Reporting Date and Participation in Four Upcoming Investor Conferences
LGND,LGND:US,BBG000BKF014,Ligand Enters Into OmniAb® Platform License Agreement With ABBA Therapeutics,2016-03-28 13:22:06 +0000,http://www.publicnow.com/view/F0EB7D7A09CF5DC9CECBD06B915CBD8FB822E751,"[at noodls] - SAN DIEGO-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide license agreement with ABBA Therapeutics AG, a Swiss biotechnology company developing innovative ..."
LGND,LGND:US,BBG000BKF014,Ligand beats 4Q profit forecasts,2016-02-10 21:51:42 +0000,http://sg.finance.yahoo.com/news/ligand-beats-4q-profit-forecasts-215142733.html,Ligand beats 4Q profit forecasts
LGND,LGND:US,BBG000BKF014,Ligand to Report Fourth Quarter and Full Year 2015 Results on February 10th,2016-01-22 14:13:16 +0000,http://www.noodls.com/view/28712EEA4D6621AA26B08E23228E117D38BF4522,"[at noodls] - SAN DIEGO-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report fourth quarter and full year 2015 financial results on February 10, 2016. Ligand's CEO John Higgins, President ..."
LGND,LGND:US,BBG000BKF014,Ligand Enters Into OmniAb® Platform License Agreement with Emergent BioSolutions,2016-01-13 14:58:04 +0000,http://www.noodls.com/view/42F8844D431373A82CAB513FAFCE3590181197F4,"[at noodls] - SAN DIEGO-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide license agreement with Emergent BioSolutions Inc. (NYSE: EBS), a global specialty biopharmaceutical ..."
LGND,LGND:US,BBG000BKF014,"Ligand to Acquire OMT, Inc., a Leader in Human Antibody Generation, for $178 Million in Cash and Stock",2015-12-17 22:17:47 +0000,http://www.noodls.com/view/3A7CDC484B7D7A7564EC9FFB81C35FAD97C28325,"[at noodls] - Gains New Revenue Streams, 16 Fully-Funded Platform Partnerships and Licensees, Patent Portfolio and Potential Long-term Royalties from Human Antibody and Transgenic Animal Businesses Transaction Expected ..."
LGND,LGND:US,BBG000BKF014,RODES Signs Exclusive Captisol® Licensing Agreement with Ligand Pharmaceuticals for Three Programs,2015-12-08 12:47:10 +0000,http://www.noodls.com/view/A04630590BEAE88AA3B7EC0F26B14838F2E6233D,"[at noodls] - PAOLI, Pa. & SAN DIEGO-- RODES, Inc. and Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announce the signing of exclusive global license and supply agreements for three Captisol-enabled™ (CE) programs. ..."
LGND,LGND:US,BBG000BKF014,Ligand Provides Highlights from Today’s Analyst Day Event,2015-11-18 21:12:35 +0000,http://www.noodls.com/view/7233D7EE0F838E5FF774628F1C746BA7BF61ABA7,"[at noodls] - Webcast available at www.ligand.com SAN DIEGO-- At an Analyst Day event held earlier today in New York City, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reviewed the recent progress of its business, ..."
LGND,LGND:US,BBG000BKF014,Ligand posts 3Q profit,2015-11-09 22:25:57 +0000,http://sg.finance.yahoo.com/news/ligand-posts-3q-profit-222557443.html,Ligand posts 3Q profit
LGND,LGND:US,BBG000BKF014,Ligand Reports Third Quarter 2015 Financial Results,2015-11-09 21:26:21 +0000,http://www.noodls.com/view/B0F95AC3E1E433552020A0AD33EEB199E1FBBCBB,"[at noodls] - Conference Call Begins at 4:30 p.m. Eastern Time Today SAN DIEGO-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and nine months ended September 30, ..."
LGND,LGND:US,BBG000BKF014,Ligand to Report Third Quarter Results on November 9th,2015-10-20 13:22:06 +0000,http://www.noodls.com/view/E7AF4569CEA11186E296098296D55939846761C0,"[at noodls] - SAN DIEGO-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report third quarter 2015 financial results on November 9, 2015. Ligand's CEO John Higgins, President and COO Matt ..."
LGND,LGND:US,BBG000BKF014,Ligand to Host Analyst Day on November 18th in New York City,2015-10-12 20:15:14 +0000,http://www.noodls.com/view/6A321067A03BEBD01A32313FE50C600B18881CF6,"[at noodls] - SAN DIEGO-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host an Analyst Day on Wednesday, November 18, 2015 from 10:00 a.m. to 11:30 a.m. Eastern time (7:00 a.m. to 8:30 a.m. Pacific time) ..."
LGND,LGND:US,BBG000BKF014,Ligand Expands Captisol License and Supply Agreements with SAGE Therapeutics to Include SAGE-689,2015-09-29 13:27:14 +0000,http://www.noodls.com/view/939929AAA9676788953C5245D624C6BEB8121C48,[at noodls] - SAN DIEGO-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has expanded its global license and supply agreements with SAGE Therapeutics (SAGE) to now also cover the use of Captisol® in ...
LGND,LGND:US,BBG000BKF014,Revolade® Receives EU Approval as First-in-Class Therapy for Patients with Severe Aplastic Anemia,2015-09-02 13:14:15 +0000,http://www.noodls.com/view/DA9AA90BF4B1B4D535B9087ACB5F484FD8AF95F1,[at noodls] - Revolade is marketed as Promacta® in the USA Revolade is the first approved therapy in the EU for patients with severe aplastic anemia (SAA) who have not responded to other treatments Two out of every ...
LGND,LGND:US,BBG000BKF014,Spectrum Pharmaceuticals Announces Publication of Pivotal EVOMELA™ (melphalan hydrochloride) for Injection Data in the Biology of Blood and Marrow Transplantation Journal,2015-09-02 11:24:11 +0000,http://www.noodls.com/view/643CB2BAD7D66EED9FEF5EF1467CE304CA96BAA3,"[at noodls] - Published Data Highlights Achievement of Myeloablation (Median Day 5) and Engraftment (Median Day 12-13) with no mortality (Day 100) EVOMELA is Free of Propylene Glycol, a Diluent Required for Reconstitution ..."
LGND,LGND:US,BBG000BKF014,FDA Expands Use of Promacta® to Include Treatment of Children Ages 1 and Older with Chronic Immune Thrombocytopenia,2015-08-24 17:43:01 +0000,http://www.noodls.com/view/954AD89264067C7A57A0E3C1FC33EB8D3FF82B89,"[at noodls] - New oral suspension formulation, designed for younger children with rare blood disorder, is now approved For about one in four children with ITP, the condition persists for more than 12 months after diagnosis ..."
LGND,LGND:US,BBG000BKF014,Ligand posts 2Q profit,2015-08-04 20:16:07 +0000,http://sg.finance.yahoo.com/news/ligand-posts-2q-profit-201607129.html,Ligand posts 2Q profit
LGND,LGND:US,BBG000BKF014,Ligand tops Street 1Q forecasts,2015-05-11 12:45:57 +0000,http://sg.finance.yahoo.com/news/ligand-tops-street-1q-forecasts-124557402.html,Ligand tops Street 1Q forecasts
LGND,LGND:US,BBG000BKF014,Ligand meets 4Q profit forecasts,2015-02-09 13:48:54 +0000,http://sg.finance.yahoo.com/news/ligand-meets-4q-profit-forecasts-134854539.html,Ligand meets 4Q profit forecasts
LGND,LGND:US,BBG000BKF014,Ligand beats Street 3Q forecasts,2014-10-27 12:16:01 +0000,http://sg.finance.yahoo.com/news/ligand-beats-street-3q-forecasts-121601771--finance.html,Ligand beats Street 3Q forecasts
